

Author Index for 1990

- Aalbers, C. 31:217
Abelson, J.M. 31:145
Adelsheimer, E.F. 34:127
Adinoff, B. 31:261, 33:215
Adler, L.E. 31:297
Agras, W.S. 32:45
Alexander, R.C. 31:221
Alexandropoulos, K. 35:137
Alexson, J. 32:125
Alfisi, S. 34:19
Allen, D. 31:311
Alper, K.R. 35:95
Alvir, J.M.J. 35:1
Amass, J. 33:83
Anderson, G.M. 33:95
Anderson, J. 34:89
Antonangeli, L. 34:13
Antonozzi, I. 34:139
Apter, A. 32:191
Arora, R.C. 32:265
Asarnow, R.F. 31:169
Ashtari, M. 35:1
Asnis, G.M. 31:179, 33:189
Azima-Heiler, R. 34:127
Baker, G.B. 31:279, 33:301
Baker, N. 31:297
Balon, R. 32:93, 32:103, 32:207
Baltazar, P.L. 32:35
Barbaccia, M. 31:261
Barbato, G. 33:259
Bartalena, L. 34:13
Baumgartner, A. 34:213, 34:217
Bell, K.M. 34:303, 34:315
Berchou, R. 32:103
Berent, S. 35:49
Berga, S.L. 33:129, 33:135
Bergman, R.L. 32:281
Berkowitz, A.L. 33:113, 33:129
Berman, N. 32:71
Berrettini, W. 31:57, 33:215
Betley, A.T. 35:49
Biggs, M.M. 33:39
Bilder, R.M. 35:1
Black, D.W. 32:151
Blockx, P. 34:59, 34:107
Bogazzi, F. 34:13
Bogerts, B. 35:1
Bois, E. 34:77
Boivin, M.J. 35:49
Borcherding, B.G. 33:83
Bornstein, R.A. 31:15, 31:279,
33:73, 33:301
Bouhuys, A.L. 34:149
Bouhuys, N. 32:113
Bowers, M.M. 33:151
Bräunig, P. 34:243
Brambilla, F. 32:229
Brewerton, T.D. 33:1
Bridger, W.H. 33:323
Brittain, H. 31:57
Brown, G.M. 31:311, 32:221
Brown, R.P. 31:99
Brown, S.-L. 32:191
Brown, T.M. 31:161
Brown, W.A. 32:213
Bruce, M.L. 33:31
Bruni, M. 32:159
Bryant, M.J. 31:131
Buchanan, R.W. 31:25
Buckman, T.D. 31:1
Buckwalter, G. 32:35
Burkett, S. 32:201
Burr, G. 35:39
Bylund, D.B. 32:125
Cahn, W. 31:179, 33:189
Calabrese, G. 32:159
Calabrese, V.P. 33:11
Campion, D. 34:77
Campos-Barros, A. 34:217
Caplan, R. 31:169
Carroll, A. 33:301
Carucci, M. 32:159
Casanova, M.F. 35:149
Catalano, M. 32:63, 32:229
Cepeda, C. 33:199
Cerilli, M. 34:139
Chabot, R.J. 35:95
Chen, J.-S. 34:127
Cheung, S.W. 31:111, 34:205
Chicz-DeMet, A. 33:221, 34:293,
34:303, 34:315
Christman, D. 35:39
Chudzik, J. 34:205
Cicin-Sain, L. 32:167
Clark, C.M. 33:129
Clark, D.B. 32:45
Cleghorn, J.M. 31:311
Coffman, J.A. 31:15

- Coger, R.W. 34:163
 Coggiano, M. 31:221
 Cohen, M.R. 32:135
 Collier, B. 31:31
 Colter, N. 35:137
 Cooper, T. 33:161
 Coppard, N. 31:235
 Corcoran, C.M. 32:125
 Cornblatt, B.A. 32:297
 Costa, D. 32:221
 Costa, E. 31:261
 Cosyns, P. 34:29, 34:43, 34:59
 Cowen, P.J. 31:201
 Crocker, B. 32:35
 Crocq, M.-A. 35:107
 Crow, T.J. 35:137
 Csernansky, J.G. 31:243, 33:171, 33:269
 D'Amato, T. 34:77
 D'Hondt, P. 34:29, 34:59
 Dam, H. 32:29
 Daniel, D.G. 31:221
 Darcourt, G. 32:253
 Dauphinais, I.D. 35:137
 Davis, J.M. 32:9
 Davis, K.L. 33:179
 de Bartolomeis, A. 33:259
 DeCaria, C.M. 31:211, 33:161
 Degreef, G. 35:1
 DeJong, J. 31:261, 33:215
 DeLisi, L.E. 35:137
 Dell'Osso, L. 34:13
 de Loof, C. 31:193
 DeMet, E.M. 33:221, 34:293, 34:303, 34:315
 Demitrack, M.A. 32:183
 den Boer, J.A. 31:267
 DeQuattro, V. 32:35
 Devanand, D.P. 31:287
 DeVeaugh-Geiss, J. 31:121, 34:223
 Dewey, S.L. 35:39
 Dilsaver, S.C. 33:139
 Docherty, J.P. 31:131
 Douglass, A.B. 33:301
 Douillet, P. 32:253
 Dragovic, L.J. 34:185
 Drebing, C. 31:297
 Drouet, A. 34:77
 Durst, P. 35:107
 Dysken, M.W. 34:99
 Easton, M. 32:9
 Edwards, J. 32:141
 Ehlers, A. 32:45
 Eiduson, S. 31:1
 Eisner, W.H. 31:235
 Ekstrom, D. 31:39, 31:161
 Elia, J. 33:83
 Emsley, R.A. 31:217
 Erlenmeyer-Kimling, L. 32:297, 32:311
 Eroglu, L. 32:203
 Esin, Y. 32:203
 Etzel, B.A. 33:39
 Evans, D.L. 31:161
 Faraone, S.V. 32:213
 Faustman, W.O. 31:243, 33:171
 Fawcett, J. 32:141
 Feingold, J. 34:77
 Ferrari, E. 32:229
 Fischer, C. 33:199
 Flekköy, K. 35:27
 Flentge, F. 34:149
 Fogg, L. 32:141
 Fowler, J.S. 35:39
 Foy, J.G. 31:169
 Frajese, G. 34:139
 Frankel, F. 32:125
 Franks, R. 31:297
 Franzén, G. 35:27
 Frazer, A. 32:71
 Fredrickson, E.R. 33:19
 Freedman, R. 31:297
 Friedman, R.A. 31:99
 Fritze, J. 32:275, 34:259, 34:271
 Frölich, L. 33:107, 34:237
 Fyer, A.J. 32:55
 Gambini, O. 32:159
 Garfinkel, P.E. 32:221
 Gehris, T.L. 32:151
 Gelder, M.G. 31:201
 George, D.T. 33:1
 Gerhardt, G.A. 31:297
 Gerner, R.H. 34:303, 34:315
 Gershon, E.S. 35:137
 Giles, D.E. 33:39
 Giller, E.L., Jr. 34:193
 Gillin, J.C. 33:113, 33:129
 Giordani, B. 35:49
 Glaser, R. 33:59
 Glitz, D. 32:207
 Glue, P. 32:201
 Golden, R.N. 31:39, 31:161
 Goldman, W. 33:323
 Goldstein, D.S. 33:1
 Goodman, W.K. 33:95
 Gordon, E. 34:89
 Gorman, J.M. 32:55
 Gosden, C. 32:1
 Gottesman, I.I. 32:297, 32:311
 Grahame-Smith, D.G. 31:201
 Green, A.I. 32:213

- Griez, E. 31:193
 Gross, G. 34:243
 Guidotti, A. 31:261
 Guilloud-Bataille, M. 34:77
 Gustafson, L. 35:27
 Gutman, R. 32:135
 Haggerty, J.J., Jr. 31:161
 Haier, R.J. 33:221
 Hakkarainen, H. 34:223
 Hamovit, J.R. 31:131
 Hardin, M.T. 33:95
 Harris, W.R. 33:199
 Harvey, I. 35:61
 Harvey, P.D. 32:281, 33:179
 Hayward, C. 32:45
 Hegarty, A. 34:221
 Heikkilä, L. 34:229
 Helmeste, D. 34:205
 Hichwa, R.D. 35:49
 Hicks, R. 31:39
 Hillaire, D. 34:77
 Hirschowitz, J. 35:39
 Hitzemann, R. 35:39
 Hoffman, A.R. 33:269
 Hoffman, H. 31:131
 Holland, T. 32:1
 Hollander, E. 31:211, 33:161
 Howson, A. 34:89
 Hsiao, J.K. 31:39
 Huber, G. 34:243
 Ihl, R. 33:107
 Inaba, T. 31:111
 Jain, A.K. 33:323
 Janowsky, D.S. 33:113, 33:139
 Jarrett, R.B. 33:285
 Jatlow, P.I. 33:51
 Javid, J.I. 32:9
 Jay, M. 34:77
 Jernej, B. 32:167
 Jernigan, T.L. 35:115
 Jimerson, D.C. 33:1
 Joffe, R.T. 32:241, 33:321
 John, E.R. 35:95
 Johnson, K.S. 34:127
 Jolkkonen, J. 33:307
 Joseph, K.C. 35:91
 Kahn, A.U. 33:313
 Kahn, J.P. 32:55
 Kahn, R.S. 31:179, 31:209, 33:189
 Kalus, O. 33:189
 Karlson, S. 35:27
 Kasper, S.F. 31:131
 Kathol, R.G. 32:151
 Katz, R.J. 31:121, 34:223
 Kay, S.R. 34:221
 Kaye, W.H. 33:1
 Keefe, R.S.E. 33:179
 Kelly, P. 34:89
 Kennedy, S. 33:59
 Kennedy, S.H. 32:221
 Kessler, R.C. 31:145
 Keysor, C.S. 33:83
 Khatami, M. 33:285
 Kiecolt-Glaser, J.K. 33:59
 Kim, A.H. 35:95
 Kim, M.Y. 32:29
 Kim, S.W. 34:99
 King, D.L. 32:55
 King, G. 33:301
 King, R. 32:45
 Kirkpatrick, B. 31:25
 Klein, D.F. 31:211, 32:55, 33:161
 Kleinman, J.E. 35:149
 Kling, A., 31:1
 Klosterkötter, J. 34:243
 Körner, J. 32:275
 Koeppe, R.A. 35:49
 Koponen, H. 33:307
 Korn, M. 32:191
 Kornhuber, J. 34:237
 Koslow, S.H. 32:71
 Kravitz, H.M. 32:141
 Kripke, D.F. 33:129, 33:135
 Kruesi, M.J.P. 32:99, 33:277
 Kuhl, D.E. 35:49
 Kuskowski, M. 34:99
 Lam, R.W. 33:129
 Lanczik, M. 34:259, 34:271
 Landau, P. 34:223
 Lane, E. 31:39
 Lasch, K. 33:31
 Lawrence, D. 31:57
 Lépine, J.-P. 34:77
 Leboyer, M. 34:77
 Leckman, J.F. 33:95
 Lee, M.A. 33:151
 Lenzenweger, M.F. 33:243
 Leon, A.C. 31:99
 Leonard, H. 33:277
 Leonard, M. 32:35
 Lesch, K.P. 33:107
 Levitt, A.J. 33:321
 Lewy, A.J. 32:183
 Lieberman, J.A. 35:1
 Liebowitz, M.R. 31:211, 32:55
 Lim, K.O. 35:15, 35:71
 Lin, M.C. 33:135
 Linnoila, M. 31:261, 33:215

- Little, K.Y. 32:19
 Logan, J. 35:39
 Loldrup, D. 32:29
 Lombrozo, L. 33:171
 Lousberg, H. 31:193
 Lucca, A. 32:63
 Maas, J.W. 32:71
 Macciardi, F. 32:63
 Macedo, C.A. 33:199
 Macher, J.-P. 35:107
 Maes, L. 34:29, 34:43, 34:59, 34:107
 Maes, M. 34:29, 34:43, 34:59, 34:107
 Maggioni, M. 32:229
 Magnani, A. 34:139
 Manevitz, A.Z.A. 34:127
 Mann, J.J. 31:99, 34:127
 Mann, N.A. 31:235
 Margraf, J. 32:45
 Marino, C. 32:63
 Markoff, E. 33:269
 Marks, B.H. 34:185
 Martin, M. 34:59, 34:107
 Massina, A. 34:127
 Maurer, K. 33:107, 34:237
 Mazure, C.M. 33:51
 Mazurek, M. 31:311
 McAllister, J.M. 32:125
 McAmis, W. 32:135
 McCance, S.L. 31:201
 McCracken, J.T. 31:49
 McFarlin, K.E. 32:99
 McGuffin, P. 35:61
 McLeod, J.D. 31:145
 McVey, G. 32:221
 Meares, R. 34:89
 Meinhold, M.S.H. 34:217
 Mellerup, E.T. 32:29
 Meltzer, H.Y. 32:265, 33:151, 34:139
 Mergenthaler, T. 34:237
 Merriam, A.E. 34:221
 Meschi, M. 34:13
 Mintz, M. 34:19
 Modell, J.G. 35:49
 Mohs, R.C. 33:179
 Mokrani, M.-C. 35:107
 Moldin, S.O. 32:297, 32:311, 33:243
 Monteleone, P. 33:259
 Moretti, C. 34:139
 Moses, J.A. 33:171
 Moskowitz, J. 33:179
 Müller, T. 34:259, 34:271
 Müller, U. 33:107
 Muench, J. 32:103
 Munjack, D.J. 32:35
 Murphy, G.M., Jr. 35:15
 Muscettola, G. 33:259
 Nadi, N.S. 32:99
 Nagamoto, H. 31:297
 Nash, J.F. 33:151
 Nasrallah, H.A. 31:15
 Nelson, J.C. 33:51
 Nerozzi, D. 34:139
 Newcomer, J.W. 31:243
 Nicholson, H. 32:201
 Nilsson, A. 35:27
 Nimgaonkar, V.L. 32:95
 Noyes, R., Jr. 32:151
 Nunes, E. 33:161
 Nurnberger, J.I., Jr. 31:57
 Nutt, D.J. 32:201
 O'Boyle, M. 32:85
 Olson, S.C. 31:15
 Opler, L.A. 34:221
 Overstreet, D.H. 33:139
 Oxenkrug, G.F. 34:185
 Palmer, R. 32:35
 Pandey, G.N. 32:9, 32:71
 Pandurangi, A.K. 33:11
 Panerai, A.E. 32:159
 Parienti, V. 32:221
 Parry, B.L. 33:135
 Peabody, C.A. 33:269
 Pedersen, C. 31:161
 Pellegrini, L. 34:13
 Pelonero, A.L. 33:11
 Perry, B.D. 34:193
 Persad, E. 33:101
 Petrie, E.C. 33:171
 Pfefferbaum, A. 35:15, 35:71, 35:115
 Pfüller, H. 34:259, 34:271
 Pickar, D. 33:259
 Pinchera, A. 34:13
 Placidi, G.F. 34:13
 Plenge, P. 32:29
 Plutchik, R. 32:191
 Pohl, R. 32:103, 32:93, 32:207
 Poland, R.E. 31:49
 Pols, H. 31:193
 Post, R.M. 31:251
 Potter, W.Z. 31:39
 Prichep, L.S. 35:95
 Propping, P. 32:275
 Prudic, J. 31:287
 Putnam, F.W. 31:251
 Putnam, K.M. 33:179
 Pylypiw, A. 33:323
 Quintana, J. 33:229
 Quitkin, F.M. 33:121, 33:161

- Raine, A. 31:85
 Rajendran, M.Y. 32:95
 Ramesh, C. 32:207
 Rao, M.L. 34:243
 Rapoport, J.L. 33:83, 33:277
 Ravitz, B. 33:215
 Ray-Prenger, C. 32:125
 Reich, J.H. 32:175, 33:207, 34:281
 Reikkinen, P.J. 33:307
 Reinikainen, K.J. 33:307
 Reinink, E. 32:113
 Reist, C. 33:221, 34:303, 34:315
 Remington, G. 33:101
 Rennie, C. 34:89
 Reus, V.I. 32:183
 Rezvani, A.H. 33:139
 Rhoades, H.M. 31:69
 Rice, J.P. 32:311
 Riddle, M.A. 33:95
 Riederer, P. 34:237, 34:259, 34:271
 Rimón, R. 34:229
 Risberg, J. 35:27
 Roberts, R.E. 31:69
 Rodriguez, G. 35:27
 Roffwarg, H.P. 33:285
 Rogeness, G.A. 33:199
 Rogers, S. 31:39
 Rosen, L.N. 31:131
 Rosenberg, R. 32:29
 Rosenblat, R. 33:101
 Rosenbloom, M.J. 35:115
 Rosenthal, N.E. 31:131
 Roth, W.T. 32:45
 Rothley, J.M. 35:49
 Roy, A. 31:31, 31:261, 33:215
 Roy, M. 31:31
 Rubin, R.T. 31:49
 Rubinow, D.R. 33:277
 Rupprecht, R. 33:107, 34:237
 Rush, A.J. 33:285
 Sacerdote, P. 32:159
 Sackeim, H.A. 31:287
 Scaramucci, E. 34:139
 Scarone, S. 32:159, 32:229
 Scharpé, S. 34:59
 Schepelern, S. 32:29
 Schlyer, D. 35:39
 Schneider, L.S. 33:19
 Schotte, C. 34:29, 34:43, 34:59, 34:107
 Schuff, N. 35:107
 Schulte, H.M. 33:107
 Schwarzkopf, S.B. 31:15
 Secunda, S. 32:71
 Self, D. 32:85
 Serafetinides, E.A. 34:163
 Serper, M.R. 32:281
 Severson, J.A. 33:19
 Sevy, S. 32:191
 Sforza, V. 34:139
 Sharma, R.P. 32:9
 Shekim, W.O. 32:125
 Sherman, T. 31:169
 Shibasaki, M. 31:111
 Sigal, M. 34:19
 Simmons-Alling, S. 31:57
 Singer, W. 32:241
 Sitaram, N. 35:91
 Smeraldi, E. 32:63
 Smith, J.E. 32:201
 Sobin, P. 32:35
 Sofic, E. 34:259, 34:271
 Someya, T. 31:111
 Souètre, E. 32:253
 Southwick, S.M. 34:193
 Sparks, D.L. 32:19
 Steinberg, A. 31:1
 Stevens, J.R. 35:149
 Stewart, J.W. 33:121
 Stoff, D.M. 33:323
 Strebel, B. 34:243
 Strijewski, A. 34:205
 Sucher, N. 34:213
 Sullivan, E.V. 35:115
 Sutphin, M.S. 31:1
 Sutton, L. 33:113
 Swann, A.C. 32:71
 Swedo, S. 33:277
 Sweeney, J.A. 31:99
 Szechtman, B. 31:311
 Takahashi, S. 31:111
 Taljaard, J.J.F. 31:217
 Tancer, M.E. 31:161
 Tandon, R. 31:235
 Tang, S.W. 31:111, 33:101, 34:205
 Targum, S.D. 31:131, 31:215
 Taylor, C.B. 32:45
 Terenius, L. 34:229
 Terman, J.S. 33:121
 Terman, M. 31:131, 33:121
 Tinklenberg, J.R. 35:115
 Todd, S. 33:313
 Tomei, L.D. 33:59
 Tomer, R. 32:289
 Toone, B.K. 35:61
 Torello, M. 31:15
 Tuma, I. 35:137
 Turnbull, J.E. 31:145
 Usigli, R. 32:35

- Van den Hoofdakker, R.H. 32:113, 34:149
Vandewoude, M. 34:59, 34:107
van Praag, H.M. 31:179, 31:209, 32:191, 33:189, 34:1
Venables, P.H. 31:85
Vernon, S.W. 31:69
Vitkun, S. 35:39
Volkow, N.D. 35:39
Wager, S. 33:161
Warkentin, S. 35:27
Warner, N.D. 33:269
Wehr, T.A. 32:253
Weissman, M. 33:31
Welch, B. 31:131
Westenberg, H.G.M. 31:267
Wetzler, S. 31:179, 33:189
Whatley, S.A. 32:95
Wickramaratne, P. 33:31
Williams, K. 32:201
Williams, M. 35:61
Wilner, P.J. 34:127
Wilson, D.M. 33:269
Wirz-Justice, A. 32:113
Wodarz, N. 34:237
Wolf, A.P. 35:39
Wong, J.T.F. 33:301
Wyatt, R.J. 31:221
Yeh, W. 31:243
Yehuda, R. 34:193
Yeragani, V.K. 32:93, 32:103, 32:207
Yesavage, J.A. 35:115
Yuwiler, A. 34:185
Zahn, T.P. 31:251
Zanardi, R. 32:63
Zandbergen, J. 31:193
Zipursky, R.B. 35:15, 35:71, 35:115
Zulueta, A. 32:35

Subject Index for 1990

Acetylserotonin

- cocaine treatment, rat pineal gland, 34:185
- melatonin, serotonin-*N*-acetyltransferase, 34:185
- rat pineal gland, cocaine treatment, 34:185
- serotonin-*N*-acetyltransferase, melatonin, 34:185

Adolescence

- affective disorders, rapid eye movement sleep, 33:307
- affective disorders, sex differences, 33:307
- rapid eye movement sleep, affective disorders, 33:307
- rapid eye movement sleep, sex differences, 33:307
- sex differences, rapid eye movement sleep, 33:307
- sleeping, affective disorders, 33:307

Adrenergic system

- affective disorder, affinity states, 34:193
- alpha-₂ receptors in platelets, affinity states, 34:193

Adrenocorticotrophic hormone

- affective disorder, bipolar, 31:57
- affective disorder, clomipramine, 31:39, 31:57, 34:107, 34:29, 34:59
- affective disorder, depressive symptoms, 34:59
- affective disorder, dexamethasone suppression test, 34:59, 34:107
- affective disorder, growth hormone, 31:39, 31:57
- affective disorder, heart rate, 31:39
- affective disorder, prolactin, 31:39, 31:57
- affective disorder, subtype diagnosis, 34:107
- affective disorder, thyroid stimulating hormone, 34:29, 34:59
- affective disorder, thyroxine, 34:29, 34:59
- affective disorder, tryptophan, 31:57, 34:29, 34:59
- affective disorder, vital depression, 34:29
- age, Alzheimer's disease, 34:237
- age, cortisol, 34:237
- age, glucocorticoid receptors, 34:237
- age, leukocytes, 34:237
- Alzheimer's disease, age, 34:237
- Alzheimer's disease, cortisol, 33:107, 34:237
- Alzheimer's disease, glucocorticoid receptors, 34:237

Adrenocorticotrophic hormone continued

- Alzheimer's disease, growth hormone, 33:107
- Alzheimer's disease, insulin-like growth factor, 33:107
- Alzheimer's disease, leukocytes, 34:237
- bipolar, affective disorder, 31:57
- bipolar, cortisol, 31:57
- bipolar, growth hormone, 31:57
- bipolar, prolactin, 31:57
- bipolar, tryptophan, 31:57
- clomipramine, affective disorder, 31:39
- clomipramine, cortisol, 31:39
- clomipramine, growth hormone response, 31:39
- clomipramine, heart rate, 31:39
- clomipramine, prolactin response, 31:39
- cortisol, affective disorder, 31:39, 31:57, 34:29, 34:59, 34:107
- cortisol, age, 34:237
- cortisol, Alzheimer's disease, 33:107, 34:237
- cortisol, bipolar, 31:57
- cortisol, clomipramine, 31:39
- cortisol, depressive symptoms, 34:59
- cortisol, dexamethasone suppression test, 31:31, 34:59, 34:107
- cortisol, duration of diabetes, 31:31
- cortisol, glucocorticoid receptors, 34:237
- cortisol, growth hormone, 31:39, 31:57, 33:107
- cortisol, heart rate, 31:39
- cortisol, insulin-like growth factor, 33:107
- cortisol, leukocytes, 34:237
- cortisol, prolactin, 31:39, 31:57
- cortisol, subtype diagnosis, 34:107
- cortisol, thyroid stimulating hormone, 34:29, 34:59
- cortisol, thyroxine, 34:29, 34:59
- cortisol, tryptophan, 31:57, 34:29, 34:59
- cortisol, vital depression, 34:29
- depressive symptoms, affective disorder, 34:59
- depressive symptoms, cortisol, 34:59
- depressive symptoms, dexamethasone suppression test, 34:59
- depressive symptoms, thyroid stimulating hormone, 34:59
- depressive symptoms, thyroxine, 34:59
- depressive symptoms, tryptophan, 34:59
- dexamethasone suppression test,

Adrenocorticotrophic hormone continued

affective disorder, 34:59, 34:107
 dexamethasone suppression test, cortisol, 31:31, 34:107, 34:59
 dexamethasone suppression test, depressive symptoms, 34:59
 dexamethasone suppression test, diabetes, 31:31
 dexamethasone suppression test, duration of diabetes, 31:31
 dexamethasone suppression test, subtype diagnosis, 34:107
 dexamethasone suppression test, thyroxine, 34:59
 dexamethasone suppression test, tryptophan, 34:59
 diabetes, cortisol, 31:31
 diabetes, dexamethasone suppression test, 31:31
 duration of diabetes, cortisol, 31:31
 duration of diabetes, dexamethasone suppression test, 31:31
 glucocorticoid receptors, age, 34:237
 glucocorticoid receptors, Alzheimer's disease, 34:237
 glucocorticoid receptors, cortisol, 34:237
 glucocorticoid receptors, leukocytes, 34:237
 growth hormone, affective disorder, 31:39, 31:57
 growth hormone, Alzheimer's disease, 33:107
 growth hormone, bipolar, 31:57
 growth hormone, cortisol, 31:39, 31:57, 33:107
 growth hormone, insulin-like growth factor, 33:107
 growth hormone, prolactin, 31:39, 31:57
 growth hormone response, clomipramine, 31:39
 growth hormone response, heart rate, 31:39
 growth hormone, tryptophan, 31:57
 heart rate, affective disorder, 31:39
 heart rate, clomipramine, 31:39
 heart rate, cortisol, 31:39
 heart rate, growth hormone response, 31:39
 heart rate, prolactin response, 31:39
 insulin-like growth factor, Alzheimer's disease, 33:107
 insulin-like growth factor, cortisol, 33:107
 insulin-like growth factor, growth hormone, 33:107
 leukocytes, age, 34:237

Adrenocorticotrophic hormone continued

leukocytes, Alzheimer's disease, 34:237
 leukocytes, cortisol, 34:237
 leukocytes, glucocorticoid receptors, 34:237
 prolactin, affective disorder, 31:39, 31:57
 prolactin, bipolar, 31:57
 prolactin, cortisol, 31:39, 31:57
 prolactin, growth hormone, 31:39, 31:57
 prolactin response, clomipramine, 31:39
 prolactin response, heart rate, 31:39
 prolactin, tryptophan, 31:57
 subtype diagnosis, affective disorder, 34:107
 subtype diagnosis, cortisol, 34:107
 subtype diagnosis, dexamethasone suppression test, 34:107
 thyroid stimulating hormone, affective disorder, 34:29, 34:59
 thyroid stimulating hormone, cortisol, 34:29, 34:59
 thyroid stimulating hormone, depressive symptoms, 34:59
 thyroid stimulating hormone, thyroxine, 34:29, 34:59
 thyroid stimulating hormone, tryptophan, 34:29, 34:59
 thyroid stimulating hormone, vital depression, 34:29
 thyroxine, affective disorder, 34:29, 34:59
 thyroxine, cortisol, 34:29, 34:59
 thyroxine, depressive symptoms, 34:59
 thyroxine, dexamethasone suppression test, 34:59
 thyroxine, tryptophan, 34:29, 34:59
 thyroxine, vital depression, 34:29
 tryptophan, affective disorder, 31:57, 34:29, 34:59
 tryptophan, bipolar, 31:57
 tryptophan, cortisol, 31:57, 34:29, 34:59
 tryptophan, depressive symptoms, 34:59
 tryptophan, dexamethasone suppression test, 34:59
 tryptophan, growth hormone, 31:57
 tryptophan, prolactin, 31:57
 tryptophan, thyroid stimulating hormone, 34:29, 34:59
 tryptophan, thyroxine, 34:29, 34:59
 tryptophan, vital depression, 34:29
 vital depression, affective disorder, 34:29
 vital depression, cortisol, 34:29
 vital depression, thyroid stimulating hormone, 34:29

Affective disorder

- adolescents, rapid eye movement sleep, 33:307
- adolescents, sex differences, 33:307
- adolescents, sleeping, 33:307
- adrenergic receptors, affinity states, 34:193
- adrenergic receptors, α_2 receptors in platelets, 34:193
- adrenocorticotrophic hormone, bipolar, 31:57
- adrenocorticotrophic hormone, clomipramine, 31:39
- adrenocorticotrophic hormone, cortisol, 31:39, 31:57, 34:107, 34:29, 34:59
- adrenocorticotrophic hormone, depressive symptoms, 34:59
- adrenocorticotrophic hormone, dexamethasone suppression test, 34:59, 34:107
- adrenocorticotrophic hormone, growth hormone, 31:39, 31:57
- adrenocorticotrophic hormone, heart rate, 31:39
- adrenocorticotrophic hormone, prolactin response, 31:39, 31:57
- adrenocorticotrophic hormone, subtype diagnosis, 34:107
- adrenocorticotrophic hormone, thyroid stimulating hormone, 34:29, 34:59
- adrenocorticotrophic hormone, thyroxine, 34:29, 34:59
- adrenocorticotrophic hormone, tryptophan, 31:57, 34:29, 34:59
- adrenocorticotrophic hormone, vital depression, 34:29
- affinity states, α_2 receptors in platelets, 34:193
- age, antidepressants, 33:51
- age, birth-cohort changes, 33:31
- age, circannual rhythms, 31:131
- age, epidemiology, 33:31
- age, growth hormone releasing hormone, 33:269
- age, growth hormone, 33:269
- age, imipramine binding in platelets, 32:29
- age, latitude, 31:131
- age, mania, 33:31
- age, panic disorder, 33:51
- age, psychogenic pain, 32:29
- age, treatment outcome, 33:51
- α_2 receptors in platelets, adrenergic receptors, 34:193
- α_2 receptors in platelets, affinity states, 34:193

Affective disorder continued

- amitriptyline, antidepressants, 31:201
- amitriptyline, Beck Depression Inventory, 31:201
- amitriptyline, growth hormone, 31:201
- amitriptyline, prolactin, 31:201
- amitriptyline, tryptophan, 31:201
- amitriptyline, weight loss, 31:201
- antidepressants, age, 33:51
- antidepressants, amitriptyline, 31:201
- antidepressants, Beck Depression Inventory, 31:201
- antidepressants, depressive mood, 32:241
- antidepressants, electroconvulsive therapy, 31:287
- antidepressants, growth hormone, 31:201
- antidepressants, panic disorder, 33:51
- antidepressants, personality disorder, 32:175
- antidepressants, pharmacotherapy response, 31:287
- antidepressants, prolactin, 31:201
- antidepressants, thyroxine, 32:241
- antidepressants, treatment outcome, 32:175, 33:51
- antidepressants, triiodothyronine, 32:241
- antidepressants, tryptophan, 31:201
- antidepressants, weight loss, 31:201
- anxiety symptoms, phosphate in serum, 31:217
- atypical depression, light therapy, 33:121
- atypical depression, seasonal affective disorder, 33:121
- Automatic Thoughts Questionnaire, unipolars, 33:39
- Beck Depression Inventory, antidepressants, 31:201
- Beck Depression Inventory, growth hormone, 31:201
- Beck Depression Inventory, prolactin, 31:201
- Beck Depression Inventory, tryptophan, 31:201
- Beck Depression Inventory, weight loss, 31:201
- binding sites, cortisol, 34:303
- binding sites, cyanoimipramine, 34:293
- binding sites, imipramine, 34:293, 34:293
- binding sites, treatment effects, 34:293
- bipolar, adrenocorticotrophic hormone, 31:57
- bipolar, cortisol, 31:57
- bipolar, growth hormone, 31:57
- bipolar, light therapy, 33:129
- bipolar, light effects, 33:129

Affective disorder continued

bipolar, melatonin, 33:129
 bipolar, prolactin, 31:57
 bipolar, rapid cyclers, 34:13
 bipolar, thyroid stimulating hormone, 34:13
 bipolar, triiodothyronine, 34:13
 bipolar, tryptophan, 31:57
 bipolar, unipolar, 33:129
 birth-cohort changes, age, 33:31
 birth-cohort changes, mania, 33:31
 blood pressure, catecholamines in plasma, 34:127
 blood pressure, electroconvulsive therapy, 34:127
 blood pressure, heart rate, 34:127
 catecholamines in plasma, blood pressure, 34:127
 catecholamines in plasma, electroconvulsive therapy, 34:127
 catecholamines in plasma, heart rate, 34:127
 caudate nucleus, endorphin, 32:159
 caudate nucleus, frontal lobe, 32:159
 caudate nucleus, hypothalamus, 32:159
 caudate nucleus, laterality, 32:159
 caudate nucleus, suicide, 32:159
 caudate nucleus, temporal lobe, 32:159
 CES-D Scale, Diagnostic Interview Schedule, 31:69
 CES-D Scale, generalized anxiety disorder, 31:69
 CES-D Scale, Mexican-Americans, 31:69
 children, heart rate, 33:199
 cholesterol in serum, imipramine effect, 32:207
 circannual rhythms, age, 31:131
 circannual rhythms, cyanoimipramine binding sites in platelets, 34:315
 circannual rhythms, imipramine, 34:315
 circannual rhythms, latitude, 31:131
 circannual rhythms, seasonal affective disorder, 32:253
 circannual rhythms, suicide, 32:253
 circannual rhythms, sunlight, 32:253
 circannual rhythms, weather, 32:253
 classification error, Diagnostic Interview Schedule, 31:145
 classification error, Research Diagnostic Criteria (RDC), 31:145
 classification error, SADS interview, 31:145
 clomipramine, adrenocorticotrophic hormone, 31:39

Affective disorder continued

clomipramine, cortisol, 31:39
 clomipramine, growth hormone response, 31:39
 clomipramine, heart rate, 31:39
 clomipramine, prolactin response, 31:39
 cortisol, adrenocorticotrophic hormone, 31:39, 31:57, 34:107, 34:29, 34:59
 cortisol, binding sites, 34:303
 cortisol, bipolar, 31:57
 cortisol, clomipramine, 31:39
 cortisol, depressive symptoms, 34:59
 cortisol, dexamethasone suppression test, 34:59, 34:107, 34:149
 cortisol, growth hormone, 31:39, 31:57
 cortisol, heart rate, 31:39
 cortisol, imipramine, 34:303
 cortisol, prolactin, 31:39, 31:57
 cortisol, sleep deprivation, 34:149
 cortisol, stress and arousal levels, 34:149
 cortisol, subtype diagnosis, 34:107
 cortisol, thyroid stimulating hormone, 34:29, 34:59
 cortisol, thyroxine, 34:29, 34:59
 cortisol, treatment effects, 34:303
 cortisol, tryptophan, 31:57, 34:29, 34:59
 cortisol, vital depression, 34:29
 cyanoimipramine binding sites in platelets, circannual rhythms, 34:315
 depressive mood, antidepressant treatment, 32:241
 depressive mood, desimipramine, 33:101
 depressive mood, diurnal rhythms, 32:113
 depressive mood, follicle stimulating hormone, 32:229
 depressive mood, luteinizing hormone, 32:229
 depressive mood, menopause, 32:229
 depressive mood, propranolol, 33:101
 depressive mood, sleep deprivation, 32:113
 depressive mood, thyroxine, 32:241
 depressive mood, treatment response, 33:101
 depressive mood, triiodothyronine, 32:241
 depressive symptoms, adrenocorticotrophic hormone, 34:59
 depressive symptoms, cortisol, 34:59
 depressive symptoms, dexamethasone suppression test, 34:59
 depressive symptoms, thyroid stimulating hormone, 34:59
 depressive symptoms, thyroxine, 34:59
 depressive symptoms, tryptophan, 34:59
 desimipramine, depressive mood, 33:101
 desimipramine, propranolol, 33:101

Affective disorder continued

desimipramine, treatment response, 33:101
 dexamethasone concentration in serum,
 dexamethasone suppression test, 31:49
 dexamethasone concentration in serum,
 receiver operating characteristic, 31:49
 dexamethasone suppression test,
 adrenocorticotrophic hormone, 34:59,
 34:107
 dexamethasone suppression test, cortisol,
 34:59, 34:107, 34:149
 dexamethasone suppression test,
 depressive symptoms, 34:59
 dexamethasone suppression test,
 dexamethasone concentration in serum,
 31:49
 dexamethasone suppression test, lithium
 pharmacokinetics, 32:71
 dexamethasone suppression test, receiver
 operating characteristic analysis, 31:49
 dexamethasone suppression test, sleep
 deprivation, 34:149
 dexamethasone suppression test, stress and
 arousal levels, 34:149
 dexamethasone suppression test, subtype
 diagnosis, 34:107
 dexamethasone suppression test, thyroid
 stimulating hormone, 34:59
 dexamethasone suppression test,
 thyroxine, 34:59
 dexamethasone suppression test,
 tryptophan, 34:59
 Diagnostic Interview Schedule, CES-D
 Scale, 31:69
 Diagnostic Interview Schedule,
 classification error, 31:145
 Diagnostic Interview Schedule, generalized
 anxiety disorder, 31:69
 Diagnostic Interview Schedule, Mexican-
 Americans, 31:69
 Diagnostic Interview Schedule, Research
 Diagnostic Criteria (RDC), 31:145
 Diagnostic Interview Schedule, SADS
 interview, 31:145
 diurnal rhythms, depressed mood, 32:113
 diurnal rhythms, sleep deprivation, 32:113
 effortful cognition, memory performance,
 31:161
 effortful cognition, neuropsychological
 performance, 31:161
 electroconvulsive therapy, antidepressants,
 31:287
 electroconvulsive therapy, blood pressure,
 34:127

Affective disorder continued

electroconvulsive therapy, catecholamines
 in plasma, 34:127
 electroconvulsive therapy, heart rate,
 34:127
 electroconvulsive therapy, oxytocin, 32:201
 electroconvulsive therapy,
 pharmacotherapy response, 31:287
 electroconvulsive therapy, vasopressin,
 32:201
 endorphin, caudate nucleus, 32:159
 endorphin, frontal lobe, 32:159
 endorphin, hypothalamus, 32:159
 endorphin, laterality, 32:159
 endorphin, suicide, 32:159
 endorphin, temporal lobe, 32:159
 epidemiology, age, 33:31
 epidemiology, birth-cohort changes, 33:31
 epidemiology, mania, 33:31
 follicle stimulating hormone, depressive
 mood, 32:229
 follicle stimulating hormone, luteinizing
 hormone, 32:229
 follicle stimulating hormone, menopause,
 32:229
 frontal lobe, caudate nucleus, 32:159
 frontal lobe, endorphin, 32:159
 frontal lobe, laterality, 32:159
 frontal lobe, suicide, 32:159
 generalized anxiety disorder, CES-D Scale,
 31:69
 generalized anxiety disorder, Diagnostic
 Interview Schedule, 31:69
 generalized anxiety disorder, Mexican-
 Americans, 31:69
 genetics, rapid eye movement sleep, 33:39
 genetics, restriction fragment length
 polymorphism, 32:275
 genetics, risk factors, 33:39
 genetics, tyrosine hydroxylase, 32:275
 growth hormone, adrenocorticotrophic
 hormone, 31:39, 31:57
 growth hormone, age, 33:269
 growth hormone, antidepressants, 31:201
 growth hormone, Beck Depression
 Inventory, 31:201
 growth hormone, bipolar, 31:57
 growth hormone, clomipramine, 31:39
 growth hormone, cortisol, 31:39, 31:57
 growth hormone, growth hormone
 releasing hormone, 33:269
 growth hormone, heart rate, 31:39
 growth hormone, prolactin, 31:39, 31:57,
 31:201

Affective disorder continued

growth hormone releasing hormone, age, 33:269
 growth hormone releasing hormone, growth hormone, 33:269
 growth hormone, tryptophan, 31:57, 31:201
 growth hormone, weight loss, 31:201
 heart rate, children, 33:199
 heart rate, adrenocorticotrophic hormone, 31:39
 heart rate, blood pressure, 34:127
 heart rate, catecholamines in plasma, 34:127
 heart rate, clomipramine, 31:39
 heart rate, cortisol, 31:39
 heart rate, electroconvulsive therapy, 34:127
 heart rate, growth hormone response, 31:39
 heart rate, prolactin response, 31:39
 heart rate, tryptophan, 31:57
 hypothalamus, endorphin, 32:159
 hypothalamus, laterality, 32:159
 hypothalamus, suicide, 32:159
 imipramine, binding sites, 34:293, 34:303
 imipramine binding, imipramine treatment, 33:229
 imipramine binding in platelets, age, 32:29
 imipramine binding in platelets, psychogenic pain, 32:29
 imipramine binding, monoamine oxidase in platelets, 33:229
 imipramine, circannual rhythms, 34:315
 imipramine, cortisol, 34:303
 imipramine, cyanoimipramine binding sites in platelets, 34:315
 imipramine effect, cholesterol in serum, 32:207
 imipramine, treatment effects, 34:303
 imipramine treatment, imipramine binding, 33:229
 imipramine treatment, monoamine oxidase in platelets, 33:229
 laterality, caudate nucleus, 32:159
 laterality, endorphin, 32:159
 laterality, frontal lobe, 32:159
 laterality, hypothalamus, 32:159
 laterality, suicide, 32:159
 laterality, temporal lobe, 32:159
 latitude, age, 31:131
 latitude, circannual rhythms, 31:131
 light effects, bipolar, 33:129
 light effects, melatonin, 33:129
 light effects, unipolar, 33:129

Affective disorder continued

light therapy, atypical depression, 33:121
 light therapy, bipolar, 33:129
 light therapy, melatonin, 33:129
 light therapy, seasonal affective disorder, 33:121
 light therapy, unipolar, 33:129
 lithium pharmacokinetics, dexamethasone suppression test, 32:71
 lithium pharmacokinetics, red blood cell distribution, 32:71
 lithium treatment, sex hormone binding globulin, 34:13
 lithium treatment, triiodothyronine and thyroxine, 34:13
 luteinizing hormone, depressive mood, 32:229
 luteinizing hormone, follicle stimulating hormone, 32:229
 luteinizing hormone, menopause, 32:229
 mania, age, 33:31
 mania, birth-cohort changes, 33:31
 mania, epidemiology, 33:31
 melatonin, bipolar, 33:129
 melatonin, light effects, 33:129
 melatonin, light therapy, 33:129
 melatonin, unipolar, 33:129
 memory performance, effortful cognition, 31:161
 memory performance, neuropsychological performance, 31:161
 menopause, depressive mood, 32:229
 menopause, follicle stimulating hormone, 32:229
 menopause, luteinizing hormone, 32:229
 Mexican-Americans, CES-D Scale, 31:69
 Mexican-Americans, Diagnostic Interview Schedule, 31:69
 Mexican-Americans, generalized anxiety disorder, 31:69
 Millon Clinical Multiaxial Inventory, panic disorder, 31:179
 Millon Clinical Multiaxial Inventory, personality disorder, 31:179
 monoamine oxidase in platelets, imipramine binding, 33:229
 monoamine oxidase in platelets, imipramine treatment, 33:229
 motor activity, sleep deprivation, 34:213
 motor activity, thyroid stimulating hormone, 34:213
 motor activity, triiodothyronine, 34:213
 neuropsychological performance, effortful cognition, 31:161

Affective disorder continued

neuropsychological performance, memory performance, 31:161
 oxytocin, electroconvulsive therapy, 32:201
 oxytocin, vasopressin, 32:201
 panic disorder, age, 33:51
 panic disorder, antidepressants, 32:175, 33:51
 panic disorder, Millon Clinical Multiaxial Inventory, 31:179
 panic disorder, personality disorder, 31:179
 panic disorder, Symptom Checklist-90, 31:179
 panic disorder, treatment outcome, 33:51
 personality disorder, panic disorder, 31:179
 personality disorder, Symptom Checklist-90, 31:179
 personality disorder, treatment outcome, 32:175
 pharmacotherapy response, antidepressants, 31:287
 pharmacotherapy response, electroconvulsive therapy, 31:287
 phosphate in serum, anxiety symptoms, 31:217
 prolactin, adrenocorticotrophic hormone, 31:39, 31:57
 prolactin, amitriptyline, 31:201
 prolactin, antidepressants, 31:201
 prolactin, Beck Depression Inventory, 31:201
 prolactin, bipolar, 31:57
 prolactin, clomipramine, 31:39
 prolactin, cortisol, 31:39, 31:57
 prolactin, growth hormone, 31:39, 31:57, 31:201
 prolactin, heart rate, 31:39
 prolactin, tryptophan, 31:57, 31:201
 prolactin, weight loss, 31:201
 propranolol, depressive mood, 33:101
 propranolol, desimipramine, 33:101
 propranolol, treatment response, 33:101
 psychogenic pain, age, 32:29
 psychogenic pain, imipramine binding in platelets, 32:29
 psychotherapy, rapid eye movement sleep, 33:285
 psychotherapy, sleeping, 33:285
 psychotherapy, treatment outcome, 33:285
 psychotic depression, thyroid hormone, 33:321
 psychotic depression, triiodothyronine, 33:321
 rapid cyclers, bipolar, 34:13

Affective disorder continued

rapid cyclers, thyroid stimulating hormone 34:13
 rapid cyclers, triiodothyronine, 34:13
 rapid eye movement sleep, adolescents, 33:307
 rapid eye movement sleep, genetics, 33:39
 rapid eye movement sleep, psychotherapy, 33:285
 rapid eye movement sleep, risk factors, 33:39
 rapid eye movement sleep, sex differences, 33:307
 rapid eye movement sleep, sleeping, 33:285, 33:307
 rapid eye movement sleep, treatment outcome, 33:285
 red blood cell distribution, lithium pharmacokinetics, 32:71
 Research Diagnostic Criteria (RDC), classification error, 31:145
 Research Diagnostic Criteria (RDC), Diagnostic Interview Schedule, 31:145
 Research Diagnostic Criteria (RDC), SADS interview, 31:145
 restriction fragment length polymorphism, genetics, 32:275
 restriction fragment length polymorphism, tyrosine hydroxylase, 32:275
 risk factors, genetics, 33:39
 risk factors, rapid eye movement sleep, 33:39
 risk factors, suicide, 31:99
 SADS interview, classification error, 31:145
 SADS interview, Diagnostic Interview Schedule, 31:145
 SADS interview, Research Diagnostic Criteria (RDC), 31:145
 seasonal affective disorder, atypical depression, 33:121
 seasonal affective disorder, circannual rhythms, 32:253
 seasonal affective disorder, light therapy, 33:121
 seasonal affective disorder, suicide, 32:253
 seasonal affective disorder, sunlight, 32:253
 seasonal affective disorder, weather, 32:253
 sex differences, adolescents, 33:307
 sex differences, rapid eye movement sleep, 33:307
 sex differences, sleeping, 33:307
 sex hormone binding globulin, lithium treatment, 34:13

Affective disorder continued

sex hormone binding globulin,
 triiodothyronine and thyroxine, 34:13
 sleep deprivation, cortisol, 34:149
 sleep deprivation, depressed mood, 32:113
 sleep deprivation, dexamethasone
 suppression test, 34:149
 sleep deprivation, diurnal rhythms, 32:113
 sleep deprivation, motor activity, 34:213
 sleep deprivation, stress and arousal levels,
 34:149
 sleep deprivation, thyroid stimulating
 hormone, 34:213
 sleep deprivation, triiodothyronine, 34:213
 sleeping, adolescents, 33:307
 sleeping, psychotherapy, 33:285
 sleeping, rapid eye movement sleep, 33:285,
 33:307
 sleeping, sex differences, 33:307
 sleeping, treatment outcome, 33:285
 stress and arousal levels, cortisol, 34:149
 stress and arousal levels, dexamethasone
 suppression test, 34:149
 stress and arousal levels, sleep deprivation,
 34:149
 subtype diagnosis, adrenocorticotrophic
 hormone, 34:107
 subtype diagnosis, cortisol, 34:107
 subtype diagnosis, dexamethasone
 suppression test, 34:107
 suicide, caudate nucleus, 32:159
 suicide, circannual rhythms, 32:253
 suicide, endorphin, 32:159
 suicide, frontal lobe, 32:159
 suicide, hypothalamus, 32:159
 suicide, laterality, 32:159
 suicide, risk factors, 31:99
 suicide, seasonal affective disorder, 32:253
 suicide, sunlight, 32:253
 suicide, temporal lobe, 32:159
 suicide, weather, 32:253
 sunlight, circannual rhythms, 32:253
 sunlight, seasonal affective disorder, 32:253
 sunlight, suicide, 32:253
 sunlight, weather, 32:253
 Symptom Checklist-90, panic disorder,
 31:179
 Symptom Checklist-90, personality
 disorder, 31:179
 symptom clustering, vital depression, 34:43
 temporal lobe, caudate nucleus, 32:159
 temporal lobe, endorphin, 32:159
 temporal lobe, frontal lobe, 32:159

Affective disorder continued

temporal lobe, hypothalamus, 32:159
 temporal lobe, laterality, 32:159
 temporal lobe, suicide, 32:159
 thyroid hormone, psychotic depression,
 33:321
 thyroid hormone, triiodothyronine, 33:321
 thyroid stimulating hormone, adreno-
 corticotrophic hormone, 34:29, 34:59
 thyroid stimulating hormone, bipolar,
 34:13
 thyroid stimulating hormone, cortisol,
 34:29, 34:59
 thyroid stimulating hormone, depressive
 symptoms, 34:59
 thyroid stimulating hormone,
 dexamethasone suppression test, 34:59
 thyroid stimulating hormone, motor
 activity, 34:213
 thyroid stimulating hormone, rapid cyclers,
 34:13
 thyroid stimulating hormone, sleep
 deprivation, 34:213
 thyroid stimulating hormone, thyroxine,
 34:29, 34:59
 thyroid stimulating hormone,
 triiodothyronine, 34:13, 34:213
 thyroid stimulating hormone, tryptophan,
 34:29, 34:59
 thyroid stimulating hormone, vital
 depression, 34:29
 thyroxine, adrenocorticotrophic hormone,
 34:29, 34:59
 thyroxine, antidepressant treatment,
 32:241
 thyroxine, cortisol, 34:29, 34:59
 thyroxine, depressive mood, 32:241
 thyroxine, depressive symptoms, 34:59
 thyroxine, dexamethasone suppression
 test, 34:59
 thyroxine, thyroid stimulating hormone,
 34:29, 34:59
 thyroxine, thyroxine-binding globulin,
 34:13
 thyroxine, triiodothyronine, 32:241
 thyroxine, tryptophan, 34:29, 34:59
 thyroxine, vital depression, 34:29
 thyroxine-binding globulin, thyroxine,
 34:13
 treatment effects, binding sites, 34:303
 treatment effects, cortisol, 34:303
 treatment effects, imipramine, 34:303
 treatment outcome, age, 33:51

Affective disorder continued

- treatment outcome, antidepressants, 32:175, 33:51
- treatment outcome, panic disorder, 33:51
- treatment outcome, personality disorder, 32:175
- treatment outcome, psychotherapy, 33:285
- treatment outcome, rapid eye movement sleep, 33:285
- treatment outcome, sleeping, 33:285
- treatment response, depressive mood, 33:101
- treatment response, desimipramine, 33:101
- treatment response, propranolol, 33:101
- triiodothyronine, antidepressant treatment, 32:241
- triiodothyronine, bipolar, 34:13
- triiodothyronine, depressive mood, 32:241
- triiodothyronine, motor activity, 34:213
- triiodothyronine, psychotic depression, 33:321
- triiodothyronine, rapid cyclers, 34:13
- triiodothyronine, sleep deprivation, 34:213
- triiodothyronine, thyroid hormone, 33:321
- triiodothyronine, thyroid stimulating hormone, 34:13, 34:213
- triiodothyronine, thyroxine, 32:241
- triiodothyronine, thyroxine, lithium treatment, 34:13
- triiodothyronine, thyroxine, sex hormone binding globulin, 34:13
- tryptophan, adrenocorticotrophic hormone, 31:57, 34:29, 34:59
- tryptophan, amitriptyline, 31:201
- tryptophan, antidepressants, 31:201
- tryptophan, Beck Depression Inventory, 31:201
- tryptophan, bipolar, 31:57
- tryptophan, cortisol, 31:57, 34:29, 34:59
- tryptophan, depressive symptoms, 34:59
- tryptophan, dexamethasone suppression test, 34:59
- tryptophan, growth hormone, 31:57, 31:201
- tryptophan, heart rate, 31:57
- tryptophan, prolactin, 31:57, 31:201
- tryptophan, thyroid stimulating hormone, 34:29, 34:59
- tryptophan, thyroxine, 34:29, 34:59
- tryptophan, vital depression, 34:29
- tryptophan, weight loss, 31:201
- tyrosine hydroxylase, genetics, 32:275
- tyrosine hydroxylase, restriction fragment length polymorphism, 32:275

Affective disorder continued

- unipolar, Automatic Thoughts Questionnaire, 33:39
- unipolar, light effects, 33:129
- unipolar, light therapy, 33:129
- unipolar, melatonin, 33:129
- vasopressin, electroconvulsive therapy, 32:201
- vasopressin, oxytocin, 32:201
- vital depression, adrenocorticotrophic hormone, 34:29
- vital depression, cortisol, 34:29
- vital depression, symptom clustering, 34:43
- vital depression, thyroid stimulating hormone, 34:29
- vital depression, thyroxine, 34:29
- vital depression, tryptophan, 34:29
- weather, circannual rhythms, 32:253
- weather, seasonal affective disorder, 32:253
- weather, suicide, 32:253
- weather, sunlight, 32:253
- weight loss, amitriptyline, 31:201
- weight loss, antidepressants, 31:201
- weight loss, Beck Depression Inventory, 31:201
- weight loss, growth hormone, 31:201
- weight loss, prolactin, 31:201
- weight loss, tryptophan, 31:201

Age

- admixture analysis, computed tomography, 35:61
- admixture analysis, schizophrenia, 35:61
- admixture analysis, ventricle-brain ratio, 35:61
- adrenocorticotrophic hormone, Alzheimer's disease, 34:237
- adrenocorticotrophic hormone, cortisol, 34:237
- adrenocorticotrophic hormone, dexamethasone suppression test, 34:107
- adrenocorticotrophic hormone, glucocorticoid receptors, 34:237
- adrenocorticotrophic hormone, leukocytes, 34:237
- affective disorder, antidepressants, 33:51
- affective disorder, circannual rhythms, 31:131
- affective disorder, growth hormone, 33:269
- affective disorder, growth hormone releasing hormone, 33:269
- affective disorder, imipramine binding in platelets, 32:29

Age continued

affective disorder, latitude, 31:131
 affective disorder, panic disorder, 33:51
 affective disorder, psychogenic pain, 32:29
 affective disorder, treatment outcome, 33:51
 affective illness, birth-cohort changes, 33:31
 affective illness, epidemiology, 33:31
 affective illness, mania, 33:31
 alcoholism, corticotropin releasing hormone, 31:261
 alcoholism, diazepam binding inhibitor in CSF, 31:261
 Alzheimer's disease, adrenocorticotrophic hormone, 34:237
 Alzheimer's disease, cortisol, 34:237
 Alzheimer's disease, glucocorticoid receptors, 34:237
 Alzheimer's disease, leukocytes, 34:237
 antidepressants, affective disorder, 33:51
 antidepressants, panic disorder, 33:51
 antidepressants, treatment outcome, 33:51
 anxiety, glucose metabolic rate, 35:49
 anxiety, positron emission tomography, 35:49
 anxiety, sex differences, 35:49
 attentional performance, schizophrenic children, 31:169
 birth-cohort changes, affective illness, 33:31
 birth-cohort changes, epidemiology, 33:31
 birth-cohort changes, mania, 33:31
 brain atrophy, duration of illness, 31:1
 circannual rhythms, affective disorder, 31:131
 circannual rhythms, latitude, 31:131
 computed tomography, ventricles, 35:115
 computed tomography, admixture analysis, 35:61
 computed tomography, glutathione peroxidase, 31:1
 computed tomography, monoamine oxidase, 31:1
 computed tomography, neuroleptics, 31:1
 computed tomography, schizophrenia, 31:1, 35:61
 computed tomography, third ventricle, 31:1
 computed tomography, ventricle-brain ratio, 31:1, 35:61
 computed tomography, volumetric measurement, 35:115
 conduct disorder, heart rate, 33:199

Age continued

conduct disorder, separation anxiety, 33:199
 corticotropin releasing hormone, alcoholism, 31:261
 corticotropin releasing hormone, diazepam binding inhibitor in CSF, 31:261
 cortisol, adrenocorticotrophic hormone, 34:237
 cortisol, Alzheimer's disease, 34:237
 cortisol, glucocorticoid receptors, 34:237
 cortisol, leukocytes, 34:237
 depression, schizophrenia, 31:243
 dexamethasone suppression test, adrenocorticotrophic hormone, 34:107
 diazepam binding inhibitor in CSF, alcoholism, 31:261
 diazepam binding inhibitor in CSF, corticotropin releasing hormone, 31:261
 duration of illness, brain atrophy, 31:1
 epidemiology, affective illness, 33:31
 epidemiology, birth-cohort changes, 33:31
 epidemiology, mania, 33:31
 eye tracking, Scale for the Assessment of Negative Symptoms, 34:89
 eye tracking, schizophrenia, 34:89
 glucocorticoid receptors, adrenocorticotrophic hormone, 34:237
 glucocorticoid receptors, Alzheimer's disease, 34:237
 glucocorticoid receptors, cortisol, 34:237
 glucocorticoid receptors, leukocytes, 34:237
 glucose metabolic rate, anxiety, 35:49
 glucose metabolic rate, positron emission tomography, 35:49
 glucose metabolic rate, sex differences, 35:49
 glutathione peroxidase, computed tomography, 31:1
 glutathione peroxidase, monoamine oxidase, 31:1
 glutathione peroxidase, neuroleptics, 31:1
 glutathione peroxidase, schizophrenia, 31:1
 glutathione peroxidase, third ventricle, 31:1
 glutathione peroxidase, ventricle-brain ratio, 31:1
 growth hormone, affective disorder, 33:269
 growth hormone, growth hormone releasing hormone, 33:269
 growth hormone, schizophrenia, 33:269
 growth hormone releasing hormone, affective disorder, 33:269

Age continued

growth hormone releasing hormone, growth hormone, 33:269
 growth hormone releasing hormone, schizophrenia, 33:269
 heart rate, conduct disorder, 33:199
 heart rate, separation anxiety, 33:199
 imipramine binding in platelets, affective disorder, 32:29
 imipramine binding in platelets, psychogenic pain, 32:29
 intracranial volume, limbic system, 35:15
 intracranial volume, magnetic resonance imaging, 35:15
 intracranial volume, temporal lobe, 35:15
 intracranial volume, ventricular volume, 35:15
 intracranial volume, volume reduction, 35:15
 latitude, affective disorder, 31:131
 latitude, circannual rhythms, 31:131
 leukocytes, adrenocorticotrophic hormone, 34:237
 leukocytes, Alzheimer's disease, 34:237
 leukocytes, cortisol, 34:237
 leukocytes, glucocorticoid receptors, 34:237
 limbic system, intracranial volume, 35:15
 limbic system, magnetic resonance imaging, 35:15
 limbic system, temporal lobe, 35:15
 limbic system, ventricular volume, 35:15
 limbic system, volume reduction, 35:15
 magnetic resonance imaging, intracranial volume, 35:15
 magnetic resonance imaging, limbic system, 35:15
 magnetic resonance imaging, temporal lobe, 35:15
 magnetic resonance imaging, ventricular volume, 35:15
 magnetic resonance imaging, volume reduction, 35:15
 mania, affective illness, 33:31
 mania, birth-cohort changes, 33:31
 mania, epidemiology, 33:31
 3-methoxy-4-hydroxyphenylglycol, phenylethylamine, 31:279
 3-methoxy-4-hydroxyphenylglycol, Tourette's syndrome, 31:279
 monoamine oxidase, computed tomography, 31:1

Age continued

monoamine oxidase, glutathione peroxidase, 31:1
 monoamine oxidase, neuroleptics, 31:1
 monoamine oxidase, schizophrenia, 31:1
 monoamine oxidase, third ventricle, 31:1
 monoamine oxidase, ventricle-brain ratio, 31:1
 neuroleptics, computed tomography, 31:1
 neuroleptics, glutathione peroxidase, 31:1
 neuroleptics, monoamine oxidase, 31:1
 neuroleptics, schizophrenia, 31:1
 neuroleptics, third ventricle, 31:1
 neuroleptics, ventricle-brain ratio, 31:1
 panic disorder, affective disorder, 33:51
 panic disorder, antidepressants, 33:51
 panic disorder, treatment outcome, 33:51
 phenylethylamine, 3-methoxy-4-hydroxyphenylglycol, 31:279
 phenylethylamine, Tourette's syndrome, 31:279
 positron emission tomography, anxiety, 35:49
 positron emission tomography, glucose metabolic rate, 35:49
 positron emission tomography, sex differences, 35:49
 psychogenic pain, affective disorder, 32:29
 psychogenic pain, imipramine binding in platelets, 32:29
 Scale for the Assessment of Negative Symptoms, eye tracking, 34:89
 Scale for the Assessment of Negative Symptoms, schizophrenia, 34:89
 schizophrenia, admixture analysis, 35:61
 schizophrenia, computed tomography, 31:1, 35:61
 schizophrenia, depression, 31:243
 schizophrenia, eye tracking, 34:89
 schizophrenia, glutathione peroxidase, 31:1
 schizophrenia, growth hormone, 33:269
 schizophrenia, growth hormone releasing hormone, 33:269
 schizophrenia, monoamine oxidase, 31:1
 schizophrenia, neuroleptics, 31:1
 schizophrenia, Scale for the Assessment of Negative Symptoms, 34:89
 schizophrenia, third ventricle, 31:1
 schizophrenia, ventricle-brain ratio, 31:1, 35:61
 schizophrenic children, attentional performance, 31:169

Age continued

- separation anxiety, conduct disorder, 33:199
- separation anxiety, heart rate, 33:199
- sex differences, anxiety, 35:49
- sex differences, glucose metabolic rate, 35:49
- sex differences, positron emission tomography, 35:49
- temporal lobe, intracranial volume, 35:15
- temporal lobe, limbic system, 35:15
- temporal lobe, magnetic resonance imaging, 35:15
- temporal lobe, ventricular volume, 35:15
- temporal lobe, volume reduction, 35:15
- third ventricle, computed tomography, 31:1
- third ventricle, glutathione peroxidase, 31:1
- third ventricle, monoamine oxidase, 31:1
- third ventricle, neuroleptics, 31:1
- third ventricle, schizophrenia, 31:1
- third ventricle, ventricle-brain ratio, 31:1
- Tourette's syndrome, 3-methoxy-4-hydroxyphenylglycol, 31:279
- Tourette's syndrome, phenylethylamine, 31:279
- treatment outcome, affective disorder, 33:51
- treatment outcome, antidepressants, 33:51
- treatment outcome, panic disorder, 33:51
- ventricle, computed tomography, 35:115
- ventricle, volumetric measurement, 35:115
- ventricle-brain ratio, admixture analysis, 35:61
- ventricle-brain ratio, computed tomography, 31:1, 35:61
- ventricle-brain ratio, glutathione peroxidase, 31:1
- ventricle-brain ratio, monoamine oxidase, 31:1
- ventricle-brain ratio, neuroleptics, 31:1
- ventricle-brain ratio, schizophrenia, 31:1, 35:61
- ventricle-brain ratio, third ventricle, 31:1
- ventricular volume, intracranial volume, 35:15
- ventricular volume, limbic system, 35:15
- ventricular volume, magnetic resonance imaging, 35:15
- ventricular volume, temporal lobe, 35:15
- ventricular volume, volume reduction, 35:15

Age continued

- volumetric measurement, computed tomography, 35:115

Alcoholism

- age, corticotropin releasing hormone, 31:261
- age, diazepam binding inhibitor in CSF, 31:261
- apomorphine, cocaine, 33:151
- apomorphine, growth hormone, 33:151
- apomorphine, prolactin, 33:151
- apomorphine, substance abuse, 33:151
- benzodiazepine receptors, ethanol, 35:39
- benzodiazepine receptors, fluorodeoxyglucose, 35:39
- benzodiazepine receptors, frontal lobe, 35:39
- benzodiazepine receptors, positron emission tomography, 35:39
- cerebrospinal fluid, corticotropin releasing hormone, 33:215
- cerebrospinal fluid, growth hormone releasing hormone, 33:215
- cerebrospinal fluid, neuropeptide Y, 33:215
- cerebrospinal fluid, somatostatin, 33:215
- cocaine, apomorphine, 33:151
- cocaine, growth hormone, 33:151
- cocaine, prolactin, 33:151
- cocaine, substance abuse, 33:151
- corticotropin releasing hormone, age, 31:261
- corticotropin releasing hormone, cerebrospinal fluid, 33:215
- corticotropin releasing hormone, diazepam binding inhibitor in CSF, 31:261
- corticotropin releasing hormone, growth hormone releasing hormone, 33:215
- corticotropin releasing hormone, neuropeptide Y, 33:215
- corticotropin releasing hormone, somatostatin, 33:215
- diazepam binding inhibitor in CSF, age, 31:261
- diazepam binding inhibitor in CSF, corticotropin releasing hormone, 31:262
- ethanol, benzodiazepine receptors, 35:39
- ethanol, fluorodeoxyglucose, 35:39
- ethanol, frontal lobe, 35:39
- ethanol, positron emission tomography, 35:39
- fluorodeoxyglucose, benzodiazepine receptors, 35:39

Alcoholism continued

- fluorodeoxyglucose, ethanol, 35:39
- fluorodeoxyglucose, frontal lobe, 35:39
- fluorodeoxyglucose, positron emission tomography, 35:39
- frontal lobe, benzodiazepine receptors, 35:39
- frontal lobe, ethanol, 35:39
- frontal lobe, fluorodeoxyglucose, 35:39
- frontal lobe, positron emission tomography, 35:39
- growth hormone, apomorphine, 33:151
- growth hormone, cocaine, 33:151
- growth hormone, prolactin, 33:151
- growth hormone releasing hormone, cerebrospinal fluid, 33:215
- growth hormone releasing hormone, corticotropin releasing hormone, 33:215
- growth hormone releasing hormone, neuropeptide Y, 33:215
- growth hormone releasing hormone, somatostatin, 33:215
- growth hormone, substance abuse, 33:151
- neuropeptide Y, cerebrospinal fluid, 33:215
- neuropeptide Y, corticotropin releasing hormone, 33:215
- neuropeptide Y, growth hormone releasing hormone, 33:215
- neuropeptide Y, somatostatin, 33:215
- positron emission tomography, benzodiazepine receptors, 35:39
- positron emission tomography, ethanol, 35:39
- positron emission tomography, fluorodeoxyglucose, 35:39
- positron emission tomography, frontal lobe, 35:39
- prolactin, apomorphine, 33:151
- prolactin, cocaine, 33:151
- prolactin, growth hormone, 33:151
- prolactin, substance abuse, 33:151
- somatostatin, cerebrospinal fluid, 33:215
- somatostatin, corticotropin releasing hormone, 33:215
- somatostatin, growth hormone releasing hormone, 33:215
- somatostatin, neuropeptide Y, 33:215
- substance abuse, apomorphine, 33:151
- substance abuse, cocaine, 33:151
- substance abuse, growth hormone, 33:151
- substance abuse, prolactin, 33:151

Alpha₂-adrenergic receptor

- Minnesota Multiphasic Personality Inventory, normal volunteers, 32:125
- normal volunteers, Minnesota Multiphasic Personality Inventory, 32:125
- personality traits, Sensation Seeking Scale, 32:125
- Sensation Seeking Scale, personality traits, 32:125

Alprazolam

- antidepressants, anxiety symptoms, 32:141
- antidepressants, course of illness, 32:141
- anxiety symptoms, antidepressants, 32:141
- anxiety symptoms, course of illness, 32:141
- anxiety symptoms, depressive symptoms, 32:141
- course of illness, anxiety symptoms, 32:141
- course of illness, desipramine, 32:141
- depressive symptoms, antidepressants, 32:141
- depressive symptoms, course of illness, 32:141
- depressive symptoms, desipramine, 32:141
- desipramine, anxiety symptoms, 32:141
- desipramine, course of illness, 32:141
- desipramine, depressive symptoms, 32:141

Alzheimer's disease

- adrenocorticotrophic hormone, age, 34:237
- adrenocorticotrophic hormone, cortisol, 33:107, 34:237
- adrenocorticotrophic hormone, glucocorticoid receptors, 34:237
- adrenocorticotrophic hormone, growth hormone, 33:107
- adrenocorticotrophic hormone, insulin-like growth factor, 33:107
- adrenocorticotrophic hormone, leukocytes, 34:237
- age, adrenocorticotrophic hormone, 34:237
- age, cortisol, 34:237
- age, glucocorticoid receptors, 34:237
- age, leukocytes, 34:237
- astrocytes, dentate gyrus, 35:149
- astrocytes, entorhinal cortex, 35:149
- astrocytes, granule cell layer, 35:149
- astrocytes, hippocampus, 35:149
- astrocytes, parahippocampal gyrus, 35:149
- astrocytes, subiculum, 35:149
- cortisol, adrenocorticotrophic hormone, growth hormone, 33:107
- cortisol, glucocorticoid receptors, adrenocorticotrophic hormone, 34:237

Alzheimer's disease continued

- glucocorticoid receptors, age, 34:237
- glucocorticoid receptors, cortisol, 34:237
- glucocorticoid receptors, leukocytes, 34:237
- granule cell layer, astrocytes, 35:149
- granule cell layer, dentate gyrus, 35:149
- granule cell layer, entorhinal cortex, 35:149
- granule cell layer, hippocampus, 35:149
- granule cell layer, parahippocampal gyrus, 35:149
- granule cell layer, subiculum, 35:149
- growth hormone, adrenocorticotrophic hormone, 33:107
- growth hormone, cortisol, 33:107
- growth hormone, insulin-like growth factor, 33:107
- hippocampus, astrocytes, 35:149
- hippocampus, granule cell layer, 35:149
- insulin-like growth factor,
 - adrenocorticotrophic hormone, 33:107
- insulin-like growth factor, cortisol, 33:107
- insulin-like growth factor, growth hormone, 33:107
- leukocytes, adrenocorticotrophic hormone, 34:237
- leukocytes, age, 34:237
- leukocytes, cortisol, 34:237
- leukocytes, glucocorticoid receptors, 34:237
- parahippocampal gyrus, astrocytes, 35:149
- parahippocampal gyrus, granule cell layer, 35:149
- parahippocampal gyrus, subiculum, 35:149
- subiculum, astrocytes, 35:149

Amino acids

- catecholamines, cortisol, 34:243
- catecholamines, melatonin, 34:243
- catecholamines, neuroleptics, 34:243
- catecholamines, schizophrenia, 34:243
- cerebrospinal fluid, red blood cell contamination, 32:99
- Conners Parent Questionnaire scores, hyperactivity, 33:301
- cortisol, catecholamines, 34:243
- hyperactivity, Conners Parent Questionnaire scores, 33:301
- melatonin, neuroleptics, 34:243
- neuroleptics, schizophrenia, 34:243
- paranoid subtype, schizophrenia, 32:63
- red blood cell contamination, cerebrospinal fluid, 32:99
- schizophrenia, catecholamines, 34:243

Amino acids continued

- schizophrenia, cortisol, 34:243
- schizophrenia, melatonin, 34:243
- schizophrenia, neuroleptics, 34:243
- schizophrenia, paranoid subtype, 32:63
- schizophrenia, tryptophan, 34:243
- tryptophan, catecholamines, 34:243
- tryptophan, cortisol, 34:243
- tryptophan, melatonin, 34:243
- tryptophan, neuroleptics, 34:243
- tryptophan, schizophrenia, 34:243

Amitriptyline

- affective disorder, Beck Depression Inventory, 31:201
- affective disorder, growth hormone, 31:201
- affective disorder, prolactin, 31:201
- affective disorder, tryptophan, 31:201
- affective disorder, weight loss, 31:201
- Beck Depression Inventory, growth hormone, 31:201
- growth hormone, prolactin, 31:201
- prolactin, tryptophan, 31:201
- tryptophan, weight loss, 31:201
- weight loss, antidepressants, 31:201

Amygdala

- magnetic resonance imaging,
 - schizophrenia, 35:1, 35:137
- magnetic resonance imaging, volume reduction, 35:1
- schizophrenia, magnetic resonance imaging, 35:1, 35:137

Anhedonia

- schizophrenia, deficit syndrome, 31:25

Antidepressants

- affective disorder, age, 33:51
- affective disorder, amitriptyline, 31:201
- affective disorder, Beck Depression Inventory, 31:201
- affective disorder, electroconvulsive therapy, 31:287
- affective disorder, growth hormone, 31:201
- affective disorder, panic disorder, 33:51
- affective disorder, personality disorder, 32:175
- affective disorder, pharmacotherapy response, 31:287
- affective disorder, prolactin, 31:201
- affective disorder, treatment outcome, 32:175, 33:51
- affective disorder, tryptophan, 31:201
- affective disorder, weight loss, 31:201
- age, affective disorder, 33:51
- age, panic disorder, 33:51
- age, treatment outcome, 33:51

Antidepressants continued

alprazolam, anxiety symptoms, 32:141
 alprazolam, course of illness, 32:141
 alprazolam, depressive symptoms, 32:141
 alprazolam, desipramine, 32:141
 alprazolam in combination, course of illness, 32:141
 alprazolam in combination, treatment outcome, 32:141
 amitriptyline, affective disorder, 31:201
 amitriptyline, Beck Depression Inventory, 31:201
 amitriptyline, growth hormone, 31:201
 amitriptyline, prolactin, 31:201
 amitriptyline, tryptophan, 31:201
 amitriptyline, weight loss, 31:201
 anti-imipramine antiserum affinities, serotonin uptake, 34:205
 anxiety symptoms, alprazolam, 32:141
 anxiety symptoms, course of illness, 32:141
 anxiety symptoms, depressive symptoms, 32:141
 anxiety symptoms, desipramine, 32:141
 Beck Depression Inventory, affective disorder, 31:201
 Beck Depression Inventory, amitriptyline, 31:201
 Beck Depression Inventory, growth hormone, 31:201
 Beck Depression Inventory, prolactin, 31:201
 Beck Depression Inventory, tryptophan, 31:201
 Beck Depression Inventory, weight loss, 31:201
 calcium channel blockers, rat immobility, 32:203
 cholesterol in serum, imipramine effect, 32:207
 cortisol, dexamethasone suppression test, 34:107
 course of illness, alprazolam, 32:141
 course of illness, anxiety symptoms, 32:141
 course of illness, depressive symptoms, 32:141
 course of illness, desipramine, 32:141
 course of illness, treatment outcome, 32:141
 depressive mood, thyroxine, 32:241
 depressive mood, triiodothyronine, 32:241
 depressive symptoms, alprazolam, 32:141
 depressive symptoms, anxiety symptoms, 32:141
 depressive symptoms, course of illness, 32:141

Antidepressants continued

depressive symptoms, desipramine, 32:141
 desipramine, alprazolam, 32:141
 desipramine, anxiety symptoms, 32:141
 desipramine, course of illness, 32:141
 desipramine, depressive symptoms, 32:141
 dexamethasone suppression test, cortisol, 34:107
 electroconvulsive therapy, affective disorder, 31:287
 electroconvulsive therapy, pharmacotherapy response, 31:287
 growth hormone, affective disorder, 31:201
 growth hormone, amitriptyline, 31:201
 growth hormone, Beck Depression Inventory, 31:201
 growth hormone, prolactin, 31:201
 growth hormone, tryptophan, 31:201
 growth hormone, weight loss, 31:201
 imipramine effect, cholesterol in serum, 32:207
 panic disorder, affective disorder, 33:51
 panic disorder, age, 33:51
 panic disorder, treatment outcome, 33:51
 personality disorder, affective disorder, 32:175
 personality disorder, treatment outcome, 32:175
 pharmacotherapy response, affective disorder, 31:287
 pharmacotherapy response, electroconvulsive therapy, 31:287
 prolactin, affective disorder, 31:201
 prolactin, amitriptyline, 31:201
 prolactin, Beck Depression Inventory, 31:201
 prolactin, growth hormone, 31:201
 prolactin, tryptophan, 31:201
 prolactin, weight loss, 31:201
 rat immobility, calcium channel blockers, 32:203
 serotonin uptake, anti-imipramine antiserum affinities, 34:205
 thyroxine, depressive mood, 32:241
 thyroxine, triiodothyronine, 32:241
 treatment outcome, affective disorder, 32:175, 33:51
 treatment outcome, age, 33:51
 treatment outcome, alprazolam in combination, 32:141
 treatment outcome, course of illness, 32:141
 treatment outcome, panic disorder, 33:51
 treatment outcome, personality disorder, 32:175

Antidepressants continued

- triiodothyronine, depressive mood, 32:241
- triiodothyronine, thyroxine, 32:241
- tryptophan, affective disorder, 31:201
- tryptophan, amitriptyline, 31:201
- tryptophan, Beck Depression Inventory, 31:201
- tryptophan, growth hormone, 31:201
- tryptophan, prolactin, 31:201
- tryptophan, weight loss, 31:201
- weight loss, affective disorder, 31:201
- weight loss, amitriptyline, 31:201
- weight loss, Beck Depression Inventory, 31:201
- weight loss, growth hormone, 31:201
- weight loss, prolactin, 31:201
- weight loss, tryptophan, 31:201

Anti-thyroid peroxidase

- bipolar affective disorder, lithium treatment, 34:13

Anxiety

- affective disorder, phosphate in serum, 31:217
- age, glucose metabolic rate, 35:49
- age, positron emission tomography, 35:49
- age, sex differences, 35:49
- glucose metabolic rate, age, 35:49
- glucose metabolic rate, positron emission tomography, 35:49
- glucose metabolic rate, sex differences, 35:49
- heart rate, panic disorder, 32:45
- motor activity, heart rate, 32:45
- motor activity, panic disorder, 32:45
- panic disorder, heart rate, 32:45
- panic disorder, motor activity, 32:45
- phosphate in serum, affective disorder, 31:217
- positron emission tomography, age, 35:49
- positron emission tomography, glucose metabolic rate, 35:49
- positron emission tomography, sex differences, 35:49
- sex differences, age, 35:49
- sex differences, glucose metabolic rate, 35:49

Apomorphine

- alcoholism, cocaine, 33:151
- alcoholism, growth hormone, 33:151
- alcoholism, prolactin, 33:151
- alcoholism, substance abuse, 33:151
- cocaine, alcoholism, 33:151
- cocaine, growth hormone, 33:151, 33:161
- cocaine, homovanillic acid, 33:161

Apomorphine continued

- cocaine, prolactin, 33:151, 33:161
- cocaine, substance abuse, 33:151
- growth hormone, alcoholism, 33:151
- growth hormone, cocaine, 33:151, 33:161
- growth hormone, homovanillic acid, 33:161
- growth hormone, prolactin, 33:151, 33:161
- growth hormone, substance abuse, 33:151
- homovanillic acid, cocaine, 33:161
- homovanillic acid, growth hormone, 33:161
- homovanillic acid, prolactin, 33:161
- prolactin, alcoholism, 33:151
- prolactin, cocaine, 33:151, 33:161
- sleeping, computerized electroencephalographic topography, 35:91

Asymmetry. See Laterality**Atenolol**

- cortisol, melatonin in urine, 32:175
- melatonin in urine, normal volunteers, 32:175

Attention

- catecholamine metabolites, evoked potentials, 31:297
- catecholamine metabolites, schizophrenia, 31:297
- continuous performance test, neuroleptic treatment, 32:281, 33:179
- continuous performance test, schizophrenia, 33:179
- distractibility, formal thought disorder, 31:169
- distractibility, schizophrenia, 31:169
- distractibility, span of apprehension, 31:169
- distractibility, Wechsler Intelligence Scale for Children, 31:169
- evoked potentials, catecholamine metabolites, 31:297
- evoked potentials, schizophrenia, 31:297
- formal thought disorder, distractibility, 31:169
- formal thought disorder, schizophrenia, 31:169
- formal thought disorder, span of apprehension, 31:169
- formal thought disorder, Wechsler Intelligence Scale for Children, 31:169
- neuroleptic treatment, continuous performance test, 32:281, 33:179
- neuroleptic treatment, schizophrenia, 32:281, 33:179
- neuroleptic withdrawal, skin conductance, 34:19
- schizophrenia, catecholamine metabolites, 31:297

Attention continued

- schizophrenia, continuous performance test, 33:179
- schizophrenia, distractibility, 31:169
- schizophrenia, evoked potentials, 31:297
- schizophrenia, formal thought disorder, 31:169
- schizophrenia, neuroleptic treatment, 32:281, 33:179
- schizophrenia, span of apprehension, 31:169
- schizophrenia, Wechsler Intelligence Scale for Children, 31:169
- skin conductance, neuroleptic withdrawal, 34:19
- span of apprehension, distractibility, 31:169
- span of apprehension, formal thought disorder, 31:169
- span of apprehension, schizophrenia, 31:169
- span of apprehension, Wechsler Intelligence Scale for Children, 31:169
- Wechsler Intelligence Scale for Children, distractibility, 31:169
- Wechsler Intelligence Scale for Children, formal thought disorder, 31:169
- Wechsler Intelligence Scale for Children, schizophrenia, 31:169
- Wechsler Intelligence Scale for Children, span of apprehension, 31:169

Augmenting-reducing

- criminality, evoked potentials, 31:85
- criminality, eye tracking, 31:85
- criminality, schizophrenia, 31:85
- evoked potentials, eye tracking, 31:85
- eye tracking, schizophrenia, 31:85
- schizophrenia, criminality, 31:85

Basal ganglia

- ethanol, glucose metabolic rate, 35:39
- glucose metabolic rate, positron emission tomography, 35:39
- positron emission tomography, ethanol, 35:39

Beck Depression Inventory

- affective disorder, amitriptyline, 31:201
- affective disorder, antidepressants, 31:201
- affective disorder, growth hormone, 31:201
- affective disorder, prolactin, 31:201
- affective disorder, tryptophan, 31:201
- affective disorder, weight loss, 31:201
- amitriptyline, affective disorder, 31:201
- amitriptyline, growth hormone, 31:201
- amitriptyline, prolactin, 31:201
- amitriptyline, tryptophan, 31:201
- amitriptyline, weight loss, 31:201
- antidepressants, affective disorder, 31:201

Beck Depression Inventory continued

- antidepressants, prolactin, 31:201
- antidepressants, tryptophan, 31:201
- antidepressants, weight loss, 31:201
- growth hormone, amitriptyline, 31:201
- normal volunteers, Perceptual Aberration Scale, 33:243
- panic disorder, phobic avoidance, 32:45
- Perceptual Aberration Scale, normal volunteers, 33:243
- phobic avoidance, panic disorder, 32:45
- prolactin, tryptophan, 31:201
- prolactin, weight loss, 31:201
- psychotherapy, rapid eye movement sleep, 33:285
- psychotherapy, treatment outcome, 33:285
- rapid eye movement sleep, psychotherapy, 33:285
- rapid eye movement sleep, treatment outcome, 33:285
- treatment outcome, psychotherapy, 33:285
- treatment outcome, rapid eye movement sleep, 33:285
- tryptophan, affective disorder, 31:201
- tryptophan, amitriptyline, 31:201
- tryptophan, antidepressants, 31:201
- tryptophan, growth hormone, 31:201
- tryptophan, prolactin, 31:201
- tryptophan, weight loss, 31:201
- weight loss, affective disorder, 31:201
- weight loss, antidepressants, 31:201
- weight loss, growth hormone, 31:201
- weight loss, prolactin, 31:201
- weight loss, tryptophan, 31:201

Benzodiazepines

- alcoholism, ethanol, 35:39
- alcoholism, fluorodeoxyglucose, 35:39
- alcoholism, frontal lobe, 35:39
- alcoholism, positron emission tomography, 35:39
- ethanol, fluorodeoxyglucose, 35:39
- fluorodeoxyglucose, frontal lobe, 35:39
- fluorodeoxyglucose, positron emission tomography, 35:39
- frontal lobe, positron emission tomography, 35:39
- positron emission tomography, alcoholism, 35:39
- positron emission tomography, ethanol, 35:39
- positron emission tomography, frontal lobe, 35:39

Beta blockers

- blood pressure, cortisol, 32:175

Beta blockers continued

blood pressure, melatonin, 32:175
 blood pressure, normal volunteers, 32:175
 cortisol, blood pressure, 32:175
 cortisol, heart rate, 32:175
 cortisol, melatonin, 32:175
 cortisol, normal volunteers, 32:175
 heart rate, lactate infusion, 32:93
 heart rate, melatonin, 32:175
 heart rate, normal volunteers, 32:175
 heart rate, panic disorder, 32:93
 lactate infusion, heart rate, 32:93
 lactate infusion, panic disorder, 32:93
 melatonin, cortisol, 32:175
 melatonin, heart rate, 32:175
 melatonin, normal volunteers, 32:175
 panic disorder, heart rate, 32:93
 panic disorder, lactate infusion, 32:93

Biperiden

negative symptoms, schizophrenia, 31:235
 schizophrenia, negative symptoms, 31:235

Blood pressure

affective disorder, catecholamines in plasma, 34:127
 affective disorder, electroconvulsive therapy, 34:127
 affective disorder, heart rate, 34:127
 beta blockers, cortisol, 32:175
 beta blockers, heart rate, 32:175
 beta blockers, melatonin, 32:175
 beta blockers, normal volunteers, 32:175
 catecholamines in plasma, affective disorder, 34:127
 catecholamines in plasma, electroconvulsive therapy, 34:127
 catecholamines in plasma, heart rate, 34:127
 children, conduct disorder, 33:199
 children, heart rate, 33:199
 children, separation anxiety, 33:199
 clonidine, growth hormone, 31:311
 clonidine, heart rate, 31:311
 clonidine, vasopressin, 31:311
 conduct disorder, children, 33:199
 conduct disorder, heart rate, 33:199
 conduct disorder, separation anxiety, 33:199
 cortisol, beta blockers, 32:175
 cortisol, heart rate, 32:175
 cortisol, melatonin, 32:175
 cortisol, normal volunteers, 32:175
 eating disorders, heart rate, 33:1
 eating disorders, isoproterenol, 33:1
 eating disorders, temperature of body, 33:1

Blood pressure continued

eating disorders, weight, 33:1
 electroconvulsive therapy, affective disorder, 34:127
 electroconvulsive therapy, catecholamines in plasma, 34:127
 electroconvulsive therapy, heart rate, 34:127
 growth hormone, clonidine, 31:311
 growth hormone, heart rate, 31:311
 growth hormone, vasopressin, 31:311
 heart rate, affective disorder, 34:127
 heart rate, beta blockers, 32:175
 heart rate, catecholamines in plasma, 34:127
 heart rate, children, 33:199
 heart rate, clonidine, 31:311
 heart rate, conduct disorder, 33:199
 heart rate, cortisol, 32:175
 heart rate, eating disorders, 33:1
 heart rate, electroconvulsive therapy, 34:127
 heart rate, growth hormone, 31:311
 heart rate, isoproterenol, 33:1
 heart rate, melatonin, 32:175
 heart rate, normal volunteers, 32:175, 34:259
 heart rate, physostigmine, 34:259
 heart rate, scopolamine, 34:259
 heart rate, separation anxiety, 33:199
 heart rate, temperature of body, 33:1
 heart rate, vasopressin, 31:311
 heart rate, weight, 33:1
 isoproterenol, eating disorders, 33:1
 isoproterenol, heart rate, 33:1
 isoproterenol, temperature of body, 33:1
 isoproterenol, weight, 33:1
 melatonin, beta blockers, 32:175
 melatonin, cortisol, 32:175
 melatonin, heart rate, 32:175
 melatonin, normal volunteers, 32:175
 normal volunteers, beta blockers, 32:175
 normal volunteers, cortisol, 32:175
 normal volunteers, heart rate, 32:175, 34:259
 normal volunteers, melatonin, 32:175
 normal volunteers, physostigmine, 34:259
 normal volunteers, scopolamine, 34:259
 physostigmine, heart rate, 34:259
 physostigmine, normal volunteers, 34:259
 physostigmine, scopolamine, 34:259
 scopolamine, heart rate, 34:259
 scopolamine, normal volunteers, 34:259
 scopolamine, physostigmine, 34:259

Blood pressure continued

- separation anxiety, children, 33:199
- separation anxiety, conduct disorder, 33:199
- separation anxiety, heart rate, 33:199
- temperature of body, eating disorders, 33:1
- temperature of body, heart rate, 33:1
- temperature of body, isoproterenol, 33:1
- temperature of body, weight, 33:1
- vasopressin, clonidine, 31:311
- vasopressin, growth hormone, 31:311
- vasopressin, heart rate, 31:311
- weight, eating disorders, 33:1
- weight, heart rate, 33:1
- weight, isoproterenol, 33:1
- weight, temperature of body, 33:1

Boston Naming Test

- frontal lobe, magnetic resonance imaging, 35:115
- frontal lobe, sulcal width, 35:115
- magnetic resonance imaging, frontal lobe, 35:115
- magnetic resonance imaging, sulcal width, 35:115
- sulcal width, frontal lobe, 35:115

Brain atrophy

- age, duration of illness, 31:1
- age, limbic system, 35:15
- computed tomography, neuroleptic treatment, 33:307
- computed tomography, schizophrenia, 33:307
- computed tomography, somatostatin, 33:307
- duration of illness, age, 31:1
- neuroleptic treatment, computed tomography, 33:307
- neuroleptic treatment, schizophrenia, 33:307
- neuroleptic treatment, somatostatin, 33:307
- schizophrenia, computed tomography, 33:307, 35:61
- schizophrenia, neuroleptic treatment, 33:307
- schizophrenia, somatostatin, 33:307
- schizophrenia, temporal lobe, 35:1, 35:137
- somatostatin, computed tomography, 33:307
- somatostatin, neuroleptic treatment, 33:307
- somatostatin, schizophrenia, 33:307

Brief Psychiatric Rating Scale

- depressed mood, Hamilton Rating Scale for Depression, 31:243

Brief Psychiatric Rating Scale continued

- depressed mood, schizophrenia, 31:243
- dynorphin, schizophrenia, 34:229
- Hamilton Rating Scale for Depression, depressed mood, 31:243
- Hamilton Rating Scale for Depression, schizophrenia, 31:243
- homovanillic acid, neuroleptic response, 33:171
- homovanillic acid, schizophrenia, 33:171
- homovanillic acid, tardive dyskinesia, 33:259
- neuroleptic response, homovanillic acid, 33:171
- neuroleptic response, schizophrenia, 33:171
- neuroleptic withdrawal, skin conductance, 34:19
- schizophrenia, depressed mood, 31:243
- schizophrenia, dynorphin, 34:229
- schizophrenia, Hamilton Rating Scale for Depression, 31:243
- schizophrenia, homovanillic acid, 33:171
- schizophrenia, neuroleptic response, 33:171
- skin conductance, neuroleptic withdrawal, 34:19
- tardive dyskinesia, homovanillic acid, 33:259

Buss-Durkee Hostility Inventory

- affective disorder, panic disorder, 31:179

Butyrylcholinesterase

- physostigmine, normal volunteers, 34:259

Calcium channel blocking agents

- imipramine, rat immobility, 32:203
- nifedipine, forced swimming test, 32:203
- rat immobility, imipramine, 32:203

Carbon dioxide

- anxiety symptoms, panic disorder, 31:193

Catecholamines

- affective disorder, blood pressure, 34:127
- affective disorder, electroconvulsive therapy, 34:127
- affective disorder, heart rate, 34:127
- amino acids, cortisol, 34:243
- amino acids, melatonin, 34:243
- amino acids, neuroleptics, 34:243
- amino acids, schizophrenia, 34:243
- amino acids, tryptophan, 34:243
- blood pressure, affective disorder, 34:127
- blood pressure, electroconvulsive therapy, 34:127
- blood pressure, heart rate, 34:127
- cholinergic system, cortisol, 34:259
- cholinergic system, heart rate, 34:259
- cholinergic system, physostigmine, 34:259
- cholinergic system, stress, 34:259

Catecholamines continued

- cortisol, amino acids, 34:259
- cortisol, cholinergic system, 34:259
- cortisol, heart rate, 34:259
- cortisol, melatonin, 34:259
- cortisol, neuroleptics, 34:259
- cortisol, physostigmine, 34:259
- cortisol, schizophrenia, 34:259
- cortisol, stress, 34:259
- cortisol, tryptophan, 34:243
- depressed mood, generalized anxiety disorder, 32:35
- electroconvulsive therapy, affective disorder, 34:127
- electroconvulsive therapy, blood pressure, 34:127
- electroconvulsive therapy, heart rate, 34:127
- evoked potentials, neuroleptic treatment, 31:297
- evoked potentials, schizophrenia, 31:297
- excretion in urine, lithium pharmacokinetics, 32:71
- excretion in urine, mania, 32:71
- generalized anxiety disorder, depressed mood, 32:35
- heart rate, affective disorder, 34:127
- heart rate, blood pressure, 34:127
- heart rate, cholinergic system, 34:259
- heart rate, cortisol, 34:259
- heart rate, electroconvulsive therapy, 34:127
- heart rate, physostigmine, 34:259
- heart rate, stress, 34:259
- lithium pharmacokinetics, excretion in urine, 32:71
- lithium pharmacokinetics, mania, 32:71
- mania, lithium pharmacokinetics, 32:71
- melatonin, amino acids, 34:243
- melatonin, cortisol, 34:243
- melatonin, neuroleptics, 34:243
- melatonin, schizophrenia, 34:243
- melatonin, tryptophan, 34:243
- neuroleptics, amino acids, 34:243
- neuroleptics, cortisol, 34:243
- neuroleptics, evoked potentials, 31:297
- neuroleptics, melatonin, 34:243
- neuroleptics, schizophrenia, 31:297, 34:243
- neuroleptics, tryptophan, 34:243
- physostigmine, cholinergic system, 34:259
- physostigmine, cortisol, 34:259
- physostigmine, heart rate, 34:259
- physostigmine, stress, 34:259
- schizophrenia, amino acids, 34:243

Catecholamines continued

- schizophrenia, cortisol, 34:243
- schizophrenia, evoked potentials, 31:297
- schizophrenia, melatonin, 34:243
- schizophrenia, neuroleptics, 31:297, 34:243
- schizophrenia, tryptophan, 34:243
- stress, cholinergic system, 34:259
- stress, cortisol, 34:259
- stress, heart rate, 34:259
- stress, physostigmine, 34:259
- Tourette's syndrome, tyramine, 31:279
- tryptophan, amino acids, 34:243
- tryptophan, cortisol, 34:243
- tryptophan, melatonin, 34:243
- tryptophan, neuroleptics, 34:243
- tryptophan, schizophrenia, 34:243
- tyramine, Tourette's syndrome, 31:279

Caudate nucleus

- affective disorder, endorphin, 32:159
- affective disorder, frontal lobe, 32:159
- affective disorder, hypothalamus, 32:159
- affective disorder, laterality, 32:159
- affective disorder, suicide, 32:159
- affective disorder, temporal lobe, 32:159
- endorphin, affective disorder, 32:159
- frontal lobe, endorphin, 32:159
- hypothalamus, laterality, 32:159
- laterality, suicide, 32:159
- suicide, affective disorder, 32:159
- temporal lobe, affective disorder, 32:159
- temporal lobe, endorphin, 32:159
- temporal lobe, frontal lobe, 32:159
- temporal lobe, hypothalamus, 32:159
- temporal lobe, laterality, 32:159
- temporal lobe, suicide, 32:159

Cerebral blood flow

- frontal lobe, fronto-occipital ratio, 35:27
- frontal lobe, Scale for the Assessment of Negative Symptoms, 35:27
- frontal lobe, schizophrenia, 35:27
- fronto-occipital ratio, frontal lobe, 35:27
- fronto-occipital ratio, Scale for the Assessment of Negative Symptoms, 35:27
- fronto-occipital ratio, schizophrenia, 35:27
- laterality, schizophrenia, 35:27
- Scale for the Assessment of Negative Symptoms, frontal lobe, 35:27
- Scale for the Assessment of Negative Symptoms, fronto-occipital ratio, 35:27
- Scale for the Assessment of Negative Symptoms, schizophrenia, 35:27
- schizophrenia, frontal lobe, 35:27
- schizophrenia, fronto-occipital ratio, 35:27

Cerebral blood flow continued

- schizophrenia, laterality, 35:27
- schizophrenia, Scale for the Assessment of Negative Symptoms, 35:27

Cerebrospinal fluid

- alcoholics, diazepam-binding inhibitor, 31:261
- alcoholism, corticotropin releasing hormone, 33:215
- alcoholism, growth hormone releasing hormone, 33:215
- alcoholism, neuropeptide Y, 33:215
- alcoholism, somatostatin, 33:215
- children, red blood cell contamination, 32:99
- corticotropin releasing hormone, alcoholism, 33:215
- corticotropin releasing hormone, growth hormone releasing hormone, 33:215
- corticotropin releasing hormone, neuropeptide Y, 33:215
- corticotropin releasing hormone, somatostatin, 33:215
- diazepam-binding inhibitor, alcoholics, 31:261
- dynorphin, endorphin, 34:229
- dynorphin, schizophrenia, 34:229
- endorphin, dynorphin, 34:229
- endorphin, schizophrenia, 34:229
- endorphin, substance P, 34:229
- growth hormone releasing hormone, alcoholism, 33:215
- growth hormone releasing hormone, corticotropin releasing hormone, 33:215
- growth hormone releasing hormone, neuropeptide Y, 33:215
- growth hormone releasing hormone, somatostatin, 33:215
- 5-hydroxyindoleacetic acid, 5-hydroxytryptamine, 33:95
- 5-hydroxyindoleacetic acid, obsessive-compulsive disorder, 33:95
- 5-hydroxyindoleacetic acid, platelet imipramine binding, 33:323
- 5-hydroxytryptamine, 5-hydroxyindoleacetic acid, 33:95
- 5-hydroxytryptamine, obsessive-compulsive disorder, 33:95
- 5-hydroxytryptamine, serotonin, 33:95
- magnetic resonance imaging, sulcal width measurement, 35:115
- neuropeptide Y, alcoholism, 33:215
- neuropeptide Y, corticotropin releasing hormone, 33:215

Cerebrospinal fluid continued

- neuropeptide Y, growth hormone releasing hormone, 33:215
- neuropeptide Y, somatostatin, 33:215
- obsessive-compulsive disorder, 5-hydroxyindoleacetic acid, 33:95
- obsessive-compulsive disorder, 5-hydroxytryptamine, 33:95
- obsessive-compulsive disorder, serotonin, 33:95
- platelet imipramine binding, 5-hydroxyindoleacetic acid, 33:323
- red blood cell contamination, children, 32:99
- schizophrenia, dynorphin, 34:229
- schizophrenia, endorphin, 34:229
- schizophrenia, substance P, 34:229
- serotonin, obsessive-compulsive disorder, 33:95
- somatostatin, alcoholism, 33:215
- somatostatin, corticotropin releasing hormone, 33:215
- somatostatin, growth hormone releasing hormone, 33:215
- somatostatin, neuropeptide Y, 33:215
- substance P, dynorphin, 34:229
- substance P, endorphin, 34:229
- substance P, schizophrenia, 34:229
- sulcal width measurement, magnetic resonance imaging, 35:115

CES-D (Center for Epidemiological Studies Depression Scale)

- affective disorder, Diagnostic Interview Schedule, 31:69
- affective disorder, Mexican-Americans, 31:69
- Diagnostic Interview Schedule, affective disorder, 31:69
- Diagnostic Interview Schedule, generalized anxiety disorder, 31:69
- generalized anxiety disorder, Diagnostic Interview Schedule, 31:69
- generalized anxiety disorder, Mexican-Americans, 31:69
- Mexican-Americans, affective disorder, 31:69

Children

- affective disorder, obsessive-compulsive disorder, 33:277
- affective disorder, somatostatin, 33:277
- amino acids in urine and plasma, attention deficit disorder, 33:301
- attention deficit disorder, amino acids in urine and plasma, 33:301

Children continued

- blood pressure, conduct disorder, 33:199
- blood pressure, heart rate, 33:199
- blood pressure, separation anxiety, 33:199
- conduct disorder, blood pressure, 33:199
- conduct disorder, heart rate, 33:199
- conduct disorder, separation anxiety, 33:199
- heart rate, blood pressure, 33:199
- heart rate, conduct disorder, 33:199
- heart rate, separation anxiety, 33:199
- obsessive-compulsive disorder, affective disorder, 33:277
- obsessive-compulsive disorder, somatostatin, 33:277
- separation anxiety, blood pressure, 33:199
- separation anxiety, conduct disorder, 33:199
- separation anxiety, heart rate, 33:199
- somatostatin, affective disorder, 33:277
- somatostatin, obsessive-compulsive disorder, 33:277

Cholesterol

- affective disorder, imipramine effect, 32:207

Cholinergic system

- adrenergic-cholinergic balance, cortisol, 34:259, 34:271
- adrenergic-cholinergic balance, cyclic adenosine monophosphate, 34:259
- adrenergic-cholinergic balance, glucose, 34:259, 34:271
- adrenergic-cholinergic balance, heart rate, 34:259, 34:271
- adrenergic-cholinergic balance, neostigmine, 34:259, 34:271
- adrenergic-cholinergic balance, physostigmine, 34:259, 34:271
- anticholinergic medication, schizophrenia, 31:235
- anticholinergic medication, symptom severity, 31:235
- catecholamines, cortisol, 34:259, 34:271
- catecholamines, heart rate, 34:259, 34:271
- catecholamines, physostigmine, 34:259, 34:271
- catecholamines, stress, 34:259, 34:271
- cortisol, adrenergic-cholinergic balance, 34:259, 34:271
- cortisol, catecholamines, 34:259, 34:271
- cortisol, neostigmine, 34:259
- cortisol, stress, 34:259, 34:271
- cyclic adenosine monophosphate, adrenergic-cholinergic balance, 34:259, 34:271

Cholinergic system continued

- glucose, cortisol, 34:259, 34:271
- glucose, cyclic adenosine monophosphate, 34:259, 34:271
- glucose, heart rate, 34:259, 34:271
- glucose, neostigmine, 34:259, 34:271
- glucose, physostigmine, 34:259, 34:271
- heart rate, catecholamines, 34:259
- heart rate, cortisol, 34:259, 34:271
- heart rate, stress, 34:259, 34:271
- neostigmine, cyclic adenosine monophosphate, 34:259, 34:271
- physostigmine, cortisol, 34:259, 34:271
- physostigmine, stress, 34:259
- schizophrenia, anticholinergic medication, 31:235
- schizophrenia, symptom severity, 31:235
- stress, catecholamines, 34:259
- stress, cortisol, 34:259, 34:271
- stress, heart rate, 34:259, 34:271
- stress, physostigmine, 34:259, 34:271
- symptom severity, anticholinergic medication, 31:235
- symptom severity, schizophrenia, 31:235

Chromosomal translocation

- suicide, genetics, 32:1

Circadian rhythms

- affective disorder, depressed mood, 32:113
- affective disorder, sleep deprivation, 32:113
- circannual rhythm, eating disorder, 32:221
- circannual rhythm, melatonin, 32:221
- circannual rhythm, weight, 32:221
- cocaine, light effects, 34:185
- cocaine, melatonin, 34:185
- cocaine, rat pineal glands, 34:185
- depressed mood, affective disorder, 32:113
- depressed mood, sleep deprivation, 32:113, 34:149
- eating disorder, circannual rhythm, 32:221
- eating disorder, melatonin, 32:221
- eating disorder, weight, 32:221
- light effects, cocaine, 34:185
- light effects, melatonin, 34:185
- light effects, rat pineal glands, 34:185
- melatonin, circannual rhythm, 32:221
- melatonin, cocaine, 34:185
- melatonin, eating disorder, 32:221
- melatonin, light effects, 34:185
- melatonin, rat pineal glands, 34:185
- melatonin, weight, 32:221
- oxytremorine response, rats, 33:139
- rat pineal glands, cocaine, 34:185
- rat pineal glands, light effects, 34:185
- rat pineal glands, melatonin, 34:185
- rats, oxytremorine response, 33:139

Circadian rhythms continued

- sleep deprivation, affective disorder, 32:113
- sleep deprivation, depressed mood, 32:113, 34:149
- weight, circannual rhythm, 32:221
- weight, eating disorder, 32:221
- weight, melatonin, 32:221

Circannual rhythms

- affective disorder, age, 31:131
- affective disorder, cyanoimipramine binding sites in platelets, 34:315
- affective disorder, imipramine, 34:315
- affective disorder, latitude, 31:131
- affective disorder, suicide, 32:253
- affective disorder, sunlight, 32:253
- affective disorder, weather, 32:253
- age, affective disorder, 31:131
- atypical depression, phototherapy, 33:121
- atypical depression, seasonal affective disorder, 33:121
- cyanoimipramine binding sites in platelets, affective disorder, 34:315
- diurnal rhythm, eating disorder, 32:221
- diurnal rhythm, melatonin, 32:221
- diurnal rhythm, weight, 32:221
- eating disorder, diurnal rhythm, 32:221
- eating disorder, melatonin, 32:221
- eating disorder, weight, 32:221
- imipramine, affective disorder, 34:315
- imipramine, cyanoimipramine binding sites in platelets, 34:315
- latitude, affective disorder, 31:131
- latitude, age, 31:131
- melatonin, diurnal rhythm, 32:221
- melatonin, eating disorder, 32:221
- melatonin, weight, 32:221
- phototherapy, atypical depression, 33:121
- phototherapy, seasonal affective disorder, 33:121
- seasonal affective disorder, atypical depression, 33:121
- seasonal affective disorder, phototherapy, 33:121
- seasonal affective disorder, suicide, 32:253
- seasonal affective disorder, sunlight, 32:253
- seasonal affective disorder, weather, 32:253
- suicide, affective disorder, 32:253
- suicide, seasonal affective disorder, 32:253
- suicide, sunlight, 32:253
- suicide, weather, 32:253
- sunlight, affective disorder, 32:253
- sunlight, seasonal affective disorder, 32:253
- sunlight, suicide, 32:253
- weather, affective disorder, 32:253

Circannual rhythms continued

- weather, seasonal affective disorder, 32:253
- weather, suicide, 32:253
- weight, diurnal rhythm, 32:221
- weight, eating disorder, 32:221
- weight, melatonin, 32:221

Clomipramine

- adrenocorticotrophic hormone, affective disorder, 31:39
- adrenocorticotrophic hormone, growth hormone response, 31:39
- adrenocorticotrophic hormone, heart rate, 31:39
- adrenocorticotrophic hormone, prolactin response, 31:39
- affective disorder, adrenocorticotrophic hormone, 31:39
- affective disorder, cortisol, 31:39
- affective disorder, growth hormone response, 31:39
- affective disorder, heart rate, 31:39
- affective disorder, prolactin response, 31:39
- anxiety symptoms, depressive symptoms, 31:121
- anxiety symptoms, obsessive-compulsive disorder, 31:121
- cortisol, adrenocorticotrophic hormone, 31:39
- cortisol, affective disorder, 31:39
- cortisol, depressed mood, 32:151
- cortisol, dexamethasone suppression test, 32:151
- cortisol, growth hormone response, 31:39
- cortisol, heart rate, 31:39
- cortisol, obsessive-compulsive disorder, 32:151
- cortisol, prolactin response, 31:39
- depressed mood, cortisol, 32:151
- depressed mood, dexamethasone suppression test, 32:151
- depressed mood, obsessive-compulsive disorder, 32:151
- depressive symptoms, anxiety symptoms, 31:121
- depressive symptoms, obsessive-compulsive disorder, 31:121
- dermatitis, hand washing, 34:223
- dermatitis, treatment response, 34:223
- dexamethasone suppression test, cortisol, 32:151
- dexamethasone suppression test, depressed mood, 32:151
- dexamethasone suppression test, obsessive-compulsive disorder, 32:151

Clomipramine continued

- growth hormone response,
 - adrenocorticotrophic hormone, 31:39
- growth hormone response, affective disorder, 31:39
- growth hormone response, cortisol, 31:39
- growth hormone response, heart rate, 31:39
- growth hormone response, prolactin response, 31:39
- growth hormone, serotonin, 31:39
- hand washing, dermatitis, 34:223
- hand washing, treatment response, 34:223
- heart rate, adrenocorticotrophic hormone, 31:39
- heart rate, affective disorder, 31:39
- heart rate, cortisol, 31:39
- heart rate, growth hormone response, 31:39
- heart rate, prolactin response, 31:39
- obsessive-compulsive disorder, anxiety symptoms, 31:121
- obsessive-compulsive disorder, cortisol, 32:151
- obsessive-compulsive disorder, depressed mood, 32:151
- obsessive-compulsive disorder, depressive symptoms, 31:121
- obsessive-compulsive disorder,
 - dexamethasone suppression test, 32:151
- obsessive-compulsive disorder, symptom assessment, 34:99
- obsessive-compulsive disorder, Yale-Brown Scale, 34:99
- prolactin response, adrenocorticotrophic hormone, 31:39
- prolactin response, affective disorder, 31:39
- prolactin response, cortisol, 31:39
- prolactin response, growth hormone, 31:39
- prolactin response, heart rate, 31:39
- prolactin response, serotonin, 31:39
- serotonin, growth hormone, 31:39
- serotonin, prolactin response, 31:39
- treatment response, dermatitis, 34:223
- treatment response, hand washing, 34:223
- Yale-Brown Scale, obsessive-compulsive disorder, 34:99

Clonidine

- blood pressure, growth hormone, 31:311
- growth hormone, heart rate, 31:311
- heart rate, vasopressin, 31:311
- vasopressin, blood pressure, 31:311
- vasopressin, growth hormone, 31:311
- vasopressin, heart rate, 31:311

Cocaine

- alcoholism, apomorphine, 33:151

Cocaine continued

- alcoholism, growth hormone, 33:151
- alcoholism, prolactin, 33:151
- alcoholism, substance abuse, 33:151
- alpha power, computerized electroencephalographic topography, 35:95
- apomorphine, growth hormone, 33:151, 33:161
- apomorphine, homovanillic acid, 33:161
- apomorphine, prolactin, 33:151, 33:161
- apomorphine, substance abuse, 33:151
- circadian rhythms, light effects, 34:185
- circadian rhythms, melatonin, 34:185
- circadian rhythms, rat pineal glands, 34:185
- computerized electroencephalographic topography, alpha power, 35:95
- computerized electroencephalographic topography, substance abuse, 35:95
- electroencephalogram, alpha power, 35:95
- electroencephalogram, substance abuse, 35:95
- growth hormone, alcoholism, 33:151
- growth hormone, apomorphine, 33:151, 33:161
- growth hormone, homovanillic acid, 33:161
- growth hormone, prolactin, 33:151, 33:161
- growth hormone, substance abuse, 33:151
- homovanillic acid, apomorphine, 33:161
- homovanillic acid, growth hormone, 33:161
- homovanillic acid, prolactin, 33:161
- light effects, circadian rhythms, 34:185
- light effects, melatonin, 34:185
- light effects, rat pineal glands, 34:185
- melatonin, circadian rhythms, 34:185
- melatonin, light effects, 34:185
- melatonin, rat pineal glands, 34:185
- prolactin, alcoholism, 33:151
- prolactin, apomorphine, 33:151, 33:161
- prolactin, growth hormone, 33:151, 33:161
- prolactin, homovanillic acid, 33:161
- prolactin, substance abuse, 33:151
- rat pineal glands, circadian rhythms, 34:185
- rat pineal glands, light effects, 34:185
- rat pineal glands, melatonin, 34:185
- substance abuse, alcoholism, 33:151
- substance abuse, alpha power, 35:95
- substance abuse, apomorphine, 33:151
- substance abuse, computerized electroencephalographic topography, 35:95
- substance abuse, electroencephalogram, 35:95
- substance abuse, growth hormone, 33:151
- substance abuse, prolactin, 33:151

Computed tomography (CT scans)

admixture analysis, age, 35:61
 admixture analysis, schizophrenia, 35:61
 admixture analysis, ventricle-brain ratio, 35:61
 age, glutathione peroxidase, 31:1
 age, monoamine oxidase, 31:1
 age, neuroleptics, 31:1
 age, schizophrenia, 31:1, 35:61
 age, third ventricle, 31:1
 age, ventricle, 35:115
 age, ventricle-brain ratio, 31:1, 35:61
 age, volumetric measurement, 35:115
 brain atrophy, neuroleptic treatment, 33:307
 brain atrophy, schizophrenia, 33:307
 brain atrophy, somatostatin, 33:307
 corpus callosum, laterality, 34:163
 corpus callosum, magnetic resonance imaging, 34:163
 corpus callosum, schizophrenia, 34:163
 frontal lobe, HLA antigen, 31:221
 frontal lobe, laterality, 31:221
 frontal lobe, neuroleptic response, 31:221
 frontal lobe, schizophrenia, 31:221
 frontal lobe, ventricle-brain ratio, 31:221
 glutathione peroxidase, age, 31:1
 glutathione peroxidase, monoamine oxidase, 31:1
 glutathione peroxidase, neuroleptics, 31:1
 glutathione peroxidase, schizophrenia, 31:1
 glutathione peroxidase, third ventricle, 31:1
 glutathione peroxidase, ventricle-brain ratio, 31:1
 head tilt correction, laterality, 35:71
 HLA antigen, frontal lobe, 31:221
 HLA antigen, laterality, 31:221
 HLA antigen, neuroleptic response, 31:221
 HLA antigen, schizophrenia, 31:221
 HLA antigen, ventricle-brain ratio, 31:221
 laterality, corpus callosum, 34:163
 laterality, frontal lobe, 31:221
 laterality, head tilt correction, 35:71
 laterality, HLA antigen, 31:221
 laterality, magnetic resonance imaging, 34:163
 laterality, neuroleptic response, 31:221
 laterality, schizophrenia, 31:221, 34:163
 laterality, ventricle-brain ratio, 31:221
 magnetic resonance imaging, corpus callosum, 34:163
 magnetic resonance imaging, laterality, 34:163
 magnetic resonance imaging, schizophrenia, 34:163

Computed tomography continued

monoamine oxidase, age, 31:1
 monoamine oxidase, glutathione peroxidase, 31:1
 monoamine oxidase, neuroleptics, 31:1
 monoamine oxidase, schizophrenia, 31:1
 monoamine oxidase, third ventricle, 31:1
 monoamine oxidase, ventricle-brain ratio, 31:1
 neuroleptic response, frontal lobe, 31:221
 neuroleptic response, HLA antigen, 31:221
 neuroleptic response, laterality, 31:221
 neuroleptic response, schizophrenia, 31:221
 neuroleptic response, ventricle-brain ratio, 31:221
 neuroleptic treatment, brain atrophy, 33:307
 neuroleptic treatment, schizophrenia, 33:307
 neuroleptic treatment, somatostatin, 33:307
 neuroleptics, age, 31:1
 neuroleptics, glutathione peroxidase, 31:1
 neuroleptics, monoamine oxidase, 31:1
 neuroleptics, schizophrenia, 31:1
 neuroleptics, third ventricle, 31:1
 neuroleptics, ventricle-brain ratio, 31:1
 schizophrenia, admixture analysis, 35:61
 schizophrenia, age, 31:1, 35:61
 schizophrenia, brain atrophy, 33:307
 schizophrenia, corpus callosum, 34:163
 schizophrenia, frontal lobe, 31:221
 schizophrenia, glutathione peroxidase, 31:1
 schizophrenia, HLA antigen, 31:221
 schizophrenia, laterality, 31:221, 34:163
 schizophrenia, magnetic resonance imaging, 34:163
 schizophrenia, monoamine oxidase, 31:1
 schizophrenia, neuroleptic response, 31:221
 schizophrenia, neuroleptic treatment, 33:307
 schizophrenia, neuroleptics, 31:1
 schizophrenia, somatostatin, 33:307
 schizophrenia, third ventricle, 31:1
 schizophrenia, ventricle-brain ratio, 31:1
 schizophrenia, ventricle-brain ratio, 31:1, 31:221, 35:61
 somatostatin, brain atrophy, 33:307
 somatostatin, neuroleptic treatment, 33:307
 somatostatin, schizophrenia, 33:307
 third ventricle, age, 31:1
 third ventricle, glutathione peroxidase, 31:1
 third ventricle, monoamine oxidase, 31:1
 third ventricle, neuroleptics, 31:1
 third ventricle, schizophrenia, 31:1

Computed tomography continued

- third ventricle, ventricle-brain ratio, 31:1
- ventricle, age, 35:115
- ventricle, volumetric measurement, 35:115
- ventricle-brain ratio, admixture analysis, 35:61
- ventricle-brain ratio, age, 31:1, 35:61
- ventricle-brain ratio, frontal lobe, 31:221
- ventricle-brain ratio, glutathione peroxidase, 31:1
- ventricle-brain ratio, HLA antigen, 31:221
- ventricle-brain ratio, laterality, 31:221
- ventricle-brain ratio, monoamine oxidase, 31:1
- ventricle-brain ratio, neuroleptic response, 31:221
- ventricle-brain ratio, neuroleptics, 31:1
- ventricle-brain ratio, schizophrenia, 31:1, 31:221, 35:61
- ventricle-brain ratio, third ventricle, 31:1
- volumetric measurement, age, 35:115
- volumetric measurement, ventricle, 35:115

Computerized electroencephalographic topography

- alpha power, cocaine, 35:95
- alpha power, electroencephalogram, 35:95
- alpha power, substance abuse, 35:95
- arecoline, sleep, 35:91
- cocaine, alpha power, 35:95
- cocaine, electroencephalogram, 35:95
- cocaine, substance abuse, 35:95
- electroencephalogram, cocaine, 35:95
- electroencephalogram, substance abuse, 35:95
- sleep, REM induction, 35:91
- substance abuse, alpha power, 35:95
- substance abuse, electroencephalogram, 35:95

Conduct disorder

- blood pressure, children, 33:199
- blood pressure, heart rate, 33:199
- blood pressure, separation anxiety, 33:199
- childhood depression, obsessive-compulsive disorder, 33:277
- childhood depression, somatostatin, 33:277
- children, blood pressure, 33:199
- children, heart rate, 33:199
- children, separation anxiety, 33:199
- heart rate, separation anxiety, 33:199
- obsessive-compulsive disorder, somatostatin, 33:277
- separation anxiety, blood pressure, 33:199
- separation anxiety, children, 33:199
- separation anxiety, heart rate, 33:199
- somatostatin, childhood depression, 33:277

Conduct disorder continued

- somatostatin, obsessive-compulsive disorder, 33:277

Continuous performance test

- attention, neuroleptic treatment, 32:281, 33:179
- attention, schizophrenia, 33:179
- neuroleptic treatment, attention, 32:281, 33:179
- neuroleptic treatment, schizophrenia, 33:179
- schizophrenia, attention, 33:179
- schizophrenia, neuroleptic treatment, 33:179

Corpus callosum

- computed tomography, laterality, 34:163
- computed tomography, schizophrenia, 34:163
- ethanol, glucose metabolic rate, 35:39
- ethanol, positron emission tomography, 35:39
- glucose metabolic rate, ethanol, 35:39
- glucose metabolic rate, positron emission tomography, 35:39
- laterality, computed tomography, 34:163
- laterality, magnetic resonance imaging, 34:163
- laterality, schizophrenia, 34:163
- magnetic resonance imaging, laterality, 34:163
- magnetic resonance imaging, schizophrenia, 34:163
- positron emission tomography, ethanol, 35:39
- positron emission tomography, glucose metabolic rate, 35:39
- schizophrenia, computed tomography, 34:163
- schizophrenia, laterality, 34:163
- schizophrenia, magnetic resonance imaging, 34:163

Corticotropin releasing hormone

- age, alcoholism, 31:261
- age, diazepam binding inhibitor in CSF, 31:261
- alcoholism, age, 31:261
- alcoholism, cerebrospinal fluid, 33:215
- alcoholism, diazepam binding inhibitor in CSF, 31:261
- alcoholism, growth hormone releasing hormone, 33:215
- alcoholism, neuropeptide Y, 33:215
- alcoholism, somatostatin, 33:215
- cerebrospinal fluid, alcoholism, 33:215

Corticotropin releasing hormone continued

- cerebrospinal fluid, growth hormone releasing hormone, 33:215
- cerebrospinal fluid, neuropeptide Y, 33:215
- cerebrospinal fluid, somatostatin, 33:215
- diazepam binding inhibitor in CSF, age, 31:261
- diazepam binding inhibitor in CSF, alcoholism, 31:261
- growth hormone releasing hormone, alcoholism, 33:215
- growth hormone releasing hormone, cerebrospinal fluid, 33:215
- neuropeptide Y, alcoholism, 33:215
- neuropeptide Y, cerebrospinal fluid, 33:215
- neuropeptide Y, growth hormone releasing hormone, 33:215
- somatostatin, alcoholism, 33:215
- somatostatin, cerebrospinal fluid, 33:215
- somatostatin, growth hormone releasing hormone, 33:215

Cortisol

- adrenergic-cholinergic balance, cholinergic system, 34:259
- adrenergic-cholinergic balance, cyclic adenosine monophosphate, 34:259
- adrenergic-cholinergic balance, glucose, 34:259
- adrenergic-cholinergic balance, heart rate, 34:259
- adrenergic-cholinergic balance, neostigmine, 34:259
- adrenergic-cholinergic balance, physostigmine, 34:259
- adrenocorticotrophic hormone, affective disorder, 31:39, 31:57, 34:29, 34:59, 34:107
- adrenocorticotrophic hormone, age, 34:237
- adrenocorticotrophic hormone, Alzheimer's disease, 33:107, 34:237
- adrenocorticotrophic hormone, bipolar, 31:57
- adrenocorticotrophic hormone, clomipramine, 31:39
- adrenocorticotrophic hormone, depressive symptoms, 34:59
- adrenocorticotrophic hormone, dexamethasone suppression test, 31:31, 34:107, 34:59
- adrenocorticotrophic hormone, duration of diabetes, 31:31
- adrenocorticotrophic hormone, glucocorticoid receptors, 34:237
- adrenocorticotrophic hormone, growth hormone, 31:57, 33:107, 31:39

Cortisol continued

- adrenocorticotrophic hormone, heart rate, 31:39
- adrenocorticotrophic hormone, insulin-like growth factor, 33:107
- adrenocorticotrophic hormone, leukocytes, 34:237
- adrenocorticotrophic hormone, prolactin, 31:39, 31:57
- adrenocorticotrophic hormone, subtype diagnosis, 34:107
- adrenocorticotrophic hormone, thyroid stimulating hormone, 34:29, 34:59
- adrenocorticotrophic hormone, thyroxine, 34:29, 34:59
- adrenocorticotrophic hormone, tryptophan, 31:57, 34:29, 34:59
- adrenocorticotrophic hormone, vital depression, 34:29
- affective disorder, adrenocorticotrophic hormone, 31:39, 31:57, 34:29, 34:59, 34:107
- affective disorder, binding sites, 34:303
- affective disorder, bipolar, 31:57
- affective disorder, clomipramine, 31:39
- affective disorder, depressive symptoms, 34:59
- affective disorder, dexamethasone suppression test, 34:59, 34:107, 34:149
- affective disorder, growth hormone, 31:39, 31:57
- affective disorder, heart rate, 31:39
- affective disorder, imipramine, 34:303
- affective disorder, prolactin, 31:39, 31:57
- affective disorder, sleep deprivation, 34:149
- affective disorder, stress and arousal levels, 34:149
- affective disorder, subtype diagnosis, 34:107
- affective disorder, thyroid stimulating hormone, 34:29, 34:59
- affective disorder, thyroxine, 34:29, 34:59
- affective disorder, treatment effects, 34:303
- affective disorder, tryptophan, 31:57, 34:29, 34:59
- affective disorder, vital depression, 34:29
- age, adrenocorticotrophic hormone, 34:237
- age, Alzheimer's disease, 34:237
- age, glucocorticoid receptors, 34:237
- age, leukocytes, 34:237
- Alzheimer's disease, adrenocorticotrophic hormone, 33:107, 34:237
- Alzheimer's disease, age, 34:237
- Alzheimer's disease, glucocorticoid receptors, 34:237

Cortisol continued

Alzheimer's disease, growth hormone, 33:107
 Alzheimer's disease, insulin-like growth factor, 33:107
 Alzheimer's disease, leukocytes, 34:237
 amino acids, catecholamines, 34:243
 amino acids, melatonin, 34:243
 amino acids, neuroleptics, 34:243
 amino acids, schizophrenia, 34:243
 amino acids, tryptophan, 34:243
 beta blockers, blood pressure, 32:175
 beta blockers, heart rate, 32:175
 beta blockers, melatonin, 32:175
 beta blockers, normal volunteers, 32:175
 binding sites, affective disorder, 34:303
 binding sites, imipramine, 34:303
 binding sites, treatment effects, 34:303
 bipolar, adrenocorticotrophic hormone, 31:57
 bipolar, affective disorder, 31:57
 bipolar, growth hormone, 31:57
 bipolar, prolactin, 31:57
 bipolar, tryptophan, 31:57
 blood pressure, beta blockers, 32:175
 blood pressure, heart rate, 32:175
 blood pressure, melatonin, 32:175
 blood pressure, normal volunteers, 32:175
 catecholamines, amino acids, 34:243
 catecholamines, cholinergic system, 34:259
 catecholamines, heart rate, 34:259
 catecholamines, melatonin, 34:243
 catecholamines, neuroleptics, 34:243
 catecholamines, physostigmine, 34:259
 catecholamines, schizophrenia, 34:243
 catecholamines, stress, 34:259
 catecholamines, tryptophan, 34:243
 cholinergic system, adrenergic-cholinergic balance, 34:259
 cholinergic system, catecholamines, 34:259
 cholinergic system, cyclic adenosine monophosphate, 34:259
 cholinergic system, glucose, 34:259
 cholinergic system, heart rate, 34:259
 cholinergic system, neostigmine, 34:259
 cholinergic system, physostigmine, 34:259
 cholinergic system, stress, 34:259
 clomipramine, adrenocorticotrophic hormone, 31:39
 clomipramine, affective disorder, 31:39
 clomipramine, depressed mood, 32:151
 clomipramine, dexamethasone suppression test, 32:151
 clomipramine, growth hormone response, 31:39

Cortisol continued

clomipramine, heart rate, 31:39
 clomipramine, obsessive-compulsive disorder, 32:151
 clomipramine, prolactin response, 31:39
 cyclic adenosine monophosphate, adrenergic-cholinergic balance, 34:259
 cyclic adenosine monophosphate, cholinergic system, 34:259
 cyclic adenosine monophosphate, glucose, 34:259
 cyclic adenosine monophosphate, heart rate, 34:259
 cyclic adenosine monophosphate, neostigmine, 34:259
 cyclic adenosine monophosphate, physostigmine, 34:259
 depressed mood, clomipramine, 32:151
 depressed mood, dexamethasone suppression test, 32:151
 depressed mood, obsessive-compulsive disorder, 32:151
 depressive symptoms, adrenocorticotrophic hormone, 34:59
 depressive symptoms, affective disorder, 34:59
 depressive symptoms, dexamethasone suppression test, 34:59
 depressive symptoms, thyroid stimulating hormone, 34:59
 depressive symptoms, thyroxine, 34:59
 depressive symptoms, tryptophan, 34:59
 dexamethasone suppression test, adrenocorticotrophic hormone, 31:31, 34:59, 34:107
 dexamethasone suppression test, affective disorder, 34:59, 34:107, 34:149
 dexamethasone suppression test, clomipramine, 32:151
 dexamethasone suppression test, depressed mood, 32:151
 dexamethasone suppression test, depressive symptoms, 34:59
 dexamethasone suppression test, diabetes, 31:31
 dexamethasone suppression test, duration of diabetes, 31:31
 dexamethasone suppression test, obsessive-compulsive disorder, 32:151
 dexamethasone suppression test, sleep deprivation, 34:149
 dexamethasone suppression test, stress and arousal levels, 34:149
 dexamethasone suppression test, subtype diagnosis, 34:107

Cortisol continued

dexamethasone suppression test, thyroid stimulating hormone, 34:59
 dexamethasone suppression test, thyroxine, 34:59
 dexamethasone suppression test, tryptophan, 34:59
 diabetes, adrenocorticotrophic hormone, 31:31
 diabetes, dexamethasone suppression test, 31:31
 diabetes, duration of diabetes, 31:31
 fenfluramine, panic-disorder, 31:211
 glucocorticoid receptors, adrenocorticotrophic hormone, 34:237
 glucocorticoid receptors, age, 34:237
 glucocorticoid receptors, Alzheimer's disease, 34:237
 glucocorticoid receptors, leukocytes, 34:237
 glucose, adrenergic-cholinergic balance, 34:259
 glucose, cholinergic system, 34:259
 glucose, cyclic adenosine monophosphate, 34:259
 glucose, heart rate, 34:259
 glucose, neostigmine, 34:259
 glucose, physostigmine, 34:259
 growth hormone, adrenocorticotrophic hormone, 31:57, 33:107
 growth hormone, affective disorder, 31:57
 growth hormone, Alzheimer's disease, 33:107
 growth hormone, bipolar, 31:57
 growth hormone, insulin-like growth factor, 33:107
 growth hormone, prolactin, 31:57
 growth hormone response, adrenocorticotrophic hormone, 31:39
 growth hormone response, affective disorder, 31:39
 growth hormone response, clomipramine, 31:39
 growth hormone response, heart rate, 31:39
 growth hormone response, prolactin response, 31:39
 growth hormone, tryptophan, 31:57
 heart rate, adrenergic-cholinergic balance, 34:259
 heart rate, adrenocorticotrophic hormone, 31:39
 heart rate, affective disorder, 31:39
 heart rate, beta blockers, 32:175
 heart rate, blood pressure, 32:175
 heart rate, catecholamines, 34:259

Cortisol continued

heart rate, cholinergic system, 34:259
 heart rate, clomipramine, 31:39
 heart rate, cyclic adenosine monophosphate, 34:259
 heart rate, glucose, 34:259
 heart rate, growth hormone response, 31:39
 heart rate, melatonin, 32:175
 heart rate, neostigmine, 34:259
 heart rate, normal volunteers, 32:175
 heart rate, physostigmine, 34:259, 34:
 heart rate, prolactin response, 31:39
 heart rate, stress, 34:259
 imipramine, affective disorder, 34:303
 imipramine, binding sites, 34:303
 imipramine, treatment effects, 34:303
 insulin-like growth factor, adrenocorticotrophic hormone, 33:107
 insulin-like growth factor, Alzheimer's disease, 33:107
 insulin-like growth factor, growth hormone, 33:107
 leukocytes, adrenocorticotrophic hormone, 34:237
 leukocytes, age, 34:237
 leukocytes, Alzheimer's disease, 34:237
 leukocytes, glucocorticoid receptors, 34:237
 lithium, 3-methoxy-4-hydroxyphenylglycol, 32:71
m-chlorophenylpiperazine, metergoline, 33:189
m-chlorophenylpiperazine, methysergide, 33:189
m-chlorophenylpiperazine, normal volunteers, 33:189
m-chlorophenylpiperazine, prolactin, 33:189
 melatonin, amino acids, 34:243
 melatonin, beta blockers, 32:175
 melatonin, blood pressure, 32:175
 melatonin, catecholamines, 34:243
 melatonin, heart rate, 32:175
 melatonin, neuroleptics, 34:243
 melatonin, normal volunteers, 32:175
 melatonin, schizophrenia, 34:243
 melatonin, tryptophan, 34:243
 metergoline, *m*-chlorophenylpiperazine, 33:189
 metergoline, methysergide, 33:189
 metergoline, normal volunteers, 33:189
 metergoline, prolactin, 33:189
 3-methoxy-4-hydroxyphenylglycol, lithium, 32:71

Cortisol continued

methysergide, *m*-chlorophenylpiperazine, 33:189
 methysergide, metergoline, 33:189
 methysergide, normal volunteers, 33:189
 methysergide, prolactin, 33:189
 neostigmine, adrenergic-cholinergic balance, 34:259
 neostigmine, cholinergic system, 34:259
 neostigmine, cyclic adenosine monophosphate, 34:259
 neostigmine, glucose, 34:259
 neostigmine, heart rate, 34:259
 neostigmine, physostigmine, 34:259
 neuroleptics, amino acids, 34:243
 neuroleptics, catecholamines, 34:243
 neuroleptics, melatonin, 34:243
 neuroleptics, schizophrenia, 34:243
 neuroleptics, tryptophan, 34:243
 normal volunteers, beta blockers, 32:175
 normal volunteers, blood pressure, 32:175
 normal volunteers, heart rate, 32:175
 normal volunteers, *m*-chlorophenylpiperazine, 33:189
 normal volunteers, melatonin, 32:175
 normal volunteers, metergoline, 33:189
 normal volunteers, methysergide, 33:189
 normal volunteers, prolactin, 33:189
 obsessive-compulsive disorder, clomipramine, 32:151
 obsessive-compulsive disorder, depressed mood, 32:151
 obsessive-compulsive disorder, dexamethasone suppression test, 32:151
 panic-disorder, fenfluramine, 31:211
 physostigmine, adrenergic-cholinergic balance, 34:259
 physostigmine, catecholamines, 34:259
 physostigmine, cholinergic system, 34:259
 physostigmine, cyclic adenosine monophosphate, 34:259
 physostigmine, glucose, 34:259
 physostigmine, heart rate, 34:259
 physostigmine, neostigmine, 34:259
 physostigmine, stress, 34:259
 prolactin, adrenocorticotrophic hormone, 31:39, 31:57
 prolactin, affective disorder, 31:39, 31:57
 prolactin, bipolar, 31:57
 prolactin, clomipramine, 31:39
 prolactin, growth hormone, 31:39, 31:57
 prolactin, heart rate, 31:39
 prolactin, *m*-chlorophenylpiperazine, 33:189

Cortisol continued

prolactin, metergoline, 33:189
 prolactin, methysergide, 33:189
 prolactin, normal volunteers, 33:189
 prolactin, tryptophan, 31:57
 schizophrenia, amino acids, 34:243
 schizophrenia, catecholamines, 34:243
 schizophrenia, melatonin, 34:243
 schizophrenia, neuroleptics, 34:243
 schizophrenia, tryptophan, 34:243
 sleep deprivation, affective disorder, 34:149
 sleep deprivation, dexamethasone suppression test, 34:149
 sleep deprivation, stress and arousal levels, 34:149
 stress and arousal levels, affective disorder, 34:149
 stress and arousal levels, dexamethasone suppression test, 34:149
 stress and arousal levels, sleep deprivation, 34:149
 stress, catecholamines, 34:259
 stress, cholinergic system, 34:259
 stress, heart rate, 34:259
 stress, physostigmine, 34:259
 subtype diagnosis, adrenocorticotrophic hormone, 34:107
 subtype diagnosis, affective disorder, 34:107
 subtype diagnosis, dexamethasone suppression test, 34:107
 thyroid stimulating hormone, adrenocorticotrophic hormone, 34:29, 34:59
 thyroid stimulating hormone, affective disorder, 34:29, 34:59
 thyroid stimulating hormone, depressive symptoms, 34:59
 thyroid stimulating hormone, dexamethasone suppression test, 34:59
 thyroid stimulating hormone, thyroxine, 34:29, 34:59
 thyroid stimulating hormone, tryptophan, 34:29, 34:59
 thyroid stimulating hormone, vital depression, 34:29
 thyroxine, adrenocorticotrophic hormone, 34:29, 34:59
 thyroxine, affective disorder, 34:29, 34:59
 thyroxine, depressive symptoms, 34:59
 thyroxine, dexamethasone suppression test, 34:59
 thyroxine, thyroid stimulating hormone, 34:29, 34:59
 thyroxine, tryptophan, 34:29, 34:59

Cortisol continued

- thyroxine, vital depression, 34:29
- treatment effects, affective disorder, 34:303
- treatment effects, binding sites, 34:303
- treatment effects, imipramine, 34:303
- tryptophan, adrenocorticotrophic hormone, 31:57, 34:29, 34:59
- tryptophan, affective disorder, 31:57, 34:29, 34:59
- tryptophan, amino acids, 34:243
- tryptophan, bipolar, 31:57
- tryptophan, catecholamines, 34:243
- tryptophan, depressive symptoms, 34:59
- tryptophan, dexamethasone suppression test, 34:59
- tryptophan, growth hormone, 31:57
- tryptophan, melatonin, 34:243
- tryptophan, neuroleptics, 34:243
- tryptophan, prolactin, 31:57
- tryptophan, schizophrenia, 34:243
- tryptophan, thyroid stimulating hormone, 34:29, 34:59
- tryptophan, thyroxine, 34:29, 34:59
- tryptophan, vital depression, 34:29
- vital depression, adrenocorticotrophic hormone, 34:29
- vital depression, affective disorder, 34:29
- vital depression, thyroid stimulating hormone, 34:29
- vital depression, thyroxine, 34:29
- vital depression, tryptophan, 34:29

Criminality

- evoked potentials, augmenting-reducing, 31:85
- evoked potentials, schizophrenia, 31:85
- evoked potentials, eye tracking, 31:85
- augmenting-reducing, evoked potentials, 31:85
- augmenting-reducing, schizophrenia, 31:85
- schizophrenia, evoked potentials, 31:85
- schizophrenia, augmenting-reducing, 31:85
- schizophrenia, eye tracking, 31:85
- eye tracking, augmenting-reducing, 31:85

Cyclic adenosine monophosphate

- adrenergic-cholinergic balance, cholinergic system, 34:259
- adrenergic-cholinergic balance, cortisol, 34:259
- adrenergic-cholinergic balance, glucose, 34:259
- adrenergic-cholinergic balance, heart rate, 34:259
- adrenergic-cholinergic balance, neostigmine, 34:259

Cyclic adenosine monophosphate continued

- adrenergic-cholinergic balance, physostigmine, 34:259
- bulimia, eating disorder, 33:1
- cortisol, cholinergic system, 34:259
- eating disorder, bulimia, 33:1
- glucose, heart rate, 34:259
- heart rate, neostigmine, 34:259
- physostigmine, cholinergic system, 34:259
- physostigmine, cortisol, 34:259
- physostigmine, glucose, 34:259
- physostigmine, heart rate, 34:259

Cytomegalovirus

- schizophrenia, immunoglobulins, 33:11

Deficit syndrome

- age of illness onset, depression, 31:243
- age of illness onset, duration of illness, 31:243
- age of illness onset, schizophrenia, 31:243
- anhedonia, schizophrenia, 31:25
- depression, age of illness onset, 31:243
- depression, duration of illness, 31:243
- depression, schizophrenia, 31:243
- duration of illness, age of illness onset, 31:243
- duration of illness, depression, 31:243
- duration of illness, schizophrenia, 31:243
- schizophrenia, age of illness onset, 31:243
- schizophrenia, anhedonia, 31:25
- schizophrenia, depression, 31:243
- schizophrenia, duration of illness, 31:243

Depressed mood

- age of illness onset, deficit syndrome, 31:243
- age of illness onset, duration of illness, 31:243
- age of illness onset, schizophrenia, 31:243
- deficit syndrome, age of illness onset, 31:243
- duration of illness, deficit syndrome, 31:243
- schizophrenia, age of illness onset, 31:243
- schizophrenia, deficit syndrome, 31:243
- schizophrenia, duration of illness, 31:243

Desipramine

- affective disorder, depressive mood, 33:101
- affective disorder, displaceable imipramine binding sites, 34:303
- affective disorder, propranolol, 33:101
- affective disorder, treatment response, 33:101
- alprazolam, antidepressants, 32:141
- alprazolam, anxiety symptoms, 32:141
- alprazolam, course of illness, 32:141
- alprazolam, depressive symptoms, 32:141

Desipramine continued

- antidepressants, alprazolam, 32:141
- antidepressants, anxiety symptoms, 32:141
- antidepressants, course of illness, 32:141
- antidepressants, depressive symptoms, 32:141
- anxiety symptoms, alprazolam, 32:141
- anxiety symptoms, antidepressants, 32:141
- anxiety symptoms, course of illness, 32:141
- anxiety symptoms, depressive symptoms, 32:141
- course of illness, alprazolam, 32:141
- course of illness, antidepressants, 32:141
- course of illness, anxiety symptoms, 32:141
- course of illness, depressive symptoms, 32:141
- depressive mood, affective disorder, 33:101
- depressive mood, propranolol, 33:101
- depressive mood, treatment response, 33:101
- depressive symptoms, alprazolam, 32:141
- depressive symptoms, antidepressants, 32:141
- depressive symptoms, anxiety symptoms, 32:141
- depressive symptoms, course of illness, 32:141
- displaceable imipramine binding sites, affective disorder, 34:303
- propranolol, affective disorder, 33:101
- propranolol, depressive mood, 33:101
- propranolol, treatment response, 33:101
- rat brain, thyroxine, 34:217
- thyroxine, rat brain, 34:217
- treatment response, affective disorder, 33:101
- treatment response, depressive mood, 33:101
- treatment response, propranolol, 33:101

Dexamethasone

- adrenocorticotrophic hormone, affective disorder, 34:59, 34:107
- adrenocorticotrophic hormone, cortisol, 31:31, 34:59, 34:107
- adrenocorticotrophic hormone, depressive symptoms, 34:59
- adrenocorticotrophic hormone, diabetes, 31:31
- adrenocorticotrophic hormone, subtype diagnosis, 34:107
- adrenocorticotrophic hormone, thyroid stimulating hormone, 34:59
- adrenocorticotrophic hormone, thyroxine, 34:59

Dexamethasone continued

- adrenocorticotrophic hormone, tryptophan, 34:59
- affective disorder, adrenocorticotrophic hormone, 34:59, 34:107
- affective disorder, cortisol, 34:59, 34:107, 34:149
- affective disorder, depressive symptoms, 34:59
- affective disorder, dexamethasone concentration in serum, 31:49
- affective disorder, lithium pharmacokinetics, 32:71
- affective disorder, sleep deprivation, 34:149
- affective disorder, stress and arousal levels, 34:149
- affective disorder, subtype diagnosis, 34:107
- affective disorder, thyroid stimulating hormone, 34:59
- affective disorder, thyroxine, 34:59
- affective disorder, tryptophan, 34:59
- clomipramine, cortisol, 32:151
- clomipramine, depressed mood, 32:151
- clomipramine, obsessive-compulsive disorder, 32:151
- cortisol, adrenocorticotrophic hormone, 31:31, 34:59, 34:107
- cortisol, affective disorder, 34:59, 34:107, 34:149
- cortisol, clomipramine, 32:151
- cortisol, depressed mood, 32:151
- cortisol, depressive symptoms, 34:59
- cortisol, diabetes, 31:31
- cortisol, duration of diabetes, 31:31
- cortisol, obsessive-compulsive disorder, 32:151
- cortisol, sleep deprivation, 34:149
- cortisol, stress and arousal levels, 34:149
- cortisol, subtype diagnosis, 34:107
- cortisol, thyroid stimulating hormone, 34:59
- cortisol, thyroxine, 34:59
- cortisol, tryptophan, 34:59
- depressed mood, clomipramine, 32:151
- depressed mood, cortisol, 32:151
- depressed mood, obsessive-compulsive disorder, 32:151
- depressive symptoms, adrenocorticotrophic hormone, 34:59
- depressive symptoms, affective disorder, 34:59
- depressive symptoms, cortisol, 34:59

Dexamethasone continued

depressive symptoms, thyroid stimulating hormone, 34:59
 depressive symptoms, thyroxine, 34:59
 depressive symptoms, tryptophan, 34:59
 dexamethasone concentration in serum, affective disorder, 31:49
 diabetes, adrenocorticotrophic hormone, 31:31
 diabetes, cortisol, 31:31
 diabetes, duration of diabetes, 31:31
 duration of diabetes, adrenocorticotrophic hormone, 31:31
 duration of diabetes, cortisol, 31:31
 lithium pharmacokinetics, affective disorder, 32:71
 obsessive-compulsive disorder, clomipramine, 32:151
 obsessive-compulsive disorder, cortisol, 32:151
 obsessive-compulsive disorder, depressed mood, 32:151
 receiver operating characteristic analysis, affective disorder, 31:49
 receiver operating characteristic analysis, dexamethasone concentration in serum, 31:49
 sleep deprivation, affective disorder, 34:149
 sleep deprivation, cortisol, 34:149
 sleep deprivation, stress and arousal levels, 34:149
 stress and arousal levels, affective disorder, 34:149
 stress and arousal levels, cortisol, 34:149
 stress and arousal levels, sleep deprivation, 34:149
 subtype diagnosis, adrenocorticotrophic hormone, 34:107
 subtype diagnosis, affective disorder, 34:107
 subtype diagnosis, cortisol, 34:107
 thyroid stimulating hormone, adrenocorticotrophic hormone, 34:59
 thyroid stimulating hormone, affective disorder, 34:59
 thyroid stimulating hormone, cortisol, 34:59
 thyroid stimulating hormone, depressive symptoms, 34:59
 thyroid stimulating hormone, thyroxine, 34:59
 thyroid stimulating hormone, tryptophan, 34:59
 thyroxine, adrenocorticotrophic hormone, 34:59

Dexamethasone continued

thyroxine, affective disorder, 34:59
 thyroxine, cortisol, 34:59
 thyroxine, depressive symptoms, 34:59
 thyroxine, thyroid stimulating hormone, 34:59
 thyroxine, tryptophan, 34:59
 tryptophan, adrenocorticotrophic hormone, 34:59
 tryptophan, affective disorder, 34:59
 tryptophan, cortisol, 34:59
 tryptophan, depressive symptoms, 34:59
 tryptophan, thyroid stimulating hormone, 34:59
 tryptophan, thyroxine, 34:59

Dextroamphetamine

hyperactivity, motor tics, 33:83
 hyperactivity, obsessive-compulsive disorder, 33:83
 motor tics, hyperactivity, 33:83
 obsessive-compulsive disorder, motor tics, 33:83

Diabetes

adrenocorticotrophic hormone, cortisol, 31:31
 adrenocorticotrophic hormone, dexamethasone suppression test, 31:31
 adrenocorticotrophic hormone, duration of diabetes, 31:31
 cortisol, dexamethasone suppression test, 31:31
 dexamethasone suppression test, duration of diabetes, 31:31
 duration of diabetes, adrenocorticotrophic hormone, 31:31

Diagnosis

affective disorder, CES-D Scale, 31:69
 affective disorder, classification error, 31:145
 affective disorder, generalized anxiety disorder, 31:69
 affective disorder, Mexican-Americans, 31:69
 affective disorder, Research Diagnostic Criteria (RDC), 31:145
 affective disorder, SADS interview, 31:145
 avoidant personality disorder, criteria sensitivity, 34:281
 avoidant personality disorder, personality disorder, 34:281
 biological markers, vital depression, 34:59
 biological psychiatry, syndromal organization, 34:1
 CES-D Scale, affective disorder, 31:69

Diagnosis continued

- CES-D Scale, generalized anxiety disorder, 31:69
- CES-D Scale, Mexican-Americans, 31:69
- classification error, affective disorder, 31:145
- classification error, Research Diagnostic Criteria (RDC), 31:145
- classification error, SADS interview, 31:145
- cluster analysis of symptoms, vital depression, 34:29
- criteria sensitivity, avoidant personality disorder, 34:281
- criteria sensitivity, personality disorder, 34:281
- Diagnostic Interview Schedule
 - classification, lay interviews, 31:145
- Diagnostic Interview Schedule
 - classification, Schedule for Affective Disorder and Schizophrenia, 31:145
- familial schizophrenia, schizophrenia, 34:77
- familial schizophrenia, subtype stability, 34:77
- generalized anxiety disorder, affective disorder, 31:69
- generalized anxiety disorder, CES-D Scale, 31:69
- generalized anxiety disorder, Mexican-Americans, 31:69
- ICD-10, schizophrenia, 34:77
- ICD-10, Tsuang-Winokur criteria, 34:77
- lay interviews, Diagnostic Interview Schedule
 - classification, 31:145
- lay interviews, Schedule for Affective Disorders and Schizophrenia, 31:145
- Mexican-Americans, affective disorder, 31:69
- Mexican-Americans, CES-D Scale, 31:69
- Mexican-Americans, generalized anxiety disorder, 31:69
- personality disorder, avoidant personality disorder, 34:281
- personality disorder, criteria sensitivity, 34:281
- Personality Disorder Examination,
 - personality disorder, 32:85
- personality disorder, Personality Disorder Examination, 32:85
- Research Diagnostic Criteria (RDC),
 - affective disorder, 31:145
- Research Diagnostic Criteria (RDC),
 - classification error, 31:145

Diagnosis continued

- Research Diagnostic Criteria (RDC),
 - SADS interview, 31:145
- SADS interview, affective disorder, 31:145
- SADS interview, classification error, 31:145
- SADS interview, Research Diagnostic Criteria (RDC), 31:145
- Schedule for Affective Disorder and Schizophrenia, Diagnostic Interview Schedule
 - classification, 31:145
- Schedule for Affective Disorder and Schizophrenia, lay interviews, 31:145
- schizophrenia, familial schizophrenia, 34:77
- schizophrenia, ICD-10, 34:77
- schizophrenia, subtype stability, 34:77
- schizophrenia, Tsuang-Winokur criteria, 34:77
- subtype stability, familial schizophrenia, 34:77
- subtype stability, schizophrenia, 34:77
- syndromal organization, biological psychiatry, 34:1
- Tsuang-Winokur criteria, ICD-10, 34:77
- Tsuang-Winokur criteria, schizophrenia, 34:77
- vital depression, biological markers, 34:59
- vital depression, cluster analysis of symptoms, 34:29

Diazepam

- binding inhibitor, alcohol, 31:261

Domperidone

- schizophrenia, prolactin, 34:139

Dopamine

- amino acids in serum, drug-naïve patients, 34:243
- amino acids in serum, schizophrenia, 34:243
- blood pressure, electroconvulsive therapy, 34:127
- drug-naïve patients, amino acids in serum, 34:243
- drug-naïve patients, schizophrenia, 34:243
- electroconvulsive therapy, blood pressure, 34:127
- electroconvulsive therapy, heart rate, 34:127
- heart rate, electroconvulsive therapy, 34:127
- schizophrenia, amino acids in serum, 34:243

Duration of illness

- age, brain atrophy, 31:1

Duration of illness continued

- age of illness onset, deficit syndrome, 31:243
- age of illness onset, depression, 31:243
- age of illness onset, schizophrenia, 31:243
- brain atrophy, age, 31:1
- deficit syndrome, age of illness onset, 31:243
- deficit syndrome, depression, 31:243
- deficit syndrome, schizophrenia, 31:243
- depression, age of illness onset, 31:243
- depression, deficit syndrome, 31:243
- depression, schizophrenia, 31:243
- schizophrenia, age of illness onset, 31:243
- schizophrenia, deficit syndrome, 31:243
- schizophrenia, depression, 31:243

Dynorphin

- cerebrospinal fluid, endorphin, 34:229
- cerebrospinal fluid, schizophrenia, 34:229
- cerebrospinal fluid, substance P, 34:229
- schizophrenia, substance P, 34:229
- substance P, cerebrospinal fluid, 34:229

Eating disorders

- anxiety, bulimia, 33:1
- anxiety, free fatty acids, 33:1
- anxiety, isoproterenol, 33:1
- anxiety, norepinephrine, 33:1
- blood pressure, isoproterenol, 33:1
- blood pressure, temperature of body, 33:1
- blood pressure, weight, 33:1
- bulimia, anxiety, 33:1
- bulimia, isoproterenol, 33:1
- bulimia, norepinephrine, 33:1
- circannual rhythm, melatonin, 32:221
- circannual rhythm, weight, 32:221
- cyclic adenosine monophosphate, isoproterenol, 33:1
- diurnal rhythm, melatonin, 32:221
- diurnal rhythm, weight, 32:221
- free fatty acids, anxiety, 33:1
- free fatty acids, isoproterenol, 33:1
- free fatty acids, norepinephrine, 33:1
- heart rate, isoproterenol, 33:1
- isoproterenol, anxiety, 33:1
- isoproterenol, blood pressure, 33:1
- isoproterenol, free fatty acids, 33:1
- isoproterenol, heart rate, 33:1
- isoproterenol, norepinephrine, 33:1
- isoproterenol, temperature of body, 33:1
- isoproterenol, weight, 33:1
- melatonin, circannual rhythm, 32:221
- melatonin, diurnal rhythm, 32:221
- melatonin, weight, 32:221
- norepinephrine, anxiety, 33:1
- norepinephrine, free fatty acids, 33:1

Eating disorders continued

- norepinephrine, isoproterenol, 33:1
- temperature of body, blood pressure, 33:1
- temperature of body, heart rate, 33:1
- temperature of body, isoproterenol, 33:1
- temperature of body, weight, 33:1
- weight, blood pressure, 33:1
- weight, heart rate, 33:1
- weight, melatonin, 32:221
- weight, temperature of body, 33:1

Electroconvulsive therapy

- affective disorder, antidepressants, 31:287
- affective disorder, blood pressure, 34:127
- affective disorder, catecholamines in plasma, 34:127
- affective disorder, heart rate, 34:127
- affective disorder, oxytocin, 32:201
- affective disorder, pharmacotherapy response, 31:287
- affective disorder, vasopressin, 32:201
- antidepressants, pharmacotherapy response, 31:287
- blood pressure, affective disorder, 34:127
- blood pressure, catecholamines in plasma, 34:127
- catecholamines in plasma, affective disorder, 34:127
- catecholamines in plasma, blood pressure, 34:127
- catecholamines in plasma, heart rate, 34:127
- heart rate, affective disorder, 34:127
- heart rate, blood pressure, 34:127
- heart rate, catecholamines in plasma, 34:127
- oxytocin, affective disorder, 32:201
- oxytocin, vasopressin, 32:201
- pharmacotherapy response, affective disorder, 31:287
- vasopressin, affective disorder, 32:201
- vasopressin, oxytocin, 32:201

Electroencephalography

- alpha power, cocaine, 35:95
- alpha power, computerized electroencephalographic topography, 35:95
- alpha power, substance abuse, 35:95
- arecoline, computerized electroencephalographic topography, 35:91
- arecoline, REM induction, 35:91
- cocaine, alpha power, 35:95
- cocaine, computerized electroencephalographic topography, 35:95
- computerized electroencephalographic topography, alpha power, 35:95

Electroencephalography continued

computerized electroencephalographic topography, arecoline, 35:91
 computerized electroencephalographic topography, cocaine, 35:95
 computerized electroencephalographic topography, REM induction, 35:91
 computerized electroencephalographic topography, sleeping, 35:91
 computerized electroencephalographic topography, substance abuse, 35:95
 REM induction, arecoline, 35:91
 REM induction, computerized electroencephalographic topography, 35:91
 sleeping, computerized electroencephalographic topography, 35:91
 substance abuse, alpha power, 35:95
 substance abuse, cocaine, 35:95
 substance abuse, computerized electroencephalographic topography, 35:95

Endorphins

affective disorder, caudate nucleus, 32:159
 affective disorder, frontal lobe, 32:159
 affective disorder, hypothalamus, 32:159
 affective disorder, laterality, 32:159
 affective disorder, suicide, 32:159
 affective disorder, temporal lobe, 32:159
 caudate nucleus, affective disorder, 32:159
 caudate nucleus, laterality, 32:159
 caudate nucleus, suicide, 32:159
 cerebrospinal fluid, dynorphin, 34:229
 cerebrospinal fluid, schizophrenia, 34:229
 cerebrospinal fluid, substance P, 34:229
 depressed mood, 5-hydroxytryptophan, 31:267
 depressed mood, melatonin, 31:267
 depressed mood, panic disorder, 31:267
 depressed mood, platelet 5HT uptake, 31:267
 depressed mood, serotonin, 31:267
 dynorphin, cerebrospinal fluid, 34:229
 dynorphin, schizophrenia, 34:229
 frontal lobe, affective disorder, 32:159
 frontal lobe, laterality, 32:159
 frontal lobe, suicide, 32:159
 5-hydroxytryptophan, depressed mood, 31:267
 hypothalamus, affective disorder, 32:159
 hypothalamus, caudate nucleus, 32:159
 hypothalamus, laterality, 32:159
 hypothalamus, suicide, 32:159
 laterality, affective disorder, 32:159
 laterality, caudate nucleus, 32:159
 laterality, frontal lobe, 32:159
 laterality, hypothalamus, 32:159

Endorphins continued

laterality, suicide, 32:159
 laterality, temporal lobe, 32:159
 melatonin, depressed mood, 31:267
 melatonin, hydroxytryptophan, 31:267
 melatonin, panic disorder, 31:267
 panic disorder, depressed mood, 31:267
 panic disorder, hydroxytryptophan, 31:267
 panic disorder, melatonin, 31:267
 panic disorder, platelet 5HT uptake, 31:267
 panic disorder, serotonin, 31:267
 platelet serotonin uptake, depressed mood, 31:267
 platelet serotonin uptake, panic disorder, 31:267
 schizophrenia, dynorphin, 34:229
 schizophrenia, substance P, 34:229
 serotonin, depressed mood, 31:267
 serotonin, melatonin, 31:267
 serotonin, panic disorder, 31:267
 substance P, cerebrospinal fluid, 34:229
 substance P, dynorphin, 34:229
 substance P, schizophrenia, 34:229
 suicide, affective disorder, 32:159
 suicide, caudate nucleus, 32:159
 suicide, frontal lobe, 32:159
 suicide, hypothalamus, 32:159
 suicide, laterality, 32:159
 suicide, temporal lobe, 32:159
 temporal lobe, affective disorder, 32:159
 temporal lobe, laterality, 32:159
 temporal lobe, suicide, 32:159

Entorhinal cortex

Alzheimer's disease, astrocytes, 35:149
 astrocytes, dentate gyrus, 35:149
 dentate gyrus, granule cell layer, 35:149
 granule cell layer, hippocampus, 35:149
 hippocampus, parahippocampal gyrus, 35:149
 parahippocampal gyrus, subiculum, 35:149
 subiculum, Alzheimer's disease, 35:149

Epinephrine

amino acids in serum, drug-naive patients, 34:243
 amino acids in serum, schizophrenia, 34:243
 blood pressure, electroconvulsive therapy, 34:127
 depressed mood, generalized anxiety disorder, 32:35
 drug-naive patients, amino acids in serum, 34:243
 drug-naive patients, schizophrenia, 34:243
 electroconvulsive therapy, blood pressure, 34:127

Epinephrine continued

- electroconvulsive therapy, heart rate, 34:127
- generalized anxiety disorder, depressed mood, 32:35
- heart rate, electroconvulsive therapy, 34:127
- lithium pharmacokinetics, mania, 32:71
- mania, lithium pharmacokinetics, 32:71
- physostigmine, stress, 34:271
- schizophrenia, amino acids in serum, 34:243
- schizophrenia, drug-naïve patients, 34:243
- stress, physostigmine, 34:271

Epstein-Barr disease

- schizophrenia, immunoglobulins, 33:11

Ethanol

- alcoholism, benzodiazepine receptors, 35:39
- alcoholism, frontal lobe, 35:39
- alcoholism, positron emission tomography, 35:39
- benzodiazepine receptors, alcoholism, 35:39
- fluorodeoxyglucose, positron emission tomography, 35:39
- frontal lobe, alcoholism, 35:39
- frontal lobe, benzodiazepine receptors, 35:39
- frontal lobe, fluorodeoxyglucose, 35:39
- frontal lobe, positron emission tomography, 35:39
- glucose metabolic rate, alcoholism, 35:39
- pineal gland, serotonin binding, 32:19
- positron emission tomography, alcoholism, 35:39
- serotonin binding, pineal gland, 32:19

Evoked potentials

- augmenting-reducing, criminality, 31:85
- augmenting-reducing, eye tracking, 31:85
- augmenting-reducing, schizophrenia, 31:85
- catecholamine metabolites, neuroleptic treatment, 31:297
- catecholamine metabolites, schizophrenia, 31:297
- criminality, augmenting-reducing, 31:85
- criminality, eye tracking, 31:85
- criminality, schizophrenia, 31:85
- eye tracking, criminality, 31:85
- eye tracking, schizophrenia, 31:85
- neuroleptic treatment, catecholamine metabolites, 31:297
- neuroleptic treatment, schizophrenia, 31:297
- schizophrenia, augmenting-reducing, 31:85

Evoked potentials continued

- schizophrenia, catecholamine metabolites, 31:297
- schizophrenia, criminality, 31:85
- schizophrenia, eye tracking, 31:85
- schizophrenia, neuroleptic treatment, 31:297

Eye tracking

- age, Scale for the Assessment of Negative Symptoms, 34:89
- age, schizophrenia, 34:89
- augmenting-reducing, criminality, 31:85
- augmenting-reducing, evoked-potentials, 31:85
- augmenting-reducing, schizophrenia, 31:85
- criminality, augmenting-reducing, 31:85
- criminality, evoked potentials, 31:85
- evoked potentials, criminality, 31:85
- evoked potentials, intensity of stimuli, 31:85
- evoked potentials, psychopathy, 31:85
- evoked potentials, schizophrenia, 31:85
- intensity of stimuli, evoked potentials, 31:85
- intensity of stimuli, psychopathy, 31:85
- psychopathy, evoked potentials, 31:85
- psychopathy, intensity of stimuli, 31:85
- Scale for the Assessment of Negative Symptoms, schizophrenia, 34:89
- schizophrenia, age, 34:89
- schizophrenia, augmenting-reducing, 31:85
- schizophrenia, evoked potentials, 31:85
- schizophrenia, Scale for the Assessment of Negative Symptoms, 34:89

Eysenck Personality Questionnaire

- affective disorder, panic disorder, 31:179

Fenfluramine

- cortisol, panic-disorder, 31:211
- panic disorder, serotonin, 31:215

Fibroblasts

- schizophrenia, electrophoresis of protein, 32:135

Fluorodeoxyglucose

- alcoholism, benzodiazepine receptors, 35:39
- anxiety, glucose metabolic rate, 35:49
- benzodiazepine receptors, ethanol, 35:39
- ethanol, frontal lobe, 35:39
- frontal lobe, positron emission tomography, 35:39
- glucose metabolic rate, frontal lobe, 35:39, 35:49
- positron emission tomography, alcoholism, 35:39

Follicle stimulating hormone

- affective disorders, depressive mood, 32:229
- depressive mood, luteinizing hormone, 32:229
- luteinizing hormone, menopause, 32:229
- menopause, affective disorders, 32:229

Free fatty acids

- anxiety, bulimia, 33:1
- bulimia, eating disorders, 33:1
- eating disorders, isoproterenol, 33:1
- isoproterenol, norepinephrine, 33:1
- norepinephrine, anxiety, 33:1

Frontal lobe

- affective disorder, caudate nucleus, 32:159
- affective disorder, endorphin, 32:159
- affective disorder, hypothalamus, 32:159
- affective disorder, laterality, 32:159
- affective disorder, suicide, 32:159
- affective disorder, temporal lobe, 32:159
- alcoholism, benzodiazepine receptors, 35:39
- alcoholism, positron emission tomography, 35:39
- benzodiazepine receptors, alcoholism, 35:39
- Boston Naming Test, magnetic resonance imaging, 35:115
- Boston Naming Test, sulcal width, 35:115
- caudate nucleus, affective disorder, 32:159
- caudate nucleus, endorphin, 32:159
- caudate nucleus, hypothalamus, 32:159
- caudate nucleus, laterality, 32:159
- caudate nucleus, suicide, 32:159
- cerebral blood flow, fronto-occipital ratio, 35:27
- cerebral blood flow, Scale for the Assessment of Negative Symptoms, 35:27
- cerebral blood flow, schizophrenia, 35:27
- computed tomography, HLA antigen, 31:221
- computed tomography, laterality, 31:221
- computed tomography, neuroleptic response, 31:221
- computed tomography, schizophrenia, 31:221
- computed tomography, ventricular brain ratio, 31:221
- dilapidation behavior, negative symptoms, 34:221
- dilapidation behavior, schizophrenia, 34:221
- endorphin, affective disorder, 32:159
- endorphin, caudate nucleus, 32:159
- endorphin, hypothalamus, 32:159

Frontal lobe continued

- endorphin, laterality, 32:159
- endorphin, suicide, 32:159
- endorphin, temporal lobe, 32:159
- ethanol, alcoholism, 35:39
- ethanol, benzodiazepine receptors, 35:39
- ethanol, fluorodeoxyglucose, 35:39
- ethanol, positron emission tomography, 35:39
- fluorodeoxyglucose, alcoholism, 35:39
- fluorodeoxyglucose, benzodiazepine receptors, 35:39
- fluorodeoxyglucose, ethanol, 35:39
- fluorodeoxyglucose, positron emission tomography, 35:39, 35:49
- ¹⁹F-fluphenazine, magnetic resonance imaging, 35:107
- ¹⁹F-fluphenazine, neuroleptic detection, 35:107
- fronto-occipital ratio, cerebral blood flow, 35:27
- fronto-occipital ratio, Scale for the Assessment of Negative Symptoms, 35:27
- fronto-occipital ratio, schizophrenia, 35:27
- glucose metabolic rate, positron emission tomography, 35:39, 35:49
- Halstead-Reitan Battery, negative symptoms, 31:15
- Halstead-Reitan Battery, schizophrenia, 31:15
- Halstead-Reitan Battery, verbal fluency, 31:15
- Halstead-Reitan Battery, Wechsler Adult Intelligence Scale, 31:15
- HLA antigen, computed tomography, 31:221
- HLA antigen, laterality, 31:221
- HLA antigen, neuroleptic response, 31:221
- HLA antigen, schizophrenia, 31:221
- HLA antigen, ventricle-brain ratio, 31:221
- hypothalamus, affective disorder, 32:159
- hypothalamus, endorphin, 32:159
- hypothalamus, laterality, 32:159
- hypothalamus, suicide, 32:159
- laterality, affective disorder, 32:159
- laterality, caudate nucleus, 32:159
- laterality, computed tomography, 31:221
- laterality, endorphin, 32:159
- laterality, HLA antigen, 31:221
- laterality, hypothalamus, 32:159
- laterality, neuroleptic response, 31:221
- laterality, schizophrenia, 31:221
- laterality, suicide, 32:159
- laterality, temporal lobe, 32:159
- laterality, ventricle-brain ratio, 31:221

Frontal lobe continued

magnetic resonance imaging,
¹⁹F-fluphenazine, 35:107
 magnetic resonance imaging, Boston
 Naming Test, 35:115
 magnetic resonance imaging, neuroleptic
 detection, 35:107
 magnetic resonance imaging,
 pharmacokinetics, 35:107
 magnetic resonance imaging, sulcal width,
 35:115
 negative symptoms, dilapidation behavior,
 34:221
 negative symptoms, Halstead-Reitan
 Battery, 31:15
 negative symptoms, neuropsychological
 deficit, 31:15
 negative symptoms, Scale for the Assess-
 ment of Negative Symptoms, 31:15
 negative symptoms, schizoaffective
 disorder, 31:15
 negative symptoms, schizophrenia, 31:15,
 34:221
 negative symptoms, verbal fluency, 31:15
 negative symptoms, Wechsler Adult
 Intelligence Scale, 31:15
 neuroleptic detection, ¹⁹F-fluphenazine,
 35:107
 neuroleptic detection, magnetic resonance
 imaging, 35:107
 neuroleptic detection, pharmacokinetics,
 35:107
 neuroleptic response, computed
 tomography, 31:221
 neuroleptic response, HLA antigen, 31:221
 neuroleptic response, laterality, 31:221
 neuroleptic response, schizophrenia, 31:221
 neuroleptic response, ventricle-brain ratio,
 31:221
 neuropsychological deficit, negative
 symptoms, 31:15
 neuropsychological deficit, Scale for the
 Assessment of Negative Symptoms, 31:15
 neuropsychological deficit, schizoaffective
 disorder, 31:15
 pharmacokinetics, ¹⁹F-fluphenazine,
 35:107
 pharmacokinetics, magnetic resonance
 imaging, 35:107
 positron emission tomography, alcoholism,
 35:39
 positron emission tomography,
 fluorodeoxyglucose, 35:39
 Scale for the Assessment of Negative
 Symptoms, cerebral blood flow, 35:27

Frontal lobe continued

Scale for the Assessment of Negative
 Symptoms, fronto-occipital ratio, 35:27
 Scale for the Assessment of Negative
 Symptoms, negative symptoms, 31:15
 Scale for the Assessment of Negative
 Symptoms, neuropsychological deficit,
 31:15
 Scale for the Assessment of Negative
 Symptoms, schizoaffective disorder, 31:15
 Scale for the Assessment of Negative
 Symptoms, schizophrenia, 35:27
 schizoaffective disorder, negative
 symptoms, 31:15
 schizoaffective disorder, neuropsychologi-
 cal deficit, 31:15
 schizoaffective disorder, Scale for the
 Assessment of Negative Symptoms,
 31:15
 schizophrenia, cerebral blood flow, 35:27
 schizophrenia, computed tomography,
 31:221
 schizophrenia, dilapidation behavior, 34:221
 schizophrenia, fronto-occipital ratio, 35:27
 schizophrenia, Halstead-Reitan Battery,
 31:15
 schizophrenia, HLA antigen, 31:221
 schizophrenia, laterality, 31:221
 schizophrenia, negative symptoms, 31:15
 34:221
 schizophrenia, neuroleptic response, 31:221
 schizophrenia, Scale for the Assessment
 of Negative Symptoms, 35:27
 schizophrenia, ventricle-brain ratio, 31:221
 schizophrenia, verbal fluency, 31:15
 schizophrenia, Wechsler Adult Intelligence
 Scale, 31:15
 suicide, affective disorder, 32:159
 suicide, caudate nucleus, 32:159
 suicide, endorphin, 32:159
 suicide, hypothalamus, 32:159
 suicide, laterality, 32:159
 suicide, temporal lobe, 32:159
 sulcal width, Boston Naming Test, 35:115
 sulcal width, magnetic resonance
 imaging, 35:115
 temporal lobe, affective disorder, 32:159
 temporal lobe, endorphin, 32:159
 temporal lobe, laterality, 32:159
 temporal lobe, suicide, 32:159
 Tourette's syndrome, Wisconsin Card
 Sort Test, 33:73
 ventricle-brain ratio, computed
 tomography, 31:221
 ventricle-brain ratio, HLA antigen, 31:221

Frontal lobe continued

- ventricle-brain ratio, laterality, 31:221
- ventricle-brain ratio, neuroleptic response, 31:221
- ventricle-brain ratio, schizophrenia, 31:221
- verbal fluency, Halstead-Reitan Battery, 31:15
- verbal fluency, negative symptoms, 31:15
- verbal fluency, schizophrenia, 31:15
- verbal fluency, Wechsler Adult Intelligence Scale, 31:15
- Wechsler Adult Intelligence Scale, Halstead-Reitan Battery, 31:15
- Wechsler Adult Intelligence Scale, negative symptoms, 31:15
- Wechsler Adult Intelligence Scale, schizophrenia, 31:15
- Wechsler Adult Intelligence Scale, verbal fluency, 31:15
- Wisconsin Card Sort Test, Tourette's syndrome, 33:73

Generalized anxiety disorder

- affective disorder, CES-D Scale, 31:69
- affective disorder, Diagnostic Interview Schedule, 31:69
- affective disorder, Mexican-Americans, 31:69
- catecholamines in plasma, depressed mood, 32:35
- CES-D Scale, affective disorder, 31:69
- CES-D Scale, Diagnostic Interview Schedule, 31:69
- depressed mood, 3-methoxy-4-hydroxyphenylglycol, 32:35
- depressed mood, catecholamines in plasma, 32:35
- Diagnostic Interview Schedule, CES-D Scale, 31:69
- 3-methoxy-4-hydroxyphenylglycol, depressed mood, 32:35
- Mexican-Americans, Diagnostic Interview Schedule, 31:69

Genetics

- admixture analysis, MMPI, 32:311
- admixture analysis, schizophrenia, 32:311
- affective disorder, rapid eye movement sleep, 33:39
- affective disorder, risk factors, 33:39
- affective disorders, restriction fragment length polymorphism, 32:275
- affective disorders, tyrosine hydroxylase, 32:275
- Axis I diagnoses in family, dependent personality disorder, 33:207
- chromosomal translocation, suicide, 32:1

Genetics continued

- dependent personality disorder, Axis I diagnoses in family, 33:207
- imipramine binding, twin pairs, 32:265
- laterality, magnetic resonance imaging, 35:137
- laterality, schizophrenia, 35:137
- laterality, sibling pairs, 35:137
- laterality, temporal lobe, 35:137
- magnetic resonance imaging, schizophrenia, 35:137
- magnetic resonance imaging, sibling pairs, 35:137
- MMPI, schizophrenia, 32:311
- rapid eye movement sleep, affective disorder, 33:39
- rapid eye movement sleep, risk factors, 33:39
- rat selective breeding, serotonin in platelets, 32:167
- restriction fragment length polymorphism, affective disorders, 32:275
- restriction fragment length polymorphism, tyrosine hydroxylase, 32:275
- risk factors, affective disorder, 33:39
- risk factors, rapid eye movement sleep, 33:39
- schizophrenia, admixture analysis, 32:311
- schizophrenia, laterality, 35:137
- schizophrenia, magnetic resonance imaging, 35:137
- schizophrenia, MMPI, 32:311
- schizophrenia, sibling pairs, 35:137
- schizophrenia, temporal lobe, 35:137
- schizophrenia, ventricle-brain ratio, 35:137
- serotonin in platelets, rat selective breeding, 32:167
- sibling pairs, laterality, 35:137
- sibling pairs, magnetic resonance imaging, 35:137
- sibling pairs, schizophrenia, 35:137
- sibling pairs, temporal lobe, 35:137
- sibling pairs, ventricle-brain ratio, 35:137
- suicide, chromosomal translocation, 32:1
- temporal lobe, laterality, 35:137
- temporal lobe, magnetic resonance imaging, 35:137
- temporal lobe, schizophrenia, 35:137
- temporal lobe, sibling pairs, 35:137
- twin pairs, imipramine binding, 32:265
- tyrosine hydroxylase, affective disorders, 32:275
- tyrosine hydroxylase, restriction fragment length polymorphism, 32:275
- ventricle-brain ratio, schizophrenia, 35:137

Genetics continued

ventricle-brain ratio, sibling pairs, 35:137

Glucocorticoid receptors

adrenocorticotrophic hormone, age, 34:237
 age, Alzheimer's disease, 34:237
 Alzheimer's disease, cortisol, 34:237
 cortisol, leukocytes, 34:237
 leukocytes, adrenocorticotrophic hormone, 34:237

Glucose

adrenergic-cholinergic balance, cholinergic system, 34:259, 34:271
 cholinergic system, cortisol, 34:259
 cortisol, cyclic adenosine monophosphate, 34:259, 34:271
 cyclic adenosine monophosphate, heart rate, 34:259
 heart rate, neostigmine, 34:259
 metabolic rate, positron emission tomography, 35:39, 35:49
 neostigmine, physostigmine, 34:259
 physostigmine, adrenergic-cholinergic balance, 34:259
 positron emission tomography, metabolic rate 35:39, 35:49

Glutamate

schizophrenia, plasma levels, 32:63

Glutathione peroxidase

age, computed tomography, 31:1
 computed tomography, monoamine oxidase, 31:1
 monoamine oxidase, neuroleptics, 31:1
 neuroleptics, schizophrenia, 31:1
 schizophrenia, third ventricle, 31:1
 ventricle-brain ratio, age, 31:1

Glycine

schizophrenia, plasma levels, 32:63

Growth hormone

adrenocorticotrophic hormone, affective disorder, 31:39, 31:57
 adrenocorticotrophic hormone, Alzheimer's disease, 33:107
 adrenocorticotrophic hormone, bipolar, 31:57
 adrenocorticotrophic hormone, clomipramine, 31:39
 adrenocorticotrophic hormone, cortisol, 31:39, 31:57, 33:107
 adrenocorticotrophic hormone, heart rate, 31:39
 adrenocorticotrophic hormone, insulin-like growth factor, 33:107
 adrenocorticotrophic hormone, prolactin, 31:39, 31:57

Growth hormone continued

adrenocorticotrophic hormone, tryptophan, 31:57
 affective disorder, adrenocorticotrophic hormone, 31:39, 31:57
 affective disorder, age, 33:269
 affective disorder, amitriptyline, 31:201
 affective disorder, antidepressants, 31:201
 affective disorder, Beck Depression Inventory, 31:201
 affective disorder, bipolar, 31:57
 affective disorder, clomipramine, 31:39
 affective disorder, cortisol, 31:39, 31:57
 affective disorder, growth hormone releasing hormone, 33:269
 affective disorder, heart rate, 31:39
 affective disorder, prolactin, 31:39, 31:57, 31:201
 affective disorder, tryptophan, 31:57, 31:201
 affective disorder, weight loss, 31:201
 age, affective disorder, 33:269
 age, growth hormone releasing hormone, 33:269
 age, schizophrenia, 33:269
 alcoholism, apomorphine, 33:151
 alcoholism, cerebrospinal fluid, 33:215
 alcoholism, cocaine, 33:151
 alcoholism, corticotropin releasing hormone, 33:215
 alcoholism, neuropeptide Y, 33:215
 alcoholism, prolactin, 33:151
 alcoholism, somatostatin, 33:215
 alcoholism, substance abuse, 33:151
 Alzheimer's disease, adrenocorticotrophic hormone, 33:107
 Alzheimer's disease, cortisol, 33:107
 Alzheimer's disease, growth hormone releasing hormone, 33:107
 Alzheimer's disease, insulin-like growth factor, 33:107
 amino acids in serum, schizophrenia, 34:243
 amino acids in serum, sex differences, 34:243
 amitriptyline, affective disorder, 31:201
 amitriptyline, antidepressants, 31:201
 amitriptyline, Beck Depression Inventory, 31:201
 amitriptyline, prolactin, 31:201
 amitriptyline, tryptophan, 31:201
 amitriptyline, weight loss, 31:201
 antidepressants, affective disorder, 31:201
 antidepressants, amitriptyline, 31:201
 antidepressants, Beck Depression Inventory, 31:201
 antidepressants, prolactin, 31:201

Growth hormone continued

antidepressants, tryptophan, 31:201
 antidepressants, weight loss, 31:201
 apomorphine, alcoholism, 33:151
 apomorphine, cocaine, 33:151, 33:161
 apomorphine, homovanillic acid, 33:161
 apomorphine, prolactin, 33:151, 33:161
 apomorphine, substance abuse, 33:151
 Beck Depression Inventory, affective disorder, 31:201
 Beck Depression Inventory, amitriptyline, 31:201
 Beck Depression Inventory, anti-depressants, 31:201
 Beck Depression Inventory, prolactin, 31:201
 Beck Depression Inventory, tryptophan, 31:201
 Beck Depression Inventory, weight loss, 31:201
 bipolar, adrenocorticotrophic hormone, 31:57
 bipolar, affective disorder, 31:57
 bipolar, cortisol, 31:57
 bipolar, prolactin, 31:57
 bipolar, tryptophan, 31:57
 blood pressure, clonidine, 31:311
 blood pressure, heart rate, 31:311
 blood pressure, vasopressin, 31:311
 cerebrospinal fluid, alcoholism, 33:215
 cerebrospinal fluid, corticotropin releasing hormone, 33:215
 cerebrospinal fluid, neuropeptide Y, 33:215
 cerebrospinal fluid, somatostatin, 33:215
 clomipramine, adrenocorticotrophic hormone, 31:39
 clomipramine, affective disorder, 31:39
 clomipramine, cortisol, 31:39
 clomipramine, heart rate, 31:39
 clomipramine, prolactin response, 31:39
 clomipramine response, serotonin, 31:39
 clonidine, blood pressure, 31:311
 clonidine, heart rate, 31:311
 clonidine, vasopressin, 31:311
 cocaine, alcoholism, 33:151
 cocaine, apomorphine, 33:151, 33:161
 cocaine, homovanillic acid, 33:161
 cocaine, prolactin, 33:151, 33:161
 cocaine, substance abuse, 33:151
 corticotropin releasing hormone, alcoholism, 33:215
 corticotropin releasing hormone, cerebrospinal fluid, 33:215
 corticotropin releasing hormone, neuropeptide Y, 33:215

Growth hormone continued

corticotropin releasing hormone, somatostatin, 33:215
 cortisol, adrenocorticotrophic hormone, 31:39, 31:57, 33:107
 cortisol, affective disorder, 31:39, 31:57
 cortisol, Alzheimer's disease, 33:107
 cortisol, bipolar, 31:57
 cortisol, clomipramine, 31:39
 cortisol, heart rate, 31:39
 cortisol, insulin-like growth factor, 33:107
 cortisol, prolactin, 31:39, 31:57
 cortisol, tryptophan, 31:57
 growth hormone releasing hormone, affective disorder, 33:269
 growth hormone releasing hormone, age, 33:269
 growth hormone releasing hormone, Alzheimer's disease, 33:107
 growth hormone releasing hormone, schizophrenia, 33:269
 heart rate, adrenocorticotrophic hormone, 31:39
 heart rate, affective disorder, 31:39
 heart rate, blood pressure, 31:311
 heart rate, clomipramine, 31:39
 heart rate, clonidine, 31:311
 heart rate, cortisol, 31:39
 heart rate, prolactin response, 31:39
 heart rate, vasopressin, 31:311
 homovanillic acid, apomorphine, 33:161
 homovanillic acid, cocaine, 33:161
 homovanillic acid in plasma, methylphenidate, 32:9
 homovanillic acid in plasma, schizophrenia, 32:9
 homovanillic acid, prolactin, 33:161
 insulin-like growth factor, adrenocorticotrophic hormone, 33:107
 insulin-like growth factor, Alzheimer's disease, 33:107
 insulin-like growth factor, cortisol, 33:107
 methylphenidate, homovanillic acid in plasma, 32:9
 methylphenidate, schizophrenia, 32:9
 neuropeptide Y, alcoholism, 33:215
 neuropeptide Y, cerebrospinal fluid, 33:215
 neuropeptide Y, corticotropin releasing hormone, 33:215
 neuropeptide Y, somatostatin, 33:215
 prolactin, adrenocorticotrophic hormone, 31:39, 31:57
 prolactin, affective disorder, 31:39, 31:57, 31:201
 prolactin, alcoholism, 33:151

Growth hormone continued

- prolactin, amitriptyline, 31:201
- prolactin, antidepressants, 31:201
- prolactin, apomorphine, 33:151, 33:161
- prolactin, Beck Depression Inventory, 31:201
- prolactin, bipolar, 31:57
- prolactin, clomipramine, 31:39
- prolactin, cocaine, 33:151, 33:161
- prolactin, cortisol, 31:39, 31:57
- prolactin, heart rate, 31:39
- prolactin, homovanillic acid, 33:161
- prolactin, serotonin, 31:39
- prolactin, substance abuse, 33:151
- prolactin, tryptophan, 31:57, 31:201
- prolactin, weight loss, 31:201
- schizophrenia, age, 33:269
- schizophrenia, amino acids in serum, 34:243
- schizophrenia, growth hormone releasing hormone, 33:269
- schizophrenia, homovanillic acid in plasma, 32:9
- schizophrenia, methylphenidate, 32:9
- schizophrenia, sex differences, 34:243
- serotonin, clomipramine response, 31:39
- serotonin, prolactin response, 31:39
- sex differences, amino acids in serum, 34:243
- sex differences, schizophrenia, 34:243
- somatostatin, alcoholism, 33:215
- somatostatin, cerebrospinal fluid, 33:215
- somatostatin, corticotropin releasing hormone, 33:215
- somatostatin, neuropeptide Y, 33:215
- substance abuse, alcoholism, 33:151
- substance abuse, apomorphine, 33:151
- substance abuse, cocaine, 33:151
- substance abuse, prolactin, 33:151
- tryptophan, adrenocorticotrophic hormone, 31:57
- tryptophan, affective disorder, 31:57, 31:201
- tryptophan, amitriptyline, 31:201
- tryptophan, antidepressants, 31:201
- tryptophan, Beck Depression Inventory, 31:201
- tryptophan, bipolar, 31:57
- tryptophan, cortisol, 31:57
- tryptophan, prolactin, 31:57, 31:201
- tryptophan, weight loss, 31:201
- vasopressin, blood pressure, 31:311
- vasopressin, clonidine, 31:311
- vasopressin, heart rate, 31:311
- weight loss, affective disorder, 31:201
- weight loss, amitriptyline, 31:201
- weight loss, antidepressants, 31:201

Growth hormone continued

- weight loss, Beck Depression Inventory, 31:201
- weight loss, prolactin, 31:201
- weight loss, tryptophan, 31:201

Habituation

- multiple personality disorder, autonomic nervous system, 31:251

Haloperidol

- body weight, Japanese patients, 31:111
- body weight, plasma concentration, 31:111
- homovanillic acid, neuroleptic response, 33:171
- homovanillic acid, neuropsychological tests, 33:171
- homovanillic acid, rapid medication response, 33:171
- homovanillic acid, schizophrenia, 33:171
- Japanese patients, plasma concentration, 31:111
- neuroleptic response, neuropsychological tests, 33:171
- neuropsychological tests, rapid medication response, 33:171
- plasma concentration, body weight, 31:111
- plasma concentration, Japanese patients, 31:111
- rapid medication response, schizophrenia, 33:171
- schizophrenia, homovanillic acid, 33:171

Halstead-Reitan Battery

- frontal lobe, negative symptoms, 31:15
- negative symptoms, schizophrenia, 31:15
- schizophrenia, verbal fluency, 31:15
- verbal fluency, Wechsler Adult Intelligence Scale, 31:15
- Wechsler Adult Intelligence Scale, frontal lobe, 31:15

Hamilton Rating Scale for Depression

- alprazolam, desimipramine, 32:141
- alprazolam, treatment outcome, 32:141
- antidepressant treatment, electroconvulsive therapy, 31:287
- antidepressants, panic disorder, 33:51
- antidepressants, treatment outcome, 33:51
- atypical depression, light therapy, 33:121
- atypical depression, seasonal variation, 33:121
- Brief Psychiatric Rating Scale, schizophrenia, 31:243
- catecholamines in plasma, electroconvulsive therapy, 34:127
- circannual rhythms, imipramine binding sites, 34:315

Hamilton Rating Scale for Depression continued

- clomipramine, obsessive-compulsive disorder, 32:151
- desimipramine, alprazolam, 32:141
- desimipramine, treatment outcome, 32:141
- desipramine, propranolol, 33:101
- eating disorders, melatonin, 32:221
- electroconvulsive therapy, antidepressant treatment, 31:287
- electroconvulsive therapy, catecholamines in plasma, 34:127
- hypothalamic-pituitary function, thyroid function, 34:29
- hypothalamic-pituitary function, vital depression, 34:29
- imipramine binding in platelets, psychogenic pain, 32:29
- imipramine binding sites, circannual rhythms, 34:315
- light therapy, atypical depression, 33:121
- light therapy, seasonal variation, 33:121
- melatonin, eating disorders, 32:221
- obsessive-compulsive disorder, clomipramine, 32:151
- panic disorder, antidepressants, 33:51
- panic disorder, treatment outcome, 33:51
- propranolol, desipramine, 33:101
- psychogenic pain, imipramine binding in platelets, 32:29
- rapid eye movement sleep, relatives of unipolar probands, 33:39
- relatives of unipolar probands, rapid eye movement sleep, 33:39
- schizophrenia, Brief Psychiatric Rating Scale, 31:243
- seasonal variation, atypical depression, 33:121
- seasonal variation, light therapy, 33:121
- thyroid function, hypothalamic-pituitary function, 34:29
- thyroid function, vital depression, 34:29
- treatment outcome, alprazolam, 32:141
- treatment outcome, antidepressants, 33:51
- treatment outcome, desimipramine, 32:141
- treatment outcome, panic disorder, 33:51
- vital depression, hypothalamic-pituitary function, 34:29
- vital depression, thyroid function, 34:29

Heart rate

- adrenergic-cholinergic balance, cholinergic system, 34:259, 34:271
- adrenergic-cholinergic balance, cortisol, 34:159
- adrenergic-cholinergic balance, cyclic adenosine monophosphate, 34:259

Heart rate continued

- adrenergic-cholinergic balance, glucose, 34:259
- adrenergic-cholinergic balance, neostigmine, 34:259
- adrenergic-cholinergic balance, physostigmine, 34:259
- adrenocorticotrophic hormone, affective disorder, 31:39
- adrenocorticotrophic hormone, clomipramine, 31:39
- adrenocorticotrophic hormone, cortisol, 31:39
- adrenocorticotrophic hormone, growth hormone response, 31:39
- adrenocorticotrophic hormone, prolactin response, 31:39
- affective disorder, adrenocorticotrophic hormone, 31:39
- affective disorder, blood pressure, 34:127
- affective disorder, catecholamines in plasma, 34:127
- affective disorder, clomipramine, 31:39
- affective disorder, cortisol, 31:39
- affective disorder, electroconvulsive therapy, 34:127
- affective disorder, growth hormone response, 31:39
- affective disorder, prolactin response, 31:39
- affective disorder, tryptophan, 31:57
- anxiety, motor activity, 32:45
- anxiety, panic disorder, 32:45
- beta blockers, blood pressure, 32:175
- beta blockers, cortisol, 32:175
- beta blockers, lactate infusion, 32:93
- beta blockers, melatonin, 32:175
- beta blockers, normal volunteers, 32:175
- beta blockers, panic disorder, 32:93
- blood pressure, affective disorder, 34:127
- blood pressure, beta blockers, 32:175
- blood pressure, catecholamines in plasma, 34:127
- blood pressure, children, 33:199
- blood pressure, clonidine, 31:311
- blood pressure, conduct disorder, 33:199
- blood pressure, cortisol, 32:175
- blood pressure, eating disorders, 33:1
- blood pressure, electroconvulsive therapy, 34:127
- blood pressure, growth hormone, 31:311
- blood pressure, isoproterenol, 33:1
- blood pressure, melatonin, 32:175
- blood pressure, normal volunteers, 32:175, 34:259
- blood pressure, physostigmine, 34:259

Heart rate continued

blood pressure, scopolamine, 34:259
 blood pressure, separation anxiety, 33:199
 blood pressure, temperature of body, 33:1
 blood pressure, vasopressin, 31:311
 blood pressure, weight, 33:1
 catecholamines, cholinergic system, 34:259
 catecholamines, cortisol, 34:259
 catecholamines in plasma, affective disorder, 34:127
 catecholamines in plasma, blood pressure, 34:127
 catecholamines in plasma, electroconvulsive therapy, 34:127
 catecholamines, physostigmine, 34:259
 catecholamines, stress, 34:259
 children, blood pressure, 33:199
 children, conduct disorder, 33:199
 children, separation anxiety, 33:199
 cholinergic system, catecholamines, 34:259, 34:271
 cholinergic system, cortisol, 34:259
 cholinergic system, cyclic adenosine monophosphate, 34:259
 cholinergic system, glucose, 34:259
 cholinergic system, neostigmine, 34:259
 cholinergic system, physostigmine, 34:259
 cholinergic system, stress, 34:259
 clomipramine, adrenocorticotrophic hormone, 31:39
 clomipramine, affective disorder, 31:39
 clomipramine, cortisol, 31:39
 clomipramine, growth hormone response, 31:39
 clomipramine, prolactin response, 31:39
 clonidine, blood pressure, 31:311
 clonidine, growth hormone, 31:311
 clonidine, vasopressin, 31:311
 conduct disorder, blood pressure, 33:199
 conduct disorder, children, 33:199
 conduct disorder, separation anxiety, 33:199
 cortisol, adrenergic-cholinergic balance, 34:259
 cortisol, adrenocorticotrophic hormone, 31:39
 cortisol, affective disorder, 31:39
 cortisol, beta blockers, 32:175
 cortisol, blood pressure, 32:175
 cortisol, catecholamines, 34:259
 cortisol, cholinergic system, 34:259
 cortisol, clomipramine, 31:39
 cortisol, cyclic adenosine monophosphate, 34:259
 cortisol, glucose, 34:259

Heart rate continued

cortisol, growth hormone response, 31:39
 cortisol, melatonin, 32:175
 cortisol, neostigmine, 34:259
 cortisol, normal volunteers, 32:175
 cortisol, physostigmine, 34:259
 cortisol, prolactin response, 31:39
 cortisol, stress, 34:259
 cyclic adenosine monophosphate, adrenergic-cholinergic balance, 34:259
 cyclic adenosine monophosphate, cholinergic system, 34:259
 cyclic adenosine monophosphate, cortisol, 34:259
 cyclic adenosine monophosphate, glucose, 34:259
 cyclic adenosine monophosphate, neostigmine, 34:259
 cyclic adenosine monophosphate, physostigmine, 34:259
 eating disorders, blood pressure, 33:1
 eating disorders, isoproterenol, 33:1
 eating disorders, temperature of body, 33:1
 eating disorders, weight, 33:1
 electroconvulsive therapy, affective disorder, 34:127
 electroconvulsive therapy, blood pressure, 34:127
 electroconvulsive therapy, catecholamines in plasma, 34:127
 glucose, adrenergic-cholinergic balance, 34:259
 glucose, cholinergic system, 34:259
 glucose, cortisol, 34:259
 glucose, cyclic adenosine monophosphate, 34:259
 glucose, neostigmine, 34:259
 glucose, physostigmine, 34:259
 growth hormone, blood pressure, 31:311
 growth hormone, clonidine, 31:311
 growth hormone response, adrenocorticotrophic hormone, 31:39
 growth hormone response, affective disorder, 31:39
 growth hormone response, clomipramine, 31:39
 growth hormone response, cortisol, 31:39
 growth hormone response, prolactin response, 31:39
 growth hormone, vasopressin, 31:311
 isoproterenol, blood pressure, 33:1
 isoproterenol, eating disorders, 33:1
 isoproterenol, temperature of body, 33:1
 isoproterenol, weight, 33:1

Heart rate continued

lactate infusion, beta blockers, 32:93
 lactate infusion, panic disorder, 32:93
 melatonin, beta blockers, 32:175
 melatonin, blood pressure, 32:175
 melatonin, cortisol, 32:175
 melatonin, normal volunteers, 32:175
 motor activity, anxiety, 32:45
 motor activity, panic disorder, 32:45
 multiple personality disorder, reaction time, 31:251
 multiple personality disorder, skin conductance, 31:251
 neostigmine, adrenergic-cholinergic balance, 34:259
 neostigmine, cholinergic system, 34:259
 neostigmine, cortisol, 34:259
 neostigmine, cyclic adenosine monophosphate, 34:259
 neostigmine, glucose, 34:259
 neostigmine, physostigmine, 34:259
 normal volunteers, beta blockers, 32:175
 normal volunteers, blood pressure, 32:175, 34:259
 normal volunteers, cortisol, 32:175
 normal volunteers, melatonin, 32:175
 normal volunteers, physostigmine, 34:259
 normal volunteers, scopolamine, 34:259
 panic disorder, anxiety, 32:45
 panic disorder, beta blockers, 32:93
 panic disorder, lactate infusion, 32:93
 panic disorder, motor activity, 32:45
 physostigmine, adrenergic-cholinergic balance, 34:259
 physostigmine, blood pressure, 34:259
 physostigmine, catecholamines, 34:259
 physostigmine, cholinergic system, 34:259
 physostigmine, cortisol, 34:259
 physostigmine, cyclic adenosine monophosphate, 34:259
 physostigmine, glucose, 34:259
 physostigmine, neostigmine, 34:259
 physostigmine, normal volunteers, 34:269
 physostigmine, scopolamine, 34:259
 physostigmine, stress, 34:259
 prolactin response, adrenocorticotrophic hormone, 31:39
 prolactin response, affective disorder, 31:39
 prolactin response, clomipramine, 31:39
 prolactin response, cortisol, 31:39
 prolactin response, growth hormone response, 31:39
 reaction time, multiple personality disorder, 31:251
 reaction time, skin conductance, 31:251

Heart rate continued

scopolamine, blood pressure, 34:259
 scopolamine, normal volunteers, 34:259
 scopolamine, physostigmine, 34:259
 separation anxiety, blood pressure, 33:199
 separation anxiety, children, 33:199
 separation anxiety, conduct disorder, 33:199
 skin conductance, multiple personality disorder, 31:251
 skin conductance, reaction time, 31:251
 stress, catecholamines, 34:259
 stress, cholinergic system, 34:259, 34:271
 stress, cortisol, 34:259
 stress, physostigmine, 34:259
 temperature of body, blood pressure, 33:1
 temperature of body, eating disorders, 33:1
 temperature of body, isoproterenol, 33:1
 temperature of body, weight, 33:1
 tryptophan, affective disorder, 31:57
 vasopressin, blood pressure, 31:311
 vasopressin, clonidine, 31:311
 vasopressin, growth hormone, 31:311
 weight, blood pressure, 33:1
 weight, eating disorders, 33:1
 weight, isoproterenol, 33:1
 weight, temperature of body, 33:1

Herpes virus

ELISA technique, immunoglobulins, 33:11
 immunoglobulins, schizophrenia, 33:11
 schizophrenia, viral antigens, 33:11
 viral antigens, ELISA technique, 33:11

Hippocampus

Alzheimer's disease, astrocytes, 35:149
 Alzheimer's disease, dentate gyrus, 35:149
 Alzheimer's disease, entorhinal cortex, 35:149
 Alzheimer's disease, granule cell layer, 35:149
 Alzheimer's disease, parahippocampal gyrus, 35:149
 Alzheimer's disease, subiculum, 35:149
 astrocytes, dentate gyrus, 35:149
 dentate gyrus, Alzheimer's disease, 35:149
 entorhinal cortex, granule cell layer, 35:149
 granule cell layer, Alzheimer's disease, 35:149
 magnetic resonance imaging, schizophrenia, 35:1, 35:137
 magnetic resonance imaging, volume reduction, 35:1
 parahippocampal gyrus, Alzheimer's disease, 35:149
 schizophrenia, magnetic resonance imaging, 35:1, 35:137
 schizophrenia, volume reduction, 35:1

Hippocampus continued

subiculum, Alzheimer's disease, 35:149
volume reduction, magnetic resonance imaging, 35:1

volume reduction, schizophrenia, 35:1

HLA (Human leukocyte antigen)

computed tomography, frontal lobe, 31:221
frontal lobe, laterality, 31:221
laterality, neuroleptic response, 31:221
neuroleptic response, schizophrenia, 31:221
schizophrenia, ventricle-brain ratio, 31:221
ventricle-brain ratio, neuroleptic response, 31:221

Homovanillic acid

apomorphine, cocaine, 33:161
apomorphine, growth hormone, 33:161
apomorphine, prolactin, 33:161
cocaine, apomorphine, 33:161
cocaine, growth hormone, 33:161
cocaine, prolactin, 33:161
evoked potentials, schizophrenia, 31:297
growth hormone, apomorphine, 33:161
growth hormone, cocaine, 33:161
growth hormone, methylphenidate, 32:9
growth hormone, prolactin, 33:161
growth hormone, schizophrenia, 32:9
haloperidol, neuroleptic response, 33:171
haloperidol, neuropsychological tests, 33:171
haloperidol, rapid medication response, 33:171
haloperidol, schizophrenia, 33:171
methylphenidate, growth hormone, 32:9
methylphenidate, schizophrenia, 32:9
neuroleptic response, haloperidol, 33:171
neuroleptic response, neuropsychological tests, 33:171
neuroleptic response, rapid medication response, 33:171
neuroleptic response, schizophrenia, 33:171
neuropsychological tests, haloperidol, 33:171
neuropsychological tests, neuroleptic response, 33:171
neuropsychological tests, rapid medication response, 33:171
neuropsychological tests, schizophrenia, 33:171
prolactin, apomorphine, 33:161
prolactin, cocaine, 33:161
prolactin, growth hormone, 33:161
rapid medication response, haloperidol, 33:171

Homovanillic acid continued

rapid medication response, neuroleptic response, 33:171
rapid medication response, neuro-psychological tests, 33:171
rapid medication response, schizophrenia, 33:171
Scale for the Assessment of Negative Symptoms, schizophrenia, 33:259
Scale for the Assessment of Negative Symptoms, tardive dyskinesia, 33:259
schizophrenia, evoked potentials, 31:297
schizophrenia, growth hormone, 32:9
schizophrenia, haloperidol, 33:171
schizophrenia, methylphenidate, 32:9
schizophrenia, neuroleptic response, 33:171
schizophrenia, neuropsychological tests, 33:171
schizophrenia, rapid medication response, 33:171
schizophrenia, Scale for the Assessment of Negative Symptoms, 33:259
schizophrenia, tardive dyskinesia, 33:259
tardive dyskinesia, Scale for the Assessment of Negative Symptoms, 33:259
tardive dyskinesia, schizophrenia, 33:259
Tourette's syndrome, trace amines, 31:279
trace amines, Tourette's syndrome, 31:279

5-Hydroxyindoleacetic acid

cerebrospinal fluid, 5-hydroxytryptamine, 33:95
cerebrospinal fluid, obsessive-compulsive disorder, 33:95
cerebrospinal fluid, serotonin, 33:95
homovanillic acid, normetanephrine, 31:279
homovanillic acid, Tourette's syndrome, 31:279
5-hydroxytryptamine, cerebrospinal fluid, 33:95
5-hydroxytryptamine, obsessive-compulsive disorder, 33:95
5-hydroxytryptamine, serotonin, 33:95
normetanephrine, homovanillic acid, 31:279
normetanephrine, Tourette's syndrome, 31:279
obsessive-compulsive disorder, 5-hydroxytryptamine, 33:95
obsessive-compulsive disorder, cerebrospinal fluid, 33:95
obsessive-compulsive disorder, serotonin, 33:95
serotonin, cerebrospinal fluid, 33:95
serotonin, obsessive-compulsive disorder, 33:95

5-Hydroxyindoleacetic acid continued

Tourette's syndrome, homovanillic acid, 31:279

Tourette's syndrome, normetanephrine, 31:279

5-Hydroxytryptophan

depressed mood, endorphin, 31:267

endorphin, melatonin, 31:267

melatonin, panic disorder, 31:267

panic disorder, platelet 5HT uptake, 31:267

platelet serotonin uptake, 31:267

serotonin, depressed mood, 31:267

Hyperactivity

amino acids, Conners Parent

Questionnaire, 33:301

Conners Parent Questionnaire, amino acids, 33:301

dextroamphetamine, motor tics, 33:83

dextroamphetamine, obsessive-compulsive disorder, 33:83

methylphenidate, motor tics, 33:83

motor tics, dextroamphetamine, 33:83

motor tics, methylphenidate, 33:83

motor tics, obsessive-compulsive disorder, 33:83

obsessive-compulsive disorder, dextroamphetamine, 33:83

obsessive-compulsive disorder, motor tics, 33:83

Hypothalamus

affective disorder, caudate nucleus, 32:159

caudate nucleus, endorphin, 32:159

endorphin, frontal lobe, 32:159

frontal lobe, laterality, 32:159

laterality, suicide, 32:159

suicide, temporal lobe, 32:159

temporal lobe, affective disorder, 32:159

Imipramine

affective disorder, age, 32:29

affective disorder, binding sites, 34:, 34:

affective disorder, cholesterol in serum, 32:207

affective disorder, circannual rhythms, 34:315

affective disorder, cortisol, 34:303

affective disorder, cyanoimipramine

binding sites in platelets, 34:293, 34:315

affective disorder, platelet binding, 33:229

affective disorder, psychogenic pain, 32:29

affective disorder, treatment effects, 34:303

age, affective disorder, 32:29

age, psychogenic pain, 32:29

Imipramine continued

anti-imipramine antibodies, endogenous serotonin uptake modulators, 34:205

binding in platelets, twin pairs, 32:265

binding sites, affective disorder, 34:293, 34:303

binding sites, cortisol, 34:303

binding sites, cyanoimipramine, 34:293

binding sites, treatment effects, 34:303

calcium channel blockers, rat immobility, 32:203

cholesterol in serum, affective disorder, 32:207

circannual rhythms, affective disorder, 34:315

circannual rhythms, cyanoimipramine

binding sites in platelets, 34:315

cortisol, affective disorder, 34:303

cortisol, binding sites, 34:303

cortisol, treatment effects, 34:303

CSF 5-hydroxyindoleacetic acid, platelet binding, 33:323

cyanoimipramine, binding sites, 34:293

cyanoimipramine binding sites in platelets, affective disorder, 34:315

cyanoimipramine binding sites in platelets, circannual rhythms, 34:315

endogenous serotonin uptake modulators, anti-imipramine antibodies, 34:205

endogenous serotonin uptake modulators, serotonin, 34:205

genetics, twin pairs, 32:265

ion-dependence, platelet binding, 33:19

methodological issues, platelet binding, 33:19

monoamine oxidase in platelets, treatment effects, 33:229

platelet binding, affective disorder, 33:229

platelet binding, ion-dependence, 33:19

platelet binding, methodological issues, 33:19

psychogenic pain, affective disorder, 32:29

psychogenic pain, age, 32:29

rat immobility, calcium channel blockers, 32:203

serotonin, anti-imipramine antibodies, 34:205

serotonin, endogenous serotonin uptake modulators, 34:205

treatment effects, affective disorder, 34:303

treatment effects, binding sites, 34:303

treatment effects, cortisol, 34:303

Imipramine continued

treatment effects, monoamine oxidase
in platelets, 33:229

twin pairs, binding in platelets, 32:265

Immunoglobulins

ELISA technique, herpes virus, 33:11

herpes virus, schizophrenia, 33:11

schizophrenia, viral antigens, 33:11

viral antigens, ELISA technique, 33:11

Insulin-like growth factor

adrenocorticotrophic hormone, Alzheimer's
disease, 33:107

Alzheimer's disease, cortisol, 33:107

cortisol, growth hormone, 33:107

growth hormone, adrenocorticotrophic
hormone, 33:107

Isoproterenol

blood pressure, eating disorders, 33:1

eating disorders, heart rate, 33:1

heart rate, temperature of body, 33:1

panic attack, panic disorder, 32:103

temperature of body, weight, 33:1

weight, blood pressure, 33:1

Lactate infusion

beta blockers, heart rate, 32:93

heart rate, panic disorder, 32:93

panic disorder, beta blockers, 32:93

Laterality

affective disorder, caudate nucleus, 32:159

affective disorder, endorphin, 32:159

affective disorder, frontal lobe, 32:159

affective disorder, hypothalamus, 32:159

affective disorder, suicide, 32:159

affective disorder, temporal lobe, 32:159

caudate nucleus, affective disorder, 32:159

caudate nucleus, endorphin, 32:159

caudate nucleus, suicide, 32:159

cerebral asymmetry, computed
tomography, 35:71

cerebral asymmetry, handedness, 35:71

cerebral blood flow, schizophrenia, 35:27

computed tomography, cerebral
asymmetry, 35:71

computed tomography, corpus callosum,
34:163

computed tomography, frontal lobe, 31:221

computed tomography, handedness, 35:71

computed tomography, head tilt
correction, 35:71

computed tomography, HLA antigen,
31:221

computed tomography, neuroleptic
response, 31:221

computed tomography, schizophrenia,
31:221, 34:163

Laterality continued

computed tomography, ventricle-brain
ratio, 31:221

corpus callosum, computed tomography,
34:163

corpus callosum, magnetic resonance
imaging, 34:163

corpus callosum, schizophrenia, 34:163

endorphin, affective disorder, 32:159

endorphin, caudate nucleus, 32:159

endorphin, frontal lobe, 32:159

endorphin, hypothalamus, 32:159

endorphin, suicide, 32:159

endorphin, temporal lobe, 32:159

frontal lobe, affective disorder, 32:159

frontal lobe, computed tomography, 31:221

frontal lobe, endorphin, 32:159

frontal lobe, HLA antigen, 31:221

frontal lobe, suicide, 32:159

frontal lobe, neuroleptic response, 31:221

frontal lobe, schizophrenia, 31:221

frontal lobe, ventricle-brain ratio, 31:221

genetics, magnetic resonance imaging,
35:137

genetics, schizophrenia, 35:137

genetics, sibling pairs, 35:137

genetics, temporal lobe, 35:137

genetics, ventricle-brain ratio, 35:137

handedness, cerebral asymmetry, 35:71

handedness, computed tomography, 35:71

head tilt correction, computed
tomography, 35:71

HLA antigen, computed tomography,
31:221

HLA antigen, frontal lobe, 31:221

HLA antigen, neuroleptic response, 31:221

HLA antigen, schizophrenia, 31:221

HLA antigen, ventricle-brain ratio, 31:221

hypothalamus, affective disorder, 32:159

hypothalamus, endorphin, 32:159

hypothalamus, suicide, 32:159

magnetic resonance imaging, computed
tomography, 34:163

magnetic resonance imaging, corpus
callosum, 34:163

magnetic resonance imaging, genetics,
35:137

magnetic resonance imaging, schizophrenia,
34:163, 35:137

magnetic resonance imaging, sibling pairs,
35:137

magnetic resonance imaging, temporal
lobe, 35:137

magnetic resonance imaging, ventricle-brain
ratio, 35:137

Laterality continued

- neuroleptic response, computed tomography, 31:221
- neuroleptic response, frontal lobe, 31:221
- neuroleptic response, HLA antigen, 31:221
- neuroleptic response, schizophrenia, 31:221
- neuroleptic response, ventricle-brain ratio, 31:221
- neuroleptic treatment, schizophrenia, 32:289
- neuroleptic treatment, tactile discrimination, 32:289
- schizophrenia, cerebral blood flow, 35:27
- schizophrenia, computed tomography, 31:221, 34:163
- schizophrenia, corpus callosum, 34:163
- schizophrenia, frontal lobe, 31:221
- schizophrenia, genetics, 35:137
- schizophrenia, HLA antigen, 31:221
- schizophrenia, magnetic resonance imaging, 34:163, 35:137
- schizophrenia, neuroleptic response, 31:221
- schizophrenia, neuroleptic treatment, 32:289
- schizophrenia, sibling pairs, 35:137
- schizophrenia, tactile discrimination, 32:289
- schizophrenia, temporal lobe, 35:137
- schizophrenia, ventricle-brain ratio, 31:221
- ventricle-brain ratio, 35:137
- sibling pairs, magnetic resonance imaging, 35:137
- sibling pairs, schizophrenia, 35:137
- sibling pairs, temporal lobe, 35:137
- sibling pairs, ventricle-brain ratio, 35:137
- suicide, affective disorder, 32:159
- suicide, caudate nucleus, 32:159
- suicide, endorphin, 32:159
- suicide, frontal lobe, 32:159
- suicide, hypothalamus, 32:159
- suicide, temporal lobe, 32:159
- tactile discrimination, neuroleptic treatment, 32:289
- tactile discrimination, schizophrenia, 32:289
- temporal lobe, affective disorder, 32:159
- temporal lobe, endorphin, 32:159
- temporal lobe, genetics, 35:137
- temporal lobe, magnetic resonance imaging, 35:137
- temporal lobe, schizophrenia, 35:137
- temporal lobe, sibling pairs, 35:137
- temporal lobe, suicide, 32:159
- temporal lobe, ventricle-brain ratio, 35:137

Laterality continued

- ventricle-brain ratio, computed tomography, 31:221
- ventricle-brain ratio, frontal lobe, 31:221
- ventricle-brain ratio, genetics, 35:137
- ventricle-brain ratio, HLA antigen, 31:221
- ventricle-brain ratio, magnetic resonance imaging, 35:137
- ventricle-brain ratio, neuroleptic response, 31:221
- ventricle-brain ratio, schizophrenia, 31:221, 35:137
- ventricle-brain ratio, sibling pairs, 35:137
- ventricle-brain ratio, temporal lobe, 35:137

Leukocytes

- adrenocorticotrophic hormone, age, 34:237
- age, Alzheimer's disease, 34:237
- Alzheimer's disease, cortisol, 34:237
- cortisol, glucocorticoid receptors, 34:237
- glucocorticoid receptors, adrenocorticotrophic hormone, 34:237

Leyton Obsessional Inventory

- clomipramine treatment, scale validity, 34:99

Light effects

- affective disorder, bipolar, 33:129
- affective disorder, melatonin, 33:129
- affective disorder, unipolar, 33:129
- antidepressant effects, atypical depression, 33:121
- antidepressant effects, seasonal affective disorder, 33:121
- atypical depression, antidepressant effects, 33:121
- atypical depression, seasonal affective disorder, 33:121
- bipolar, affective disorder, 33:129
- bipolar, melatonin, 33:129
- bipolar, unipolar, 33:129
- circadian rhythms, cocaine, 34:185
- circadian rhythms, melatonin, 34:185
- circadian rhythms, rat pineal glands, 34:185
- cocaine, circadian rhythms, 34:185
- cocaine, melatonin, 34:185
- cocaine, rat pineal glands, 34:185
- day length, suicide, 32:253
- day length, temperature, 32:253
- Flinders Sensitive Line of rats, muscarinic agonist, 33:139
- Flinders Sensitive Line of rats, photoperiods, 33:139
- hypothermic response to oxytremorine, muscarinic agonist, 33:139

Light effects continued

- hypothermic response to oxytremorine, photoperiods, 33:139
- melatonin, affective disorder, 33:129
- melatonin, bipolar, 33:129
- melatonin, circadian rhythms, 34:185
- melatonin, cocaine, 34:185
- melatonin, rat pineal glands, 34:185
- melatonin, unipolar, 33:129
- menstrual cycle, night exposure, 33:135
- menstrual cycle, normal women, 33:135
- muscarinic agonist, Flinders Sensitive Line of rats, 33:139
- muscarinic agonist, photoperiods, 33:139
- night exposure, menstrual cycle, 33:135
- night exposure, normal women, 33:135
- normal women, menstrual cycle, 33:135
- normal women, night exposure, 33:135
- photoperiods, Flinders Sensitive Line of rats, 33:139
- photoperiods, hypothermic response to oxytremorine, 33:139
- photoperiods, muscarinic agonist, 33:139
- rat pineal glands, circadian rhythms, 34:185
- rat pineal glands, cocaine, 34:185
- rat pineal glands, melatonin, 34:185
- seasonal affective disorder, antidepressant effects, 33:121
- seasonal affective disorder, atypical depression, 33:121
- suicide, day length, 32:253
- suicide, temperature, 32:253
- temperature, day length, 32:253
- temperature, suicide, 32:253
- unipolar, affective disorder, 33:129
- unipolar, bipolar, 33:129
- unipolar, melatonin, 33:129

Limbic system

- age, intracranial volume, 35:15
- age, magnetic resonance imaging, 35:15
- age, temporal lobe, 35:15
- age, ventricular volume, 35:15
- intracranial volume, age, 35:15
- intracranial volume, magnetic resonance imaging, 35:15
- intracranial volume, temporal lobe, 35:15
- intracranial volume, ventricular volume, 35:15
- magnetic resonance imaging, age, 35:15
- magnetic resonance imaging, intracranial volume, 35:15
- magnetic resonance imaging, schizophrenia, 35:1
- magnetic resonance imaging, temporal lobe, 35:1, 35:15

Limbic system continued

- magnetic resonance imaging, ventricular volume, 35:15
- schizophrenia, magnetic resonance imaging, 35:1
- schizophrenia, temporal lobe, 35:1
- schizophrenia, volume reduction, 35:1
- temporal horn, sex differences, 35:1
- temporal lobe, age, 35:15
- temporal lobe, intracranial volume, 35:15
- temporal lobe, magnetic resonance imaging, 35:1, 35:15
- temporal lobe, schizophrenia, 35:1
- temporal lobe, ventricular volume, 35:15
- temporal lobe, volume reduction, 35:1, 35:15
- ventricular volume, age, 35:15
- ventricular volume, intracranial volume, 35:15
- ventricular volume, magnetic resonance imaging, 35:15
- ventricular volume, temporal lobe, 35:15
- ventricular volume, volume reduction, 35:15
- volume reduction, age, 35:15
- volume reduction, intracranial volume, 35:15
- volume reduction, magnetic resonance imaging, 35:1, 35:15
- volume reduction, magnetic resonance imaging, 35:15
- volume reduction, schizophrenia, 35:1
- volume reduction, temporal lobe, 35:1, 35:15
- volume reduction, ventricular volume, 35:15

Lithium

- affective disorder, dexamethasone suppression test, 32:71
- cortisol, 3-methoxy-4-hydroxyphenylglycol, 32:71
- dexamethasone suppression test, affective disorder, 32:71
- 3-methoxy-4-hydroxyphenylglycol, cortisol, 32:71
- muscle concentration, pharmacokinetics, 32:71
- muscle concentration, plasma concentration, 32:71
- pharmacokinetics, plasma concentration, 32:71
- plasma concentration, muscle concentration, 32:71

Luteinizing hormone

- affective disorders, depressive mood, 32:229
- depressive mood, follicle stimulating hormone, 32:229
- follicle stimulating hormone, menopause, 32:229
- menopause, affective disorders, 32:229

Magnetic resonance imaging

- age, intracranial volume, 35:15
- age, limbic system, 35:15
- age, temporal lobe, 35:15
- age, ventricular volume, 35:15
- age, volume reduction, 35:15
- amygdala, schizophrenia, 35:137
- asymmetry of slice, head tilt correction, 35:71
- Boston Naming Test, frontal lobe, 35:115
- Boston Naming Test, sulcal width, 35:115
- corpus callosum, laterality, 34:163
- corpus callosum, schizophrenia, 34:163
- computed tomography, laterality, 34:163
- computed tomography, schizophrenia, 34:163
- ¹⁹F-fluphenazine, neuroleptic detection, 35:107
- ¹⁹F-fluphenazine, pharmacokinetics, 35:107
- frontal lobe, ¹⁹F-fluphenazine, 35:107
- frontal lobe, Boston Naming Test, 35:115
- frontal lobe, neuroleptic detection, 35:107
- frontal lobe, pharmacokinetics, 35:107
- frontal lobe, sulcal width, 35:115
- genetics, laterality, 35:137
- genetics, schizophrenia, 35:137
- genetics, sibling pairs, 35:137
- genetics, temporal lobe, 35:137
- genetics, ventricle-brain ratio, 35:137
- head tilt correction, asymmetry of slice, 35:71
- hippocampus, schizophrenia, 35:137
- intracranial volume, age, 35:15
- intracranial volume, limbic system, 35:15
- intracranial volume, temporal lobe, 35:15
- laterality, corpus callosum, 34:163
- laterality, computed tomography, 34:163
- laterality, genetics, 35:137
- laterality, schizophrenia, 34:163, 35:137
- laterality, sibling pairs, 35:137
- laterality, temporal lobe, 35:137
- laterality, ventricle-brain ratio, 35:137
- limbic system, age, 35:15
- limbic system, intracranial volume, 35:15
- limbic system, schizophrenia, 35:1
- limbic system, temporal lobe, 35:1, 35:15
- limbic system, ventricular volume, 35:15

Magnetic resonance imaging continued

- limbic system, volume reduction, 35:1, 35:15
- neuroleptic detection, ¹⁹F-fluphenazine, 35:107
- neuroleptic detection, frontal lobe, 35:107
- neuroleptic detection, pharmacokinetics, 35:107
- pharmacokinetics, ¹⁹F-fluphenazine, 35:107
- pharmacokinetics, frontal lobe, 35:107
- pharmacokinetics, neuroleptic detection, 35:107
- schizophrenia, amygdala, 35:137
- schizophrenia, computed tomography, 34:163
- schizophrenia, corpus callosum, 34:163
- schizophrenia, genetics, 35:137
- schizophrenia, hippocampus, 35:137
- schizophrenia, laterality, 34:163, 35:137
- schizophrenia, limbic system, 35:1
- schizophrenia, sibling pairs, 35:137
- schizophrenia, temporal lobe, 35:1, 35:137
- schizophrenia, ventricle-brain ratio, 35:137
- schizophrenia, volume reduction, 35:1
- sibling pairs, genetics, 35:137
- sibling pairs, laterality, 35:137
- sibling pairs, schizophrenia, 35:137
- sibling pairs, temporal lobe, 35:137
- sibling pairs, ventricle-brain ratio, 35:137
- sulcal width, Boston Naming Test, 35:115
- sulcal width, frontal lobe, 35:115
- temporal lobe, age, 35:15
- temporal lobe, genetics, 35:137
- temporal lobe, intracranial volume, 35:15
- temporal lobe, laterality, 35:137
- temporal lobe, schizophrenia, 35:1, 35:137
- temporal lobe, sibling pairs, 35:137
- temporal lobe, ventricle-brain ratio, 35:137
- temporal lobe, ventricular volume, 35:15
- temporal lobe, volume reduction, 35:1, 35:15
- ventricle-brain ratio, genetics, 35:137
- ventricle-brain ratio, laterality, 35:137
- ventricle-brain ratio, schizophrenia, 35:137
- ventricle-brain ratio, sibling pairs, 35:137
- ventricle-brain ratio, temporal lobe, 35:137
- ventricular volume, age, 35:15
- ventricular volume, intracranial volume, 35:15
- ventricular volume, temporal lobe, 35:15
- volume reduction, age, 35:15
- volume reduction, limbic system, 35:1, 35:15
- volume reduction, schizophrenia, 35:1
- volume reduction, temporal lobe, 35:1, 35:15

Melatonin

affective disorder, bipolar, 33:129
 affective disorder, light effects, 33:129
 affective disorder, light therapy, 33:129
 affective disorder, unipolar, 33:129
 amino acids, catecholamines, 34:
 amino acids, cortisol, 34:243
 amino acids, neuroleptics, 34:243
 amino acids, schizophrenia, 34:243
 amino acids, tryptophan, 34:243
 beta blockers, blood pressure, 32:175
 beta blockers, cortisol, 32:175
 beta blockers, heart rate, 32:175
 beta blockers, normal volunteers, 32:175
 bipolar, affective disorder, 33:129
 bipolar, light therapy, 33:129
 bipolar, unipolar, 33:129
 blood pressure, beta blockers, 32:175
 blood pressure, cortisol, 32:175
 blood pressure, heart rate, 32:175
 blood pressure, normal volunteers, 32:175
 catecholamines, amino acids, 34:243
 catecholamines, cortisol, 34:243
 catecholamines, neuroleptics, 34:243
 catecholamines, schizophrenia, 34:243
 catecholamines, tryptophan, 34:243
 circadian rhythms, cocaine, 34:185
 circadian rhythms, light effects, 34:185
 circadian rhythms, rat pineal glands, 34:185
 circannual rhythm, diurnal rhythm, 32:221
 circannual rhythm, eating disorder, 32:221
 circannual rhythm, weight, 32:221
 cocaine, circadian rhythms, 34:185
 cocaine, light effects, 34:185
 cocaine, rat pineal glands, 34:185
 cortisol, amino acids, 34:243
 cortisol, beta blockers, 32:175
 cortisol, catecholamines, 34:243
 cortisol, heart rate, 32:175
 cortisol, neuroleptics, 34:243
 cortisol, normal volunteers, 32:175
 cortisol, schizophrenia, 34:243
 cortisol, tryptophan, 34:243
 depressed mood, endorphin, 31:267
 depressed mood, hydroxytryptophan, 31:267
 depressed mood, panic disorder, 31:267
 depressed mood, platelet serotonin uptake, 31:267
 depressed mood, serotonin, 31:267
 diurnal rhythm, circannual rhythm, 32:221
 diurnal rhythm, eating disorder, 32:221
 diurnal rhythm, weight, 32:221
 eating disorder, circannual rhythm, 32:221
 eating disorder, diurnal rhythm, 32:221

Melatonin continued

eating disorder, weight, 32:221
 endorphin, depressed mood, 31:267
 endorphin, panic disorder, 31:267
 endorphin, platelet serotonin uptake, 31:267
 endorphin, serotonin, 31:267
 heart rate, beta blockers, 32:175
 heart rate, blood pressure, 32:175
 heart rate, cortisol, 32:175
 heart rate, normal volunteers, 32:175
 5-hydroxytryptophan, depressed mood, 31:267
 5-hydroxytryptophan, endorphin, 31:267
 5-hydroxytryptophan, panic disorder, 31:267
 5-hydroxytryptophan, serotonin, 31:267
 light therapy, affective disorder, 33:129
 light therapy, bipolar, 33:129
 light therapy, unipolar, 33:129
 neuroleptics, amino acids, 34:243
 neuroleptics, catecholamines, 34:243
 neuroleptics, cortisol, 34:243
 neuroleptics, schizophrenia, 34:243
 neuroleptics, tryptophan, 34:243
 panic disorder, depressed mood, 31:267
 panic disorder, endorphin, 31:267
 panic disorder, hydroxytryptophan, 31:267
 panic disorder, platelet serotonin uptake, 31:267
 panic disorder, serotonin, 31:267
 platelet serotonin uptake, depressed mood, 31:267
 platelet serotonin uptake, endorphin, 31:267
 platelet serotonin uptake, panic disorder, 31:267
 rat pineal glands, circadian rhythms, 34:185
 rat pineal glands, cocaine, 34:185
 rat pineal glands, light effects, 34:185
 schizophrenia, amino acids, 34:243
 schizophrenia, catecholamines, 34:243
 schizophrenia, cortisol, 34:243
 schizophrenia, neuroleptics, 34:243
 schizophrenia, tryptophan, 34:243
 season of year, serum levels, 32:221
 season of year, sulphatoxy melatonin in urine, 32:221
 serotonin, depressed mood, 31:267
 serotonin, endorphin, 31:267
 serotonin, hydroxytryptophan, 31:267
 serotonin, panic disorder, 31:267
 serotonin, platelet serotonin uptake, 31:267
 sulphatoxy melatonin in urine, season of year, 32:221
 sulphatoxy melatonin in urine, serum levels, 32:221

Melatonin continued

- tryptophan, amino acids, 34:243
- tryptophan, catecholamines, 34:243
- tryptophan, cortisol, 34:243
- tryptophan, neuroleptics, 34:243
- tryptophan, schizophrenia, 34:243
- unipolar, light therapy, 33:129
- weight, circannual rhythm, 32:221
- weight, diurnal rhythm, 32:221
- weight, eating disorder, 32:221

Memory

- affective disorder, effortful cognition, 31:161
- effortful cognition, affective disorder, 31:161
- negative symptoms, schizophrenia, 31:15
- neuropsychological performance, affective disorder, 31:161
- schizophrenia, negative symptoms, 31:15

Menstrual cycle

- light therapy, normal women, 33:135
- night light exposure, light therapy, 33:135
- normal women, night light exposure, 33:135

Metergoline

- cortisol, *m*-chlorophenylpiperazine, 33:189
- m*-chlorophenylpiperazine, methysergide, 33:189
- methysergide, normal volunteers, 33:189
- normal volunteers, prolactin, 33:189
- prolactin, cortisol, 33:189

3-Methoxy-4-hydroxyphenylglycol (MHPG)

- age, phenylethylamine, 31:279
- age, Tourette's syndrome, 31:279
- cortisol, lithium, 32:71
- depressed mood, generalized anxiety disorder, 32:35
- evoked potentials, schizophrenia, 31:297
- generalized anxiety disorder, depressed mood, 32:35
- lithium, cortisol, 32:71
- phenylethylamine, age, 31:279
- phenylethylamine, Tourette's syndrome, 31:279
- schizophrenia, evoked potentials, 31:297
- Tourette's syndrome, age, 31:279
- Tourette's syndrome, phenylethylamine, 31:279

Methylphenidate

- growth hormone, homovanillic acid in plasma, 32:9
- homovanillic acid in plasma, schizophrenia, 32:9
- hyperactivity, motor tics, 33:83
- motor tics, hyperactivity, 33:83
- schizophrenia, growth hormone, 32:9

Methysergide

- cortisol, *m*-chlorophenylpiperazine, 33:189
- m*-chlorophenylpiperazine, metergoline, 33:189
- metergoline, normal volunteers, 33:189
- normal volunteers, prolactin, 33:189
- prolactin, cortisol, 33:189

Mexican-Americans

- affective disorder, CES-D Scale, 31:69
- CES-D Scale, Diagnostic Interview Schedule, 31:69
- Diagnostic Interview Schedule, generalized anxiety disorder, 31:69
- generalized anxiety disorder, affective disorder, 31:69

Millon Clinical Multiaxial Inventory

- affective disorder, panic disorder, 31:179
- panic disorder, personality disorder, 31:179
- personality disorder, affective disorder, 31:179

Minnesota Multiphasic Personality Inventory (MMPI)

- admixture analysis, risk factors, 32:311
- admixture analysis, schizophrenia, 32:311
- alpha-2-adrenergic receptor, normal volunteers, 32:125
- heterogeneity, risk factors, 32:311
- heterogeneity, schizophrenia, 32:311
- normal volunteers, alpha-2-adrenergic receptor, 32:125
- risk factors, admixture analysis, 32:311
- risk factors, schizophrenia, 32:297, 32:311
- schizophrenia, admixture analysis, 32:311
- schizophrenia, heterogeneity, 32:311
- schizophrenia, risk factors, 32:297, 32:311

Monoamine oxidase

- age, computed tomography, 31:1
- computed tomography, glutathione peroxidase, 31:1
- glutathione peroxidase, neuroleptics, 31:1
- neuroleptics, schizophrenia, 31:1
- personality disorders, Sensation Seeking Scale, 33:221
- schizophrenia, third ventricle, 31:1
- schizophrenia, ventricle-brain ratio, 31:1
- Sensation Seeking Scale, personality disorders, 33:221
- third ventricle, computed tomography, 31:1
- ventricle-brain ratio, age, 31:1

Mood Adjective Checklist

- risk factors, serotonin, 32:191
- serotonin, suicide, 32:191
- suicide, risk factors, 32:191

Motor activity

- affective disorder, sleep deprivation, 34:213
- affective disorder, thyroid-stimulating hormone, 34:213
- affective disorder, triiodothyronine, 34:213
- anxiety, heart rate, 32:45
- heart rate, anxiety, 32:45
- heart rate, panic disorder, 32:45
- panic disorder, heart rate, 32:45
- sleep deprivation, thyroid stimulating hormone, 34:213
- sleep deprivation, triiodothyronine, 34:213
- thyroid stimulating hormone, triiodothyronine, 34:213
- triiodothyronine, affective disorder, 34:213

Motor tics

- dextroamphetamine, hyperactivity, 33:83
- dextroamphetamine, obsessive-compulsive disorder, 33:83
- hyperactivity, dextroamphetamine, 33:83
- hyperactivity, methylphenidate, 33:83
- hyperactivity, obsessive-compulsive disorder, 33:83
- methylphenidate, hyperactivity, 33:83
- neuropsychological tests, Tourette's syndrome, 33:73
- obsessive-compulsive disorder, dextro-amphetamine, 33:83
- obsessive-compulsive disorder, hyperactivity, 33:83
- Tourette's syndrome, neuropsychological tests, 33:73

Multiple personality disorder

- heart rate, reaction time, 31:251
- reaction time, skin conductance, 31:251
- skin conductance, heart rate, 31:251

Muscarinic receptors

- delta sleep, pilocarpine, 33:113
- delta sleep, rapid eye movement sleep, 33:113
- delta sleep, sleeping, 33:113
- Flinders Sensitive Line of rats, photoperiods, 33:139
- hypothermic response to oxytremorine, rats, 33:139
- light effects, hypothermic response to oxytremorine, 33:139
- photoperiods, Flinders Sensitive Line of rats, 33:139
- photoperiods, hypothermic response to oxytremorine, 33:139
- pilocarpine, delta sleep, 33:113
- pilocarpine, rapid eye movement sleep, 33:113
- pilocarpine, sleeping, 33:113

Muscarinic receptors continued

- rapid eye movement sleep, delta sleep, 33:113
- rapid eye movement sleep, pilocarpine, 33:113
- rapid eye movement sleep, sleeping, 33:113
- sleeping, pilocarpine, 33:113

Negative symptoms

- age, eye tracking, 34:89
- age, schizophrenia, 34:89
- biperiden, schizophrenia, 31:235
- cerebral blood flow, frontal lobe, 35:27
- cerebral blood flow, fronto-occipital ratio, 35:27
- cerebral blood flow, schizophrenia, 35:27
- eye tracking, age, 34:89
- eye tracking, schizophrenia, 34:89
- frontal lobe, cerebral blood flow, 35:27
- frontal lobe, fronto-occipital ratio, 35:27
- frontal lobe, Halstead-Reitan Battery, 31:15
- frontal lobe, negative symptoms, 31:15
- frontal lobe, neuropsychological deficit, 31:15
- frontal lobe, Scale for the Assessment of Negative Symptoms, 31:15
- frontal lobe, schizoaffective disorder, 31:15
- frontal lobe, schizophrenia, 31:15, 35:27
- frontal lobe, verbal fluency, 31:15
- frontal lobe, Wechsler Adult Intelligence Scale, 31:15
- fronto-occipital ratio, cerebral blood flow, 35:27
- fronto-occipital ratio, frontal lobe, 35:27
- fronto-occipital ratio, schizophrenia, 35:27
- Halstead-Reitan Battery, frontal lobe, 31:15
- Halstead-Reitan Battery, schizophrenia, 31:15
- Halstead-Reitan Battery, verbal fluency, 31:15
- Halstead-Reitan Battery, Wechsler Adult Intelligence Scale, 31:15
- homovanillic acid, schizophrenia, 33:259
- homovanillic acid, tardive dyskinesia, 33:259
- negative symptoms, frontal lobe, 31:15
- negative symptoms, neuropsychological deficit, 31:15
- negative symptoms, schizoaffective disorder, 31:15
- neuropsychological deficit, frontal lobe, 31:15
- neuropsychological deficit, negative symptoms, 31:15
- neuropsychological deficit, Scale for the Assessment of Negative Symptoms, 31:15

Negative symptoms continued

- neuropsychological deficit, schizoaffective disorder, 31:15
- neuropsychological deficit, schizophrenia, 31:15
- Positive and Negative Symptom Scale, schizophrenia, 34:221
- Scale for the Assessment of Negative Symptoms, frontal lobe, 31:15
- Scale for the Assessment of Negative Symptoms, neuropsychological deficit, 31:15
- Scale for the Assessment of Negative Symptoms, schizoaffective disorder, 31:15
- schizoaffective disorder, frontal lobe, 31:15
- schizoaffective disorder, negative symptoms, 31:15
- schizoaffective disorder, neuropsychological deficit, 31:15
- schizoaffective disorder, Scale for the Assessment of Negative Symptoms, 31:15
- schizophrenia, age, 34:89
- schizophrenia, biperiden, 31:235
- schizophrenia, cerebral blood flow, 35:27
- schizophrenia, eye tracking, 34:89
- schizophrenia, frontal lobe, 31:15, 35:27
- schizophrenia, fronto-occipital ratio, 35:27
- schizophrenia, Halstead-Reitan Battery, 31:15
- schizophrenia, homovanillic acid, 33:259
- schizophrenia, neuropsychological deficit, 31:15
- schizophrenia, Positive and Negative Symptom Scale, 34:221
- schizophrenia, tardive dyskinesia, 33:259
- schizophrenia, verbal fluency, 31:15
- schizophrenia, Wechsler Adult Intelligence Scale, 31:15
- schizophrenia, Wisconsin Card Sort Test, 31:15
- tardive dyskinesia, homovanillic acid, 33:259
- tardive dyskinesia, schizophrenia, 33:259
- verbal fluency, frontal lobe, 31:15
- verbal fluency, schizophrenia, 31:15
- verbal fluency, Wechsler Adult Intelligence Scale, 31:15
- Wechsler Adult Intelligence Scale, frontal lobe, 31:15
- Wechsler Adult Intelligence Scale, schizophrenia, 31:15
- Wechsler Adult Intelligence Scale, verbal fluency, 31:15
- Wisconsin Card Sort Test, schizophrenia, 31:15

Neostigmine

- adrenergic-cholinergic balance, cholinergic system, 34:259, 34:271
- cholinergic system, cortisol, 34:259
- cortisol, cyclic adenosine monophosphate, 34:259
- cyclic adenosine monophosphate, glucose, 34:259
- glucose, heart rate, 34:259
- heart rate, physostigmine, 34:259
- physostigmine, adrenergic-cholinergic balance, 34:259
- stress, personality, 34:271

Neuroleptics

- age, computed tomography, 31:1
- age, glutathione peroxidase, 31:1
- age, monoamine oxidase, 31:1
- age, schizophrenia, 31:1
- age, third ventricle, 31:1
- age, ventricle-brain ratio, 31:1
- amino acids, catecholamines, 34:243
- amino acids, cortisol, 34:243
- amino acids, melatonin, 34:243
- amino acids, schizophrenia, 34:243
- amino acids, tryptophan, 34:243
- attention, continuous performance test, 32:281, 33:179
- attention, schizophrenia, 32:281, 33:179
- body weight, Japanese patients, 31:111
- body weight, plasma concentration, 31:111
- brain atrophy, computed tomography, 33:307
- brain atrophy, schizophrenia, 33:307
- brain atrophy, somatostatin, 33:307
- catecholamine metabolites, evoked potentials, 31:297
- catecholamine metabolites, schizophrenia, 31:297
- catecholamines, amino acids, 34:243
- catecholamines, cortisol, 34:243
- catecholamines, melatonin, 34:243
- catecholamines, schizophrenia, 34:243
- catecholamines, tryptophan, 34:243
- continuous performance test, attention, 32:281, 33:179
- continuous performance test, schizophrenia, 33:179
- cortisol, amino acids, 34:243
- cortisol, catecholamines, 34:243
- cortisol, melatonin, 34:243
- cortisol, schizophrenia, 34:243
- cortisol, tryptophan, 34:243
- computed tomography, age, 31:1
- computed tomography, brain atrophy, 33:307

Neuroleptics continued

computed tomography, glutathione peroxidase, 31:1
 computed tomography, monoamine oxidase, 31:1
 computed tomography, schizophrenia, 31:1, 33:307
 computed tomography, somatostatin, 33:307
 computed tomography, third ventricle, 31:1
 computed tomography, ventricle-brain ratio, 31:1
 dynorphin, treatment effects, 34:229
 evoked potentials, catecholamine metabolites, 31:297
 evoked potentials, schizophrenia, 31:297
¹⁹F-fluphenazine, magnetic resonance imaging, 35:107
 frontal lobe, ¹⁹F-fluphenazine, 35:107
 frontal lobe, magnetic resonance imaging, 35:107
 frontal lobe, pharmacokinetics, 35:107
 glutathione peroxidase, age, 31:1
 glutathione peroxidase, computed tomography, 31:1
 glutathione peroxidase, monoamine oxidase, 31:1
 glutathione peroxidase, schizophrenia, 31:1
 glutathione peroxidase, third ventricle, 31:1
 glutathione peroxidase, ventricle-brain ratio, 31:1
 habituation, Parkinsonian symptoms, 34:19
 habituation, schizophrenia, 34:19
 habituation, skin conductance, 34:19
 habituation, tardive dyskinesia, 34:19
 homovanillic acid, haloperidol, 33:171
 homovanillic acid, neuropsychological tests, 33:171
 homovanillic acid, rapid medication response, 33:171
 homovanillic acid, schizophrenia, 33:171
 Japanese patients, body weight, 31:111
 Japanese patients, plasma concentration, 31:111
 laterality, schizophrenia, 32:289
 laterality, tactile discrimination, 32:289
 lymphocyte protein, schizophrenia, 32:95
 magnetic resonance imaging, ¹⁹F-fluphenazine, 35:107
 melatonin, amino acids, 34:243
 melatonin, catecholamines, 34:243
 melatonin, cortisol, 34:243
 melatonin, schizophrenia, 34:243
 melatonin, tryptophan, 34:243
 monoamine oxidase, age, 31:1

Neuroleptics continued

monoamine oxidase, computed tomography, 31:1
 monoamine oxidase, glutathione peroxidase, 31:1
 monoamine oxidase, schizophrenia, 31:1
 monoamine oxidase, third ventricle, 31:1
 monoamine oxidase, ventricle-brain ratio, 31:1
 neuropsychological tests, haloperidol, 33:171
 neuropsychological tests, homovanillic acid, 33:171
 neuropsychological tests, rapid medication response, 33:171
 neuropsychological tests, schizophrenia, 33:171
 parkinsonian symptoms, habituation, 34:19
 parkinsonian symptoms, schizophrenia, 34:19
 parkinsonian symptoms, skin conductance, 34:19
 parkinsonian symptoms, tardive dyskinesia, 34:19
 pharmacokinetics, ¹⁹F-fluphenazine, 35:107
 plasma concentration, body weight, 31:111
 plasma concentration, Japanese patients, 31:111
 prolactin in serum, treatment outcome, 32:213
 rapid medication response, haloperidol, 33:171
 rapid medication response, homovanillic acid, 33:171
 rapid medication response, neuropsychological tests, 33:171
 rapid medication response, schizophrenia, 33:171
 schizophrenia, age, 31:1
 schizophrenia, amino acids, 34:243
 schizophrenia, attention, 32:281, 33:179
 schizophrenia, brain atrophy, 33:307
 schizophrenia, catecholamines, 31:297, 34:243
 schizophrenia, computed tomography, 31:1, 33:307
 schizophrenia, continuous performance test, 33:179
 schizophrenia, cortisol, 34:243
 schizophrenia, evoked potentials, 31:297
 schizophrenia, glutathione peroxidase, 31:1
 schizophrenia, habituation, 34:19
 schizophrenia, haloperidol, 33:171
 schizophrenia, homovanillic acid, 33:171
 schizophrenia, laterality, 32:289

Neuroleptics continued

- schizophrenia, lymphocyte protein, 32:95
- schizophrenia, melatonin, 34:243
- schizophrenia, monoamine oxidase, 31:1
- schizophrenia, neuropsychological tests, 33:171
- schizophrenia, parkinsonian symptoms, 34:19
- schizophrenia, rapid medication response, 33:171
- schizophrenia, skin conductance, 34:19
- schizophrenia, somatostatin, 33:307
- schizophrenia, tactile discrimination, 32:289
- schizophrenia, tardive dyskinesia, 34:19
- schizophrenia, third ventricle, 31:1
- schizophrenia, tryptophan, 34:243
- schizophrenia, ventricle-brain ratio, 31:1
- schizophrenic children, span of apprehension score, 31:169
- skin conductance, habituation, 34:19
- skin conductance, parkinsonian symptoms, 34:19
- skin conductance, schizophrenia, 34:19
- skin conductance, tardive dyskinesia, 34:19
- somatostatin, brain atrophy, 33:307
- somatostatin, computed tomography, 33:307
- somatostatin, schizophrenia, 33:307
- span of apprehension score, schizophrenic children, 31:169
- tactile discrimination, laterality, 32:289
- tactile discrimination, schizophrenia, 32:289
- tardive dyskinesia, habituation, 34:19
- tardive dyskinesia, parkinsonian symptoms, 34:19
- tardive dyskinesia, schizophrenia, 34:19
- tardive dyskinesia, skin conductance, 34:19
- third ventricle, age, 31:1
- third ventricle, computed tomography, 31:1
- third ventricle, glutathione peroxidase, 31:1
- third ventricle, monoamine oxidase, 31:1
- third ventricle, schizophrenia, 31:1
- third ventricle, ventricle-brain ratio, 31:1
- treatment effects, dynorphin, 34:229
- treatment outcome, prolactin in serum, 32:213
- tryptophan, amino acids, 34:243
- tryptophan, catecholamines, 34:243
- tryptophan, cortisol, 34:243
- tryptophan, melatonin, 34:243
- tryptophan, schizophrenia, 34:243
- ventricle-brain ratio, age, 31:1
- ventricle-brain ratio, computed tomography, 31:1

Neuroleptics continued

- ventricle-brain ratio, glutathione peroxidase, 31:1
- ventricle-brain ratio, monoamine oxidase, 31:1
- ventricle-brain ratio, schizophrenia, 31:1

Neuropeptide Y

- alcoholism, cerebrospinal fluid, 33:215
- cerebrospinal fluid, corticotropin releasing hormone, 33:215
- corticotropin releasing hormone, growth hormone releasing hormone, 33:215
- growth hormone releasing hormone, somatostatin, 33:215
- somatostatin, alcoholism, 33:215

Neuropsychological tests

- affective disorder, effortful cognition, 31:161
- affective disorder, memory performance, 31:161
- age of onset, Tourette's syndrome, 33:73
- effortful cognition, affective disorder, 31:161
- effortful cognition, memory performance, 31:161
- frontal lobe, negative symptoms, 31:15
- frontal lobe, schizoaffective disorder, 31:15
- haloperidol, homovanillic acid, 33:171
- haloperidol, rapid medication response, 33:171
- haloperidol, schizophrenia, 33:171
- homovanillic acid, haloperidol, 33:171
- homovanillic acid, neuroleptic response, 33:171
- homovanillic acid, rapid medication response, 33:171
- homovanillic acid, schizophrenia, 33:171
- memory performance, affective disorder, 31:161
- memory performance, effortful cognition, 31:161
- negative symptoms, frontal lobe, 31:15
- negative symptoms, schizoaffective disorder, 31:15
- neuroleptic response, homovanillic acid, 33:171
- neuroleptic response, schizophrenia, 33:171
- rapid medication response, haloperidol, 33:171
- rapid medication response, homovanillic acid, 33:171
- rapid medication response, schizophrenia, 33:171
- Scale for the Assessment of Negative Symptoms, frontal lobe, 31:15

Neuropsychological tests continued

- Scale for the Assessment of Negative Symptoms, negative symptoms, 31:15
- Scale for the Assessment of Negative Symptoms, schizoaffective disorder, 31:15
- Scale for the Assessment of Negative Symptoms, schizophrenia, 31:15
- Scale for the Assessment of Negative Symptoms, Wisconsin Card Sort Test, 31:15
- schizoaffective disorder, frontal lobe, 31:15
- schizoaffective disorder, negative symptoms, 31:15
- schizoaffective disorder, Scale for the Assessment of Negative Symptoms, 31:15
- schizophrenia, haloperidol, 33:171
- schizophrenia, homovanillic acid, 33:171
- schizophrenia, neuroleptic response, 33:171
- schizophrenia, rapid medication response, 33:171
- schizophrenia, Scale for the Assessment of Negative Symptoms, 31:15
- schizophrenia, Wisconsin Card Sort Test, 31:15
- tics, age of onset, 33:73
- tics, Tourette's syndrome, 33:73
- Tourette's syndrome, age of onset, 33:73
- Wisconsin Card Sort Test, Scale for the Assessment of Negative Symptoms, 31:15
- Wisconsin Card Sort Test, schizophrenia, 31:15

Nifedipine

- antidepressant properties, rat
- immobility, 32:203

Norepinephrine

- amino acids in serum, drug-naïve patients, 34:243
- amino acids in serum, schizophrenia, 34:243
- anxiety, bulimia, 33:1
- anxiety, eating disorders, 33:1
- anxiety, free fatty acids, 33:1
- anxiety, isoproterenol, 33:1
- blood pressure, electroconvulsive therapy, 34:127
- blood pressure, heart rate, 34:127
- bulimia, anxiety, 33:1
- bulimia, free fatty acids, 33:1
- bulimia, isoproterenol, 33:1
- depressed mood, generalized anxiety disorder, 32:35
- drug-naïve patients, amino acids in serum, 34:243
- drug-naïve patients, schizophrenia, 34:243
- eating disorders, anxiety, 33:1
- eating disorders, free fatty acids, 33:1

Norepinephrine continued

- eating disorders, isoproterenol, 33:1
- electroconvulsive therapy, blood pressure, 34:127
- electroconvulsive therapy, heart rate, 34:127
- free fatty acids, anxiety, 33:1
- free fatty acids, bulimia, 33:1
- free fatty acids, isoproterenol, 33:1
- generalized anxiety disorder, depressed mood, 32:35
- heart rate, blood pressure, 34:127
- heart rate, electroconvulsive therapy, 34:127
- isoproterenol, anxiety, 33:1
- isoproterenol, eating disorders, 33:1
- isoproterenol, free fatty acids, 33:1
- lithium pharmacokinetics, mania, 32:71
- mania, lithium pharmacokinetics, 32:71
- physostigmine, stress, 34:217
- schizophrenia, amino acids in serum, 34:243
- schizophrenia, drug-naïve patients, 34:243
- stress, physostigmine, 34:243

Normal volunteers

- amines, urinary 31:279
- adrenocorticotrophic hormone, plasma 31:31
- adrenocorticotrophic hormone, clomipramine 31:39
- beta-endorphin, plasma, 31:267
- catecholamines, urine, 31:279, 31:297
- cortisol, plasma 31:31
- cortisol response to clomipramine, 31:39
- cortisol, tryptophan, 31:57
- dexamethasone suppression test, 31:49
- diazepam-binding inhibitor, CSF, 31:261
- growth hormone response to clomipramine, 31:39
- growth hormone, clonidine, 31:311
- growth hormone, tryptophan 31:57
- melatonin, plasma, 31:267
- neuropsychological tests, IQ, 31:15
- phenylethylamine, urine, 31:279
- prolactin response to clomipramine, 31:39
- tryptophan, plasma, 31:57
- vasopressin, clonidine, 31:311

Normetanephrine

- homovanillic acid, 5-hydroxyindoleacetic acid, 31:279
- 5-hydroxyindoleacetic acid, Tourette's syndrome, 31:279
- Tourette's syndrome, 5-hydroxyindoleacetic acid, 31:279

Obsessive-compulsive disorder

- anxiety symptoms, clomipramine, 31:121
- anxiety symptoms, depression symptoms, 31:121

Obsessive-compulsive disorder continued

cerebrospinal fluid, 5-hydroxyindoleacetic acid, 33:95
 cerebrospinal fluid, 5-hydroxytryptamine, 33:95
 childhood depression, conduct disorder, 33:277
 childhood depression, somatostatin, 33:277
 clomipramine response, dermatitis, 34:223
 clomipramine response, hand washing, 34:223
 clomipramine, anxiety symptoms, 31:121
 clomipramine, cortisol, 32:151
 clomipramine, depressed mood, 31:121, 32:151
 clomipramine, dexamethasone suppression test, 32:151
 clomipramine, symptom assessment, 34:99
 clomipramine, Yale-Brown Scale, 34:99
 conduct disorder, childhood depression, 33:277
 conduct disorder, somatostatin, 33:277
 cortisol, clomipramine, 32:151
 cortisol, depressed mood, 32:151
 cortisol, dexamethasone suppression test, 32:151
 depressed mood, clomipramine, 32:151
 depressed mood, cortisol, 32:151
 depressed mood, dexamethasone suppression test, 32:151
 depression symptoms, anxiety symptoms, 31:121
 depression symptoms, clomipramine, 31:121
 dermatitis, clomipramine response, 34:223
 dermatitis, hand washing, 34:223
 dexamethasone suppression test, clomipramine, 32:151
 dexamethasone suppression test, cortisol, 32:151
 dexamethasone suppression test, depressed mood, 32:151
 dextroamphetamine, hyperactivity, 33:83
 dextroamphetamine, motor tics, 33:83
 hand washing, clomipramine response, 34:223
 hand washing, dermatitis, 34:223
 5-hydroxyindoleacetic acid, cerebrospinal fluid, 33:95
 5-hydroxyindoleacetic acid, serotonin, 33:95
 5-hydroxytryptamine, cerebrospinal fluid, 33:95
 hyperactivity, dextroamphetamine, 33:83
 motor tics, dextroamphetamine, 33:83
 serotonin, cerebrospinal fluid, 33:95
 somatostatin, childhood depression, 33:277

Obsessive-compulsive disorder continued

somatostatin, conduct disorder, 33:277
 symptom assessment, clomipramine, 34:99
 symptom assessment, Yale-Brown Scale, 34:99
 Yale-Brown Scale, clomipramine, 34:99

Occipital lobe

ethanol, glucose metabolic rate, 35:39
 glucose metabolic rate, positron emission tomography, 35:39
 positron emission tomography, ethanol, 35:39

Oxytocin

affective disorder, electroconvulsive therapy, 32:201
 electroconvulsive therapy, vasopressin, 32:201
 vasopressin, affective disorder, 32:201

Pain symptoms

imipramine binding in platelets, psychogenic pain, 32:29

Panic disorder

affective disorder, age, 33:51
 affective disorder, antidepressants, 33:51
 affective disorder, personality disorder, 31:179
 affective disorder, treatment outcome, 33:51
 age, affective disorder, 33:51
 age, antidepressants, 33:51
 age, treatment outcome, 33:51
 agoraphobia, cardiomyopathy, 32:55
 antidepressants, affective disorder, 33:51
 antidepressants, age, 33:51
 antidepressants, treatment outcome, 33:51
 anxiety symptoms, carbon dioxide, 31:193
 anxiety, heart rate, 32:45
 anxiety, motor activity, 32:45
 beta blockers, heart rate, 32:93
 beta blockers, lactate infusion, 32:93
 carbon dioxide, anxiety symptoms, 31:193
 cardiomyopathy, agoraphobia, 32:55
 cardiomyopathy, left ventricular mass, 32:55
 cardiomyopathy, weight, 32:55
 cortisol, fenfluramine, 31:211
 depressed mood, endorphin, 31:267
 depressed mood, hydroxytryptophan, 31:267
 depressed mood, melatonin, 31:267
 depressed mood, platelet serotonin uptake, 31:267
 depressed mood, serotonin, 31:267
 endorphin, depressed mood, 31:267
 endorphin, hydroxytryptophan, 31:267
 endorphin, melatonin, 31:267
 endorphin, platelet serotonin uptake, 31:267

Panic disorder continued

- endorphin, serotonin, 31:267
- fenfluramine, cortisol, 31:211
- heart rate, anxiety, 32:45
- heart rate, beta blockers, 32:93
- heart rate, lactate infusion, 32:93
- heart rate, motor activity, 32:45
- 5-hydroxytryptophan, depressed mood, 31:267
- 5-hydroxytryptophan, endorphin, 31:267
- isoproterenol, panic attack, 32:103
- lactate infusion, beta blockers, 32:93
- lactate infusion, heart rate, 32:93
- left ventricular mass, cardiomyopathy, 32:55
- left ventricular mass, weight, 32:55
- m*-chlorophenylpiperazine, serotonin, 31:209
- m*-chlorophenylpiperazine, tryptophan, 31:209
- melatonin, depressed mood, 31:267
- melatonin, endorphin, 31:267
- melatonin, hydroxytryptophan, 31:267
- melatonin, serotonin, 31:267
- Millon Clinical Multiaxial Inventory, personality disorder, 31:179
- motor activity, anxiety, 32:45
- motor activity, heart rate, 32:45
- panic attack, isoproterenol, 32:103
- personality disorder, Millon Clinical Multiaxial Inventory, 31:179
- platelet serotonin uptake, depressed mood, 31:267
- platelet serotonin uptake, endorphin, 31:267
- platelet serotonin uptake, hydroxytryptophan, 31:267
- platelet serotonin uptake, melatonin, 31:267
- serotonin, depressed mood, 31:267
- serotonin, endorphin, 31:267
- serotonin, *m*-chlorophenylpiperazine, 31:209
- serotonin, melatonin, 31:267
- serotonin, tryptophan, 31:209
- treatment outcome, affective disorder, 33:51
- treatment outcome, age, 33:51
- treatment outcome, antidepressants, 33:51
- tryptophan, *m*-chlorophenylpiperazine, 31:209
- tryptophan, serotonin, 31:209
- weight, cardiomyopathy, 32:55
- weight, left ventricular mass, 32:55

Parkinsonian symptoms

- schizophrenia, neuroleptic withdrawal, 34:19

Perceptual Abberation Scale

- schizophrenia risk, normal volunteers, 33:243

Personality disorder

- affective disorder, 32:175, 33:51
- affective disorder, Millon Clinical Multiaxial Inventory, 31:179
- affective disorder, Symptom Checklist-90, 31:179
- affective disorder, treatment outcome, 32:175
- alpha₂-adrenergic receptor, Sensation Seeking Scale, 32:125
- antidepressant response, affective disorder, 33:51
- antidepressants, treatment outcome, 32:175
- avoidant personality disorder, criteria sensitivity, 34:281
- avoidant personality disorder, diagnosis, 34:281
- criteria sensitivity, avoidant personality disorder, 34:
- criteria sensitivity, diagnosis, 34:281
- dependent personality disorder, sex differences, 33:207
- diagnosis, avoidant personality disorder, 34:281
- diagnosis, criteria sensitivity, 34:281
- diagnostic criteria, Personality Disorder Examination, 32:85
- Millon Clinical Multiaxial Inventory, panic disorder, 31:179
- monoamine oxidase activity, Sensation Seeking Scale, 33:221
- panic disorder, Symptom Checklist-90, 31:179
- panic disorder, Millon Clinical Multiaxial Inventory, 31:179
- Personality Disorder Examination, diagnostic criteria, 32:85
- Sensation Seeking Scale, alpha₂-adrenergic receptor, 32:125
- Sensation Seeking Scale, monoamine oxidase activity, 33:221
- sex differences, dependent personality disorder, 33:207
- Symptom Checklist-90, affective disorder, 31:179
- Symptom Checklist-90, panic disorder, 31:179
- treatment outcome, affective disorder, 32:175
- treatment outcome, antidepressants, 32:175

Phenylethylamine

age, 3-methoxy-4-hydroxyphenylglycol, 31:279

3-methoxy-4-hydroxyphenylglycol,

Tourette's syndrome, 31:279

Tourette's syndrome, age, 31:279

Phorbol esters

DNA content, leukocytes, 33:59

leukocytes, normal volunteers, 33:59

normal volunteers, stress response, 33:59

stress response, DNA content, 33:59

Phosphate

affective disorder, anxiety symptoms, 31:217

Physostigmine

adrenergic-cholinergic balance, cholinergic system, 34:259, 34:271

catecholamines, cholinergic system, 34:259

catecholamines, cortisol, 34:259

catecholamines, stress, 34:259, 34:271

cortisol, cyclic adenosine monophosphate, 34:259

cyclic adenosine monophosphate, glucose, 34:259

glucose, heart rate, 34:259

heart rate, neostigmine, 34:259

heart rate, stress, 34:259

neostigmine, adrenergic-cholinergic balance, 34:259

stress, catecholamines, 34:259

stress, cholinergic system, 34:259

stress, cortisol, 34:259

stress, heart rate, 34:259

Pilocarpine

delta sleep, muscarinic receptors, 33:113

muscarinic receptors, rapid eye movement sleep, 33:113

rapid eye movement sleep, muscarinic receptors, 33:113

sleeping, rapid eye movement sleep, 33:113

Pineal gland

ethanol, serotonin binding, 32:19

serotonin binding, suicide, 32:19

Positive symptoms

Scale for the Assessment of Negative

Symptoms, dilapidation behavior, 34:221

Positron emission tomography

age, anxiety, 35:49

age, glucose metabolic rate, 35:49

age, sex differences, 35:49

alcoholism, benzodiazepine receptors, 35:39

alcoholism, frontal lobe, 35:39

alcoholism, glucose metabolic rate, 35:39

anxiety, age, 35:49

anxiety, glucose metabolic rate, 35:49

Positron emission tomography continued

benzodiazepine receptors, alcoholism, 35:39

benzodiazepine receptors, frontal lobe, 35:39

ethanol, fluorodeoxyglucose, 35:39

ethanol, frontal lobe, 35:39

fluorodeoxyglucose, alcoholism, 35:39

fluorodeoxyglucose, ethanol, 35:39

fluorodeoxyglucose, frontal lobe, 35:39

frontal lobe, alcoholism, 35:39

frontal lobe, benzodiazepine receptors, 35:39

frontal lobe, ethanol, 35:39

glucose metabolic rate, age, 35:49

glucose metabolic rate, anxiety, 35:49

glucose metabolic rate, sex differences, 35:49

glucose metabolic rate, alcoholism, 35:39

sex differences, anxiety, 35:49

sex differences, glucose metabolic rate, 35:49

Prolactin

adrenocorticotrophic hormone, affective disorder, 31:39, 31:57

adrenocorticotrophic hormone, bipolar, 31:57

adrenocorticotrophic hormone, clomipramine, 31:39

adrenocorticotrophic hormone, cortisol, 31:39, 31:57

adrenocorticotrophic hormone, growth hormone, 31:39, 31:57

adrenocorticotrophic hormone, heart rate, 31:39

adrenocorticotrophic hormone, tryptophan, 31:57

affective disorder, amitriptyline, 31:201

affective disorder, antidepressants, 31:201

affective disorder, Beck Depression

Inventory, 31:201

affective disorder, bipolar, 31:57

affective disorder, clomipramine, 31:39

affective disorder, cortisol, 31:39, 31:57

affective disorder, growth hormone, 31:39, 31:57, 31:201

affective disorder, heart rate, 31:39

affective disorder, tryptophan, 31:57, 31:201

affective disorder, weight loss, 31:201

alcoholism, apomorphine, 33:151

alcoholism, cocaine, 33:151

alcoholism, growth hormone, 33:151

alcoholism, substance abuse, 33:151

amino acids in serum, schizophrenia, 34:243

amitriptyline, affective disorder, 31:201

amitriptyline, antidepressants, 31:201

amitriptyline, Beck Depression Inventory, 31:201

amitriptyline, growth hormone, 31:201

Prolactin continued

amitriptyline, tryptophan, 31:201
 amitriptyline, weight loss, 31:201
 antidepressants, affective disorder, 31:201
 antidepressants, amitriptyline, 31:201
 antidepressants, Beck Depression Inventory, 31:201
 antidepressants, growth hormone, 31:201
 antidepressants, tryptophan, 31:201
 antidepressants, weight loss, 31:201
 apomorphine, alcoholism, 33:151
 apomorphine, cocaine, 33:151, 33:161
 apomorphine, growth hormone, 33:151, 33:161
 apomorphine, homovanillic acid, 33:161
 apomorphine, substance abuse, 33:151
 Beck Depression Inventory, affective disorder, 31:201
 Beck Depression Inventory, amitriptyline, 31:201
 Beck Depression Inventory, antidepressants, 31:201
 Beck Depression Inventory, growth hormone, 31:201
 Beck Depression Inventory, tryptophan, 31:201
 Beck Depression Inventory, weight loss, 31:201
 bipolar, adrenocorticotrophic hormone, 31:57
 bipolar, affective disorder, 31:57
 bipolar, cortisol, 31:57
 bipolar, growth hormone, 31:57
 bipolar, tryptophan, 31:57
 clomipramine, adrenocorticotrophic hormone, 31:39
 clomipramine, affective disorder, 31:39
 clomipramine, cortisol, 31:39
 clomipramine, growth hormone response, 31:39
 clomipramine, heart rate, 31:39
 clomipramine response, serotonin, 31:39
 cocaine, alcoholism, 33:151
 cocaine, apomorphine, 33:151, 33:161
 cocaine, growth hormone, 33:151, 33:161
 cocaine, homovanillic acid, 33:161
 cocaine, substance abuse, 33:151
 cortisol, adrenocorticotrophic hormone, 31:39, 31:57
 cortisol, affective disorder, 31:39, 31:57
 cortisol, bipolar, 31:57
 cortisol, clomipramine, 31:39
 cortisol, growth hormone, 31:39, 31:57
 cortisol, heart rate, 31:39
 cortisol, *m*-chlorophenylpiperazine, 33:189

Prolactin continued

cortisol, metergoline, 33:189
 cortisol, methysergide, 33:189
 cortisol, normal volunteers, 33:189
 cortisol, tryptophan, 31:57
 domperidone, schizophrenia, 34:139
 growth hormone, adrenocorticotrophic hormone, 31:57
 growth hormone, affective disorder, 31:39, 31:57, 31:201
 growth hormone, alcoholism, 33:151
 growth hormone, amitriptyline, 31:201
 growth hormone, antidepressants, 31:201
 growth hormone, apomorphine, 33:151, 33:161
 growth hormone, Beck Depression Inventory, 31:201
 growth hormone, bipolar, 31:57
 growth hormone, clomipramine, 31:39
 growth hormone, cocaine, 33:151, 33:161
 growth hormone, cortisol, 31:39, 31:57
 growth hormone, heart rate, 31:39
 growth hormone, homovanillic acid, 33:161
 growth hormone, serotonin, 31:39
 growth hormone, substance abuse, 33:151
 growth hormone, tryptophan, 31:57, 31:201
 growth hormone, weight loss, 31:201
 heart rate, adrenocorticotrophic hormone, 31:39
 heart rate, affective disorder, 31:39
 heart rate, clomipramine, 31:39
 heart rate, cortisol, 31:39
 heart rate, growth hormone response, 31:39
 homovanillic acid, apomorphine, 33:161
 homovanillic acid, cocaine, 33:161
 homovanillic acid, growth hormone, 33:161
m-chlorophenylpiperazine, cortisol, 33:189
m-chlorophenylpiperazine, normal volunteers, 33:189
 metergoline, cortisol, 33:189
 metergoline, *m*-chlorophenylpiperazine, 33:189
 metergoline, normal volunteers, 33:189
 methysergide, cortisol, 33:189
 methysergide, *m*-chlorophenylpiperazine, 33:189
 methysergide, normal volunteers, 33:189
 neuroleptics, treatment outcome, 32:213
 normal volunteers, cortisol, 33:189
 normal volunteers, *m*-chlorophenylpiperazine, 33:189
 normal volunteers, metergoline, 33:189
 normal volunteers, methysergide, 33:189
 schizophrenia, amino acids in serum, 34:243
 schizophrenia, domperidone, 34:139

Prolactin continued

- serotonin, clomipramine response, 31:39
- serotonin, growth hormone, 31:39
- sex differences, tryptophan, 31:57
- substance abuse, alcoholism, 33:151
- substance abuse, apomorphine, 33:151
- substance abuse, cocaine, 33:151
- substance abuse, growth hormone, 33:151
- treatment outcome, neuroleptics, 32:213
- tryptophan, adrenocorticotrophic hormone, 31:57
- tryptophan, affective disorder, 31:57, 31:201
- tryptophan, amitriptyline, 31:201
- tryptophan, antidepressants, 31:201
- tryptophan, Beck Depression Inventory, 31:201
- tryptophan, bipolar, 31:57
- tryptophan, cortisol, 31:57
- tryptophan, growth hormone, 31:57, 31:201
- tryptophan, sex differences, 31:57
- tryptophan, weight loss, 31:201
- weight loss, affective disorder, 31:201
- weight loss, amitriptyline, 31:201
- weight loss, antidepressants, 31:201
- weight loss, Beck Depression Inventory, 31:201
- weight loss, growth hormone, 31:201
- weight loss, tryptophan, 31:201

Propranolol

- affective disorder, depressive mood, 33:101
- desimipramine, treatment response, 33:101
- treatment response, affective disorder, 33:101

Psychopathy

- evoked potentials, eye tracking, 31:85
- eye tracking, intensity of stimuli, 31:85
- intensity of stimuli, evoked potentials, 31:85

Race

- haloperidol concentration, Japanese patients, 31:111

Rapid eye movement sleep (REM)

- affective disorder, risk factors, 33:39
- risk factors, genetics, 33:39
- genetics, affective disorder, 33:39

Rauwolscine

- affective disorder, platelet α_2 adrenergic receptors, 34:193

Reaction time

- heart rate, multiple personality disorder, 31:251
- multiple personality disorder, skin conductance, 31:251
- skin conductance, heart rate, 31:251

Receiver operating characteristic (ROC) analysis

- adrenocorticotrophic hormone, affective disorder, 34:107
- adrenocorticotrophic hormone, cortisol, 34:107
- affective disorder, adrenocorticotrophic hormone, 34:107
- affective disorder, cortisol, 34:107
- affective disorder, dexamethasone concentration in serum, 31:49
- affective disorder, dexamethasone suppression test, 31:49
- cortisol, affective disorder, 34:107
- dexamethasone suppression test, affective disorder, 31:49

Reproterol

- physostigmine, normal volunteer, 34:259

Research Diagnostic Criteria

- affective disorder, classification error, 31:145
- classification error, Diagnostic Interview Schedule, 31:145
- Diagnostic Interview Schedule, SADS interview, 31:145
- SADS interview, affective disorder, 31:145

Reverse triiodothyronine

- bipolar affective disorder, lithium treatment, 34:13

Risk factors

- admixture analysis, Minnesota Multiphasic Personality Inventory, 32:311
- admixture analysis, Perceptual Aberration Scale, 33:243
- admixture analysis, schizophrenia, 32:311
- affective disorder, genetics, 33:39
- affective disorder, rapid eye movement sleep, 33:39
- genetics, affective disorder, 33:39
- genetics, rapid eye movement sleep, 33:39
- heterogeneity, Minnesota Multiphasic Personality Inventory, 32:311
- heterogeneity, schizophrenia, 32:311
- Minnesota Multiphasic Personality Inventory, admixture analysis, 32:311
- Perceptual Aberration Scale, admixture analysis, 33:243
- rapid eye movement sleep, affective disorder, 33:39
- rapid eye movement sleep, genetics, 33:39
- schizophrenia, admixture analysis, 32:311
- schizophrenia, heterogeneity, 32:311
- schizophrenia, Minnesota Multiphasic Personality Inventory, 32:297, 32:311

Rockland-Pollin Scale

schizophrenia, cerebral blood flow, 35:27

Schedule for Affective Disorders and Schizophrenia (SADS)

classification error, Diagnostic Interview Schedule, 31:145

Diagnostic Interview Schedule, Research Diagnostic Criteria, 31:145

Research Diagnostic Criteria, classification error, 31:145

Schizoaffective disorder

frontal lobe, negative symptoms, 31:15

negative symptoms, neuropsychological deficit, 31:15

neuropsychological deficit, Scale for the Assessment of Negative Symptoms, 31:15
Scale for the Assessment of Negative Symptoms, frontal lobe, 31:15

Schizophrenia

admixture analysis, age, 35:61

admixture analysis, computed tomography, 35:61

admixture analysis, Minnesota Multiphasic Personality Inventory, 32:311

admixture analysis, Perceptual Aberration Scale, 33:243

admixture analysis, risk factors, 32:311

admixture analysis, statistical methods, 33:243

admixture analysis, ventricle-brain ratio, 35:61

age, admixture analysis, 35:61

age, computed tomography, 31:1, 35:61

age, eye tracking, 34:89

age, glutathione peroxidase, 31:1

age, growth hormone, 33:269

age, growth hormone releasing hormone, 33:269

age, monoamine oxidase, 31:1

age, neuroleptics, 31:1

age of illness onset, deficit syndrome, 31:243

age of illness onset, depression, 31:243

age of illness onset, duration of illness, 31:243

age of onset, eye tracking, 34:89

age, Scale for the Assessment of Negative Symptoms, 34:89

age, third ventricle, 31:1

age, ventricle-brain ratio, 31:1, 35:61

amino acids in serum, growth hormone, 34:243

amino acids in serum, thyroid function, 34:243

amino acids, catecholamines, 34:243

amino acids, cortisol, 34:243

Schizophrenia continued

amino acids in plasma, paranoid subtype, 32:63

amino acids, melatonin, 34:243

amino acids, neuroleptics, 34:243

amino acids, tryptophan, 34:243

amygdala, magnetic resonance imaging, 35:137

anhedonia, deficit syndrome, 31:25

anticholinergic medication, cholinergic system, 31:235

anticholinergic medication, symptom severity, 31:235

attention, continuous performance test, 33:179

attention, distractibility, 31:169

attention, formal thought disorder, 31:169

attention, neuroleptic treatment, 32:281, 33:179

attention, span of apprehension, 31:169

attention, Wechsler Intelligence Scale for Children, 31:169

augmenting-reducing, criminality, 31:85

augmenting-reducing, evoked potentials, 31:85

augmenting-reducing, eye tracking, 31:85

biperiden, negative symptoms, 31:235

brain atrophy, computed tomography, 33:307

brain atrophy, neuroleptic treatment, 33:307

brain atrophy, somatostatin, 33:307

catecholamine metabolites, evoked potentials, 31:297

catecholamine metabolites, neuroleptic treatment, 31:297

catecholamines, amino acids, 34:243

catecholamines, cortisol, 34:243

catecholamines, melatonin, 34:243

catecholamines, neuroleptics, 34:243

catecholamines, tryptophan, 34:243

cerebral blood flow, frontal lobe, 35:27

cerebral blood flow, fronto-occipital ratio, 35:27

cerebral blood flow, hypofrontality, 35:27

cerebral blood flow, laterality, 35:27

cerebral blood flow, Scale for the

Assessment of Negative Symptoms, 35:27

cerebral blood flow, symptom severity, 35:27

cerebrospinal fluid, dynorphin, 34:229

cerebrospinal fluid, endorphin, 34:229

cerebrospinal fluid, substance P, 34:229

cholinergic system, anticholinergic medication, 31:235

cholinergic system, symptom severity, 31:235

Schizophrenia continued

continuous performance test, attention, 33:179
 continuous performance test, neuroleptics, 32:281, 33:179
 computed tomography, admixture analysis, 35:61
 computed tomography, age, 31:1, age, 35:61
 computed tomography, brain atrophy, 33:307
 computed tomography, corpus callosum, 34:163
 computed tomography, frontal lobe, 31:221
 computed tomography, glutathione peroxidase, 31:1
 computed tomography, HLA antigen, 31:221
 computed tomography, laterality, 31:221, 34:163
 computed tomography, magnetic resonance imaging, 34:163
 computed tomography, monoamine oxidase, 31:1
 computed tomography, neuroleptic response, 31:1, 31:221, 33:307
 computed tomography, somatostatin, 33:307
 computed tomography, third ventricle, 31:1
 computed tomography, ventricle-brain ratio, 31:1, 31:221, 35:61
 corpus callosum, computed tomography, 34:163
 corpus callosum, laterality, 34:163
 corpus callosum, magnetic resonance imaging, 34:163
 cortisol, amino acids, 34:243
 cortisol, catecholamines, 34:243
 cortisol, melatonin, 34:243
 cortisol, neuroleptics, 34:243
 cortisol, tryptophan, 34:243
 criminality, augmenting-reducing, 31:85
 criminality, evoked potentials, 31:85
 criminality, eye tracking, 31:85
 cytomegalovirus, immunoglobulins, 33:11
 deficit syndrome, age of illness onset, 31:243
 deficit syndrome, anhedonia, 31:25
 deficit syndrome, depression, 31:243
 deficit syndrome, duration of illness, 31:243
 depression, age of illness onset, 31:243
 depression, deficit syndrome, 31:243
 depression, duration of illness, 31:243
 diagnosis, familial schizophrenia, 34:77
 diagnosis, subtype stability, 34:77
 diagnostic criteria, paranoid subtype, 34:77
 dilapidation behavior, frontal lobe, 34:221

Schizophrenia continued

dilapidation behavior, negative symptoms, 34:221
 distractibility, formal thought disorder, 31:169
 distractibility, span of apprehension, 31:169
 distractibility, Wechsler Intelligence Scale for Children, 31:169
 domperidone, prolactin, 34:139
 duration of illness, age of illness onset, 31:243
 duration of illness, deficit syndrome, 31:243
 duration of illness, depression, 31:243
 dynorphin, cerebrospinal fluid, 34:229
 dynorphin, endorphin, 34:229
 dynorphin, substance P, 34:229
 dyskinesia, neuroleptic withdrawal, 34:19
 dyskinesia, skin conductance, 34:19
 electrophoresis of protein, fibroblasts in skin, 32:135
 ELISA technique, herpes virus, 33:11
 ELISA technique, immunoglobulins, 33:11
 ELISA technique, viral antigens, 33:11
 endorphin, cerebrospinal fluid, 34:229
 endorphin, dynorphin, 34:229
 endorphin, substance P, 34:229
 Epstein-Barr, immunoglobulins, 33:11
 evoked potentials, augmenting-reducing, 31:85
 evoked potentials, catecholamine metabolites, 31:297
 evoked potentials, criminality, 31:85
 evoked potentials, eye tracking, 31:85
 evoked potentials, neuroleptic treatment, 31:297
 eye tracking, age of onset, 34:89
 eye tracking, negative symptoms, 34:89
 eye tracking, positive symptoms, 34:89
 eye tracking, age, 34:89
 eye tracking, augmenting-reducing, 31:85
 eye tracking, criminality, 31:85
 eye tracking, evoked potentials, 31:85
 eye tracking, Scale for the Assessment of Negative Symptoms, 34:89
 familial schizophrenia, diagnosis, 34:77
 familial schizophrenia, subtype stability, 34:77
 fibroblasts in skin, electrophoresis of protein, 32:135
 formal thought disorder, attention, 31:169
 formal thought disorder, distractibility, 31:169
 formal thought disorder, span of apprehension, 31:169

Schizophrenia continued

- formal thought disorder, Wechsler Intelligence Scale for Children, 31:169
- frontal lobe, cerebral blood flow, 35:27
- frontal lobe, computed tomography, 31:221
- frontal lobe, dilapidation behavior, 34:221
- frontal lobe, fronto-occipital ratio, 35:27
- frontal lobe, Halstead-Reitan Battery, 31:15
- frontal lobe, HLA antigen, 31:221
- frontal lobe, laterality, 31:221
- frontal lobe, negative symptoms, 31:15, 34:221
- frontal lobe, neuroleptic response, 31:221
- frontal lobe, Scale for the Assessment of Negative Symptoms, 35:27
- frontal lobe, ventricle-brain ratio, 31:221
- frontal lobe, verbal fluency, 31:15
- frontal lobe, Wechsler Adult Intelligence Scale, 31:15
- fronto-occipital ratio, cerebral blood flow, 35:27
- fronto-occipital ratio, frontal lobe, 35:27
- fronto-occipital ratio, Scale for the Assessment of Negative Symptoms, 35:27
- genetics, laterality, 35:137
- genetics, magnetic resonance imaging, 35:137
- genetics, sibling pairs, 35:137
- genetics, temporal lobe, 35:137
- genetics, ventricle-brain ratio, 35:137
- glutamate, plasma levels, 32:63
- glutathione peroxidase, age, 31:1
- glutathione peroxidase, computed tomography, 31:1
- glutathione peroxidase, monoamine oxidase, 31:1
- glutathione peroxidase, neuroleptics, 31:1
- glutathione peroxidase, third ventricle, 31:1
- glutathione peroxidase, ventricle-brain ratio, 31:1
- growth hormone, age, 33:269
- growth hormone, amino acids in serum, 34:243
- growth hormone, homovanillic acid in plasma, 32:9
- growth hormone, methylphenidate, 32:9
- growth hormone releasing hormone, age, 33:269
- habituation, neuroleptic treatment, 34:19
- habituation, parkinsonian symptoms, 34:19
- habituation, skin conductance, 34:19
- habituation, tardive dyskinesia, 34:19
- haloperidol, homovanillic acid, 33:171
- haloperidol, neuroleptic response, 33:171

Schizophrenia continued

- haloperidol, neuropsychological tests, 33:171
- haloperidol, rapid medication response, 33:171
- Halstead-Reitan Battery, frontal lobe, 31:15
- Halstead-Reitan Battery, negative symptoms, 31:15
- Halstead-Reitan Battery, verbal fluency, 31:15
- Halstead-Reitan Battery, Wechsler Adult Intelligence Scale, 31:15
- herpes virus, ELISA technique, 33:11
- herpes virus, immunoglobulins, 33:11
- herpes virus, viral antigens, 33:11
- heterogeneity, admixture analysis, 32:311
- heterogeneity, risk factors, 32:311
- hippocampus, magnetic resonance imaging, 35:137
- HLA antigen, computed tomography, 31:221
- HLA antigen, frontal lobe, 31:221
- HLA antigen, neuroleptic response, 31:221
- HLA antigen, ventricle-brain ratio, 31:221
- homovanillic acid, haloperidol, 33:171
- homovanillic acid in plasma, growth hormone, 32:9
- homovanillic acid in plasma, methylphenidate, 32:9
- homovanillic acid, neuroleptic response, 33:171
- homovanillic acid, neuropsychological tests, 33:171
- homovanillic acid, rapid medication response, 33:171
- homovanillic acid, Scale for the Assessment of Negative Symptoms, 33:259
- homovanillic acid, tardive dyskinesia, 33:259
- hypofrontality, cerebral blood flow, 35:27
- hypofrontality, symptom severity, 35:27
- immunoglobulins, cytomegalovirus, 33:11
- immunoglobulins, ELISA technique, 33:11
- immunoglobulins, Epstein-Barr, 33:11
- immunoglobulins, herpes virus, 33:11
- immunoglobulins, viral antigens, 33:11
- laterality, cerebral blood flow, 35:27
- laterality, computed tomography, 31:221, 34:163
- laterality, corpus callosum, 34:163
- laterality, frontal lobe, 31:221
- laterality, genetics, 35:137
- laterality, HLA antigen, 31:221
- laterality, magnetic resonance imaging, 34:163, 35:137

Schizophrenia continued

- laterality, neuroleptic response, 31:221, 32:289
- laterality, sibling pairs, 35:137
- laterality, tactile discrimination, 32:289
- laterality, temporal lobe, 35:137
- laterality, ventricle-brain ratio, 31:221, 35:137
- limbic system, magnetic resonance imaging, 35:1
- limbic system, volume reduction, 35:1
- lymphocyte protein, neuroleptics, 32:95
- magnetic resonance imaging, amygdala, 35:137
- magnetic resonance imaging, corpus callosum, 34:163
- magnetic resonance imaging, computed tomography, 34:163
- magnetic resonance imaging, hippocampus, 35:137
- magnetic resonance imaging, laterality, 34:163, 35:137
- magnetic resonance imaging, limbic system, 35:1
- magnetic resonance imaging, sibling pairs, 35:137
- magnetic resonance imaging, temporal lobe, 35:1, 35:137
- magnetic resonance imaging, ventricle-brain ratio, 35:137
- magnetic resonance imaging, volume reduction, 35:1
- melatonin, amino acids, 34:243
- melatonin, catecholamines, 34:243
- melatonin, cortisol, 34:243
- melatonin, neuroleptics, 34:243
- melatonin, tryptophan, 34:243
- memory-performance, negative symptoms, 31:15
- methylphenidate, growth hormone, 32:9
- methylphenidate, homovanillic acid in plasma, 32:9
- Minnesota Multiphasic Personality Inventory, heterogeneity, 32:311
- Minnesota Multiphasic Personality Inventory, risk factors, 32:297, 32:311
- monoamine oxidase, age, 31:1
- monoamine oxidase, computed tomography, 31:1
- monoamine oxidase, glutathione peroxidase, 31:1
- monoamine oxidase, neuroleptics, 31:1
- monoamine oxidase, third ventricle, 31:1
- monoamine oxidase, ventricle-brain ratio, 31:1

Schizophrenia continued

- negative symptoms, biperiden, 31:235
- negative symptoms, dilapidation behavior, 34:221
- negative symptoms, eye tracking, 34:89
- negative symptoms, frontal lobe, 31:15, 34:221
- negative symptoms, Halstead-Reitan Battery, 31:15
- negative symptoms, memory performance, 31:15
- negative symptoms, verbal fluency, 31:15
- negative symptoms, Wechsler Adult Intelligence Scale, 31:15
- neuroleptic response, computed tomography, 31:221
- neuroleptic response, frontal lobe, 31:221
- neuroleptic response, haloperidol, 33:171
- neuroleptic response, HLA antigen, 31:221
- neuroleptic response, homovanillic acid, 33:171
- neuroleptic response, laterality, 31:221
- neuroleptic response, neuropsychological tests, 33:171
- neuroleptic response, prolactin level, 32:213
- neuroleptic response, rapid medication response, 33:171
- neuroleptic response, ventricle-brain ratio, 31:221
- neuroleptic treatment, attention, 32:281, 33:179
- neuroleptic treatment, brain atrophy, 33:307
- neuroleptic treatment, catecholamine metabolites, 31:297
- neuroleptic treatment, continuous performance test, 33:179
- neuroleptic treatment, computed tomography, 33:307
- neuroleptic treatment, evoked potentials, 31:297
- neuroleptic treatment, habituation, 34:19
- neuroleptic treatment, laterality, 32:289
- neuroleptic treatment, parkinsonian symptoms, 34:19
- neuroleptic treatment, skin conductance, 34:19
- neuroleptic treatment, somatostatin, 33:307
- neuroleptic treatment, tactile discrimination, 32:289
- neuroleptic treatment, tardive dyskinesia, 34:19
- neuroleptic withdrawal, dyskinesia, 34:19
- neuroleptic withdrawal, skin conductance, 34:19
- neuroleptics, age, 31:1

Schizophrenia continued

- neuroleptics, amino acids, 34:243
- neuroleptics, catecholamines, 34:243
- neuroleptics, continuous performance test, 32:281
- neuroleptics, cortisol, 34:243
- neuroleptics, computed tomography, 31:1
- neuroleptics, glutathione peroxidase, 31:1
- neuroleptics, lymphocyte protein, 32:95
- neuroleptics, melatonin, 34:243
- neuroleptics, monoamine oxidase, 31:1
- neuroleptics, third ventricle, 31:1
- neuroleptics, tryptophan, 34:243
- neuroleptics, ventricle-brain ratio, 31:1
- neuropsychological deficit, Scale for the Assessment of Negative Symptoms, 31:15
- neuropsychological deficit, Wisconsin Card Sort Test, 31:15
- neuropsychological tests, haloperidol, 33:171
- neuropsychological tests, homovanillic acid, 33:171
- neuropsychological tests, neuroleptic response, 33:171
- neuropsychological tests, rapid medication response, 33:171
- outcome, prolactin level, 32:213
- paranoid subtype, amino acids in plasma, 32:63
- paranoid subtype, diagnostic criteria, 34:77
- parkinsonian symptoms, habituation, 34:19
- parkinsonian symptoms, neuroleptic treatment, 34:19
- parkinsonian symptoms, skin conductance, 34:19
- parkinsonian symptoms, tardive dyskinesia, 34:19
- Perceptual Aberration Scale, admixture analysis, 33:243
- Perceptual Aberration Scale, statistical methods, 33:243
- plasma levels, glutamate, 32:63
- plasma levels, serine, 32:63
- positive symptoms, eye tracking, 34:89
- prolactin, domperidone, 34:139
- prolactin level, neuroleptic response, 32:213
- prolactin level, outcome, 32:213
- rapid medication response, haloperidol, 33:171
- rapid medication response, haloperidol, 33:171
- rapid medication response, homovanillic acid, 33:171
- rapid medication response, neuropsychological tests, 33:171

Schizophrenia continued

- risk factors, admixture analysis, 32:311
- risk factors, heterogeneity, 32:311
- risk factors, Minnesota Multiphasic Personality Inventory, 32:297, 32:311
- Scale for the Assessment of Negative Symptoms, age, 34:89
- Scale for the Assessment of Negative Symptoms, cerebral blood flow, 35:27
- Scale for the Assessment of Negative Symptoms, eye tracking, 34:89
- Scale for the Assessment of Negative Symptoms, frontal lobe, 35:27
- Scale for the Assessment of Negative Symptoms, fronto-occipital ratio, 35:27
- Scale for the Assessment of Negative Symptoms, homovanillic acid, 33:259
- Scale for the Assessment of Negative Symptoms, neuropsychological deficit, 31:15
- Scale for the Assessment of Negative Symptoms, tardive dyskinesia, 33:259
- Scale for the Assessment of Negative Symptoms, Wisconsin Card Sort Test, 31:15
- serine, plasma levels, 32:63
- sibling pairs, genetics, 35:149
- sibling pairs, laterality, 35:137
- sibling pairs, magnetic resonance imaging, 35:137
- sibling pairs, temporal lobe, 35:137
- sibling pairs, ventricle-brain ratio, 35:137
- skin conductance, dyskinesia, 34:19
- skin conductance, habituation, 34:19
- skin conductance, neuroleptic treatment, 34:19
- skin conductance, neuroleptic withdrawal, 34:19
- skin conductance, parkinsonian symptoms, 34:19
- skin conductance, tardive dyskinesia, 34:19
- somatostatin, brain atrophy, 33:307
- somatostatin, computed tomography, 33:307
- somatostatin, neuroleptic treatment, 33:307
- span of apprehension, attention, 31:169
- span of apprehension, distractibility, 31:169
- span of apprehension, formal thought disorder, 31:169
- span of apprehension, Wechsler Intelligence Scale for Children, 31:169
- statistical methods, admixture analysis, 33:243
- statistical methods, Perceptual Aberration Scale, 33:243
- substance P, cerebrospinal fluid, 34:229
- substance P, dynorphin, 34:229

Schizophrenia continued

- substance P, endorphin, 34:229
- subtype stability, diagnosis, 34:77
- subtype stability, familial schizophrenia, 34:77
- symptom severity, anticholinergic medication, 31:235
- symptom severity, cerebral blood flow, 35:27
- symptom severity, cholinergic system, 31:235
- symptom severity, hypofrontality, 35:27
- tactile discrimination, laterality, 32:289
- tactile discrimination, neuroleptic treatment, 32:289
- tardive dyskinesia, habituation, 34:19
- tardive dyskinesia, homovanillic acid, 33:259
- tardive dyskinesia, neuroleptic treatment, 34:19
- tardive dyskinesia, parkinsonian symptoms, 34:19
- tardive dyskinesia, Scale for the Assessment of Negative Symptoms, 33:259
- tardive dyskinesia, skin conductance, 34:19
- temporal lobe, genetics, 35:137
- temporal lobe, laterality, 35:137
- temporal lobe, magnetic resonance imaging, 35:1, 35:137
- temporal lobe, sibling pairs, 35:137
- temporal lobe, ventricle-brain ratio, 35:137
- temporal lobe, volume reduction, 35:1
- third ventricle, age, 31:1
- third ventricle, computed tomography, 31:1
- third ventricle, glutathione peroxidase, 31:1
- third ventricle, monoamine oxidase, 31:1
- third ventricle, neuroleptics, 31:1
- third ventricle, ventricle-brain ratio, 31:1
- thyroid function, amino acids in serum, 34:243
- tryptophan, amino acids, 34:243
- tryptophan, catecholamines, 34:243
- tryptophan, cortisol, 34:243
- tryptophan, melatonin, 34:243
- tryptophan, neuroleptics, 34:243
- ventricle-brain ratio, admixture analysis, 35:61
- ventricle-brain ratio, age, 31:1, 35:61
- ventricle-brain ratio, computed tomography, 31:1, 31:221, 35:61
- ventricle-brain ratio, frontal lobe, 31:221
- ventricle-brain ratio, genetics, 35:137
- ventricle-brain ratio, glutathione peroxidase, 31:1

Schizophrenia continued

- ventricle-brain ratio, HLA antigen, 31:221
- ventricle-brain ratio, laterality, 31:221, 35:137
- ventricle-brain ratio, magnetic resonance imaging, 35:137
- ventricle-brain ratio, monoamine oxidase, 31:1
- ventricle-brain ratio, neuroleptic response, 31:1, 31:221
- ventricle-brain ratio, sibling pairs, 35:137
- ventricle-brain ratio, temporal lobe, 35:137
- ventricle-brain ratio, third ventricle, 31:1
- verbal fluency, frontal lobe, 31:15
- verbal fluency, Halstead-Reitan Battery, 31:15
- verbal fluency, negative symptoms, 31:15
- verbal fluency, Wechsler Adult Intelligence Scale, 31:15
- viral antigens, ELISA technique, 33:11
- viral antigens, herpes virus, 33:11
- viral antigens, immunoglobulins, 33:11
- volume reduction, limbic system, 35:1
- volume reduction, magnetic resonance imaging, 35:1
- volume reduction, temporal lobe, 35:1
- Wechsler Adult Intelligence Scale, frontal lobe, 31:15
- Wechsler Adult Intelligence Scale, Halstead-Reitan Battery, 31:15
- Wechsler Adult Intelligence Scale, negative symptoms, 31:15
- Wechsler Adult Intelligence Scale, verbal fluency, 31:15
- Wechsler Intelligence Scale for Children, attention, 31:169
- Wechsler Intelligence Scale for Children, distractibility, 31:169
- Wechsler Intelligence Scale for Children, formal thought disorder, 31:169
- Wechsler Intelligence Scale for Children, span of apprehension, 31:169
- Wisconsin Card Sort Test, neuropsychological deficit, 31:15
- Wisconsin Card Sort Test, Scale for the Assessment of Negative Symptoms, 31:15
- SCL-90 (Symptom Checklist-90)**
 - seasonal affective disorder, light therapy, 33:121
- Scopolamine**
 - blood pressure, heart rate, 34:259
 - heart rate, normal volunteers, 34:259
 - normal volunteers, physostigmine, 34:259
 - physostigmine, blood pressure, 34:259

Seasonal affective disorder

- age, latitude, 31:131
- atypical depression, circannual rhythms, 33:121
- atypical depression, phototherapy, 33:121
- circannual rhythms, atypical depression, 33:121
- circannual rhythms, phototherapy, 33:121
- circannual rhythms, suicide, 32:253
- circannual rhythms, sunlight, 32:253
- circannual rhythms, weather, 32:253
- eating disorders, melatonin in serum, 32:221
- latitude, age, 31:131
- melatonin in serum, eating disorders, 32:221
- phototherapy, atypical depression, 33:121
- phototherapy, circannual rhythms, 33:121
- suicide, affective disorder, 32:253
- suicide, circannual rhythms, 32:253
- suicide, sunlight, 32:253
- suicide, weather, 32:253
- sunlight, circannual rhythms, 32:253
- sunlight, suicide, 32:253
- weather, circannual rhythms, 32:253
- weather, suicide, 32:253

Sensation Seeking Scale

- alpha-₂-adrenergic receptor, personality traits, 32:125
- personality disorders, monoamine oxidase activity, 33:221
- monoamine oxidase activity, personality disorders, 33:221

Separation anxiety

- blood pressure, children, 33:199
- children, conduct disorder, 33:199
- conduct disorder, heart rate, 33:199
- heart rate, blood pressure, 33:199

Serine

- schizophrenia, plasma levels, 32:63

Serotonin

- amino acids in serum, drug-naive patients, 34:243
- amino acids in serum, schizophrenia, 34:243
- anti-imipramine antibodies, endogenous serotonin uptake modulators, 34:205
- anti-imipramine antibodies, imipramine, 34:205
- cerebrospinal fluid, 5-hydroxyindoleacetic acid, 33:95
- cerebrospinal fluid, 5-hydroxytryptamine, 33:95
- cerebrospinal fluid, obsessive-compulsive disorder, 33:95
- clomipramine response, growth hormone, 31:39

Serotonin continued

- clomipramine response, prolactin response, 31:39
- depressed mood, endorphin, 31:267
- depressed mood, hydroxytryptophan, 31:267
- depressed mood, melatonin, 31:267
- depressed mood, panic disorder, 31:267
- depressed mood, platelet serotonin uptake, 31:267
- drug-naive patients, amino acids in serum, 34:243
- drug-naive patients, schizophrenia, 34:243
- endogenous serotonin uptake modulators, anti-imipramine antibodies, 34:205
- endogenous serotonin uptake modulators, imipramine, 34:205
- endorphin, depressed mood, 31:267
- endorphin, melatonin, 31:267
- endorphin, panic disorder, 31:267
- ethanol, pineal gland, 32:19
- fenfluramine, panic disorder, 31:215
- genetics, rat selective breeding, 32:167
- growth hormone, clomipramine response, 31:39
- 5-hydroxyindoleacetic acid, cerebrospinal fluid, 33:95
- 5-hydroxyindoleacetic acid, obsessive-compulsive disorder, 33:95
- 5-hydroxytryptamine, cerebrospinal fluid, 33:95
- 5-hydroxytryptamine, obsessive-compulsive disorder, 33:95
- hydroxytryptophan, depressed mood, 31:267
- hydroxytryptophan, panic disorder, 31:267
- imipramine, anti-imipramine antibodies, 34:205
- imipramine, endogenous serotonin uptake modulators, 34:205
- m*-chlorophenylpiperazine, panic disorder, 31:209
- m*-chlorophenylpiperazine, tryptophan, 31:209
- melatonin, depressed mood, 31:267
- melatonin, panic disorder, 31:267
- melatonin, platelet serotonin uptake, 31:267
- Mood Adjective Checklist, risk factors, 32:191
- Mood Adjective Checklist, suicide, 32:191
- obsessive-compulsive disorder, 5-hydroxyindoleacetic acid, 33:95
- obsessive-compulsive disorder, 5-hydroxytryptamine, 33:95

Serotonin continued

- panic disorder, fenfluramine, 31:215
- panic disorder, depressed mood, 31:267
- panic disorder, endorphin, 31:267
- panic disorder, hydroxytryptophan, 31:267
- panic disorder, *m*-chlorophenylpiperazine, 31:209
- panic disorder, melatonin, 31:267
- panic disorder, platelet serotonin uptake, 31:267
- panic disorder, tryptophan, 31:209
- pineal gland, ethanol, 32:19
- pineal gland, suicide, 32:19
- platelet serotonin uptake, depressed mood, 31:267
- platelet serotonin uptake, panic disorder, 31:267
- prolactin response, clomipramine response, 31:39
- rat selective breeding, genetics, 32:167
- risk factors, Mood Adjective Checklist, 32:191
- risk factors, suicide, 32:191
- schizophrenia, amino acids in serum, 34:243
- schizophrenia, drug-naïve patients, 34:243
- suicide, Mood Adjective Checklist, 32:191
- suicide, pineal gland, 32:19
- suicide, risk factors, 32:191
- tryptophan, *m*-chlorophenylpiperazine, 31:209
- tryptophan, panic disorder, 31:209

Sex differences

- adolescents, affective disorders, 33:307
- adolescents, rapid eye movement sleep, 33:307
- adolescents, sleeping, 33:307
- affective disorders, adolescents, 33:307
- affective disorders, rapid eye movement sleep, 33:307
- affective disorders, sleeping, 33:307
- age, anxiety, 35:49
- age, glucose metabolic rate, 35:49
- age, positron emission tomography, 35:49
- alcoholism, diazepam binding inhibitor, 31:261
- amino acids in serum, growth hormone, 34:243
- amino acids in serum, schizophrenia, 34:243
- anxiety, age, 35:49
- anxiety, glucose metabolic rate, 35:49
- anxiety, positron emission tomography, 35:49
- catecholamines in plasma, generalized anxiety disorder, 32:35
- conduct disorder, heart rate, 33:199

Sex differences continued

- dependent personality disorder, *DSM-III*, 33:207
 - diazepam binding inhibitor, alcoholism, 31:261
 - DSM-III*, dependent personality disorder, 33:207
 - generalized anxiety disorder, catecholamines in plasma, 32:35
 - glucose metabolic rate, age, 35:49
 - glucose metabolic rate, anxiety, 35:49
 - glucose metabolic rate, positron emission tomography, 35:49
 - growth hormone, amino acids in serum, 34:243
 - growth hormone, schizophrenia, 32:9, 34:243
 - growth hormone response, methylphenidate, 32:9
 - heart rate, conduct disorder, 33:199
 - isoproterenol, panic attacks, 32:103
 - latitude, seasonal affective disorder, 31:131
 - methylphenidate, growth hormone response, 32:9
 - methylphenidate, schizophrenia, 32:9
 - panic attacks, isoproterenol, 32:103
 - positron emission tomography, age, 35:49
 - positron emission tomography, anxiety, 35:49
 - positron emission tomography, glucose metabolic rate, 35:49
 - prolactin, tryptophan, 31:57
 - rapid eye movement sleep, adolescents, 33:307
 - rapid eye movement sleep, affective disorders, 33:307
 - schizophrenia, amino acids in serum, 34:243
 - schizophrenia, growth hormone response, 32:9
 - schizophrenia, growth hormone, 34:243
 - schizophrenia, methylphenidate, 32:9
 - seasonal affective disorder, latitude, 31:131
 - sleeping, adolescents, 33:307
 - sleeping, affective disorders, 33:307
 - tryptophan, prolactin, 31:57
- Sex hormone binding globulin**
- bipolar affective disorder, lithium treatment, 34:13
 - lithium treatment, thyroid stimulating hormone, 34:13
 - thyroid stimulating hormone, bipolar affective disorder, 34:13
- Skin conductance**
- habituation, neuroleptic treatment, 34:19
 - habituation, schizophrenia, 34:19

Skin conductance continued

- habituation, tardive dyskinesia, 34:19
- heart rate, multiple personality disorder, 31:251
- heart rate, reaction time, 31:251
- multiple personality disorder, heart rate, 31:251
- multiple personality disorder, reaction time, 31:251
- neuroleptic treatment, habituation, 34:19
- neuroleptic treatment, parkinsonian symptoms, 34:19
- neuroleptic treatment, schizophrenia, 34:19
- neuroleptic treatment, tardive dyskinesia, 34:19
- parkinsonian symptoms, neuroleptic treatment, 34:19
- parkinsonian symptoms, schizophrenia, 34:19
- parkinsonian symptoms, tardive dyskinesia, 34:19
- reaction time, heart rate, 31:251
- reaction time, multiple personality disorder, 31:251
- schizophrenia, habituation, 34:19
- schizophrenia, neuroleptic treatment, 34:19
- schizophrenia, parkinsonian symptoms, 34:19
- schizophrenia, tardive dyskinesia, 34:19
- tardive dyskinesia, habituation, 34:19
- tardive dyskinesia, neuroleptic treatment, 34:19
- tardive dyskinesia, parkinsonian symptoms, 34:19
- tardive dyskinesia, schizophrenia, 34:19

Sleep

- adolescents, affective disorders, 33:307
- adolescents, rapid eye movement sleep, 33:307
- adolescents, sex differences, 33:307
- affective disorder, psychotherapy, 33:285
- affective disorder, rapid eye movement sleep, 33:285
- affective disorder, treatment outcome, 33:285
- affective disorders, adolescents, 33:307
- affective disorders, rapid eye movement sleep, 33:307
- affective disorders, sex differences, 33:307
- arecoline, computer electroencephalographic topography, 35:91
- arecoline, REM induction, 35:91
- computer electroencephalographic topography, arecoline, 35:91

Sleep continued

- computer electroencephalographic topography, REM induction, 35:91
- delta sleep, muscarinic receptors, 33:113
- delta sleep, pilocarpine, 33:113
- electroencephalogram, arecoline, 35:91
- electroencephalogram, REM induction, 35:91
- heart rate, phobic avoidance, 32:45
- muscarinic receptors, delta sleep, 33:113
- muscarinic receptors, pilocarpine, 33:113
- muscarinic receptors, rapid eye movement sleep, 33:113
- phobic avoidance, heart rate, 32:45
- pilocarpine, delta sleep, 33:113
- pilocarpine, muscarinic receptors, 33:113
- pilocarpine, rapid eye movement sleep, 33:113
- polysomnography, affective disorders, 33:285
- psychotherapy, affective disorder, 33:285
- psychotherapy, rapid eye movement sleep, 33:285
- psychotherapy, treatment outcome, 33:285
- rapid eye movement sleep, adolescents, 33:307
- rapid eye movement sleep, affective disorder, 33:285, 33:307
- rapid eye movement sleep, delta sleep, 33:113
- rapid eye movement sleep, muscarinic receptors, 33:113
- rapid eye movement sleep, pilocarpine, 33:113
- rapid eye movement sleep, psychotherapy, 33:285
- rapid eye movement sleep, relatives of unipolar probands, 33:39
- rapid eye movement sleep, sex differences, 33:307
- rapid eye movement sleep, treatment outcome, 33:285
- REM induction, arecoline, 35:91
- REM induction, computerized electroencephalographic topography, 35:91
- sex differences, adolescents, 33:307
- sex differences, affective disorders, 33:307
- sex differences, rapid eye movement sleep, 33:307
- treatment outcome, psychotherapy, 33:285
- treatment outcome, rapid eye movement sleep, 33:285

Sleep deprivation

- affective disorder, cortisol, 34:149

Sleep deprivation continued

- affective disorder, depressed mood, 32:113
- affective disorder, dexamethasone suppression test, 34:149
- affective disorder, diurnal rhythms, 32:113
- affective disorder, motor activity, 34:213
- affective disorder, stress and arousal levels, 34:149
- affective disorder, thyroid stimulating hormone, 34:213
- affective disorder, triiodothyronine, 34:213
- cortisol, affective disorder, 34:149
- cortisol, stress and arousal levels, 34:149
- depressed mood, diurnal rhythms, 32:113
- dexamethasone suppression test, stress and arousal levels, 34:149
- diurnal rhythms, affective disorder, 32:113
- diurnal rhythms, depressed mood, 32:113
- motor activity, affective disorder, 34:213
- motor activity, thyroid stimulating hormone, 34:213
- motor activity, triiodothyronine, 34:213
- stress and arousal levels, cortisol, 34:149
- stress and arousal levels, dexamethasone suppression test, 34:149
- thyroid stimulating hormone, affective disorder, 34:213
- thyroid stimulating hormone, motor activity, 34:213
- triiodothyronine, affective disorder, 34:213

Somatostatin

- alcoholism, corticotropin releasing hormone, 33:215
- alcoholism, growth hormone releasing hormone, 33:215
- alcoholism, neuropeptide Y, 33:215
- brain atrophy, computed tomography, 33:307
- brain atrophy, neuroleptic treatment, 33:307
- brain atrophy, schizophrenia, 33:307
- cerebrospinal fluid, alcoholism, 33:215
- cerebrospinal fluid, corticotropin releasing hormone, 33:215
- cerebrospinal fluid, growth hormone releasing hormone, 33:215
- cerebrospinal fluid, neuropeptide Y, 33:215
- childhood depression, conduct disorder, 33:277
- childhood depression, obsessive-compulsive disorder, 33:277
- conduct disorder, childhood depression, 33:277
- conduct disorder, obsessive-compulsive disorder, 33:277

Somatostatin continued

- corticotropin releasing hormone, alcoholism, 33:215
- corticotropin releasing hormone, growth hormone releasing hormone, 33:215
- corticotropin releasing hormone, neuropeptide Y, 33:215
- computed tomography, brain atrophy, 33:307
- computed tomography, neuroleptic treatment, 33:307
- computed tomography, schizophrenia, 33:307
- growth hormone releasing hormone, alcoholism, 33:215
- growth hormone releasing hormone, cerebrospinal fluid, 33:215
- growth hormone releasing hormone, neuropeptide Y, 33:215
- neuroleptic treatment, brain atrophy, 33:307
- neuroleptic treatment, computed tomography, 33:307
- neuroleptic treatment, schizophrenia, 33:307
- neuropeptide Y, alcoholism, 33:215
- neuropeptide Y, cerebrospinal fluid, 33:215
- neuropeptide Y, growth hormone releasing hormone, 33:215
- obsessive-compulsive disorder, childhood depression, 33:277
- obsessive-compulsive disorder, conduct disorder, 33:277
- schizophrenia, brain atrophy, 33:307
- schizophrenia, computed tomography, 33:307
- schizophrenia, neuroleptic treatment, 33:307

Span of apprehension

- attention, distractibility, 31:169
- distractibility, formal thought disorder, 31:169
- formal thought disorder, schizophrenia, 31:169
- schizophrenia, Wechsler Intelligence Scale for Children, 31:169
- Wechsler Intelligence Scale for Children, attention, 31:169
- Spielberger State-Trait Anxiety Scale
- bulimia, isoproterenol, 33:1
- glucose metabolic rate, positron emission tomography, 35:49
- isoproterenol, bulimia, 33:1
- normal volunteers, Perceptual Aberration Scale, 33:243
- Perceptual Aberration Scale, normal volunteers, 33:243

Span of apprehension continued

positron emission tomography, glucose metabolic rate, 35:49

Statistical methods

admixture analysis, Minnesota Multiphasic Personality Inventory, 32:311

admixture analysis, Perceptual Aberration Scale, 33:243

admixture analysis, schizophrenia, 32:311, 33:243

admixture analysis, ventricle-brain ratio, 35:61

affective symptoms, categorical/dimensional differentiation, 34:43

affective symptoms, principal components, 34:43

categorical/dimensional differentiation, affective symptoms, 34:43

categorical/dimensional differentiation, principal components, 34:43

Cox proportional hazard model, suicide risk, 31:99

dexamethasone suppression, receiver operating characteristics, 31:49

diagnostic interview, kappa, 31:145

diagnostic interview, Yule's Y, 31:145

kappa, diagnostic interview, 31:145

kappa, Yule's Y, 31:145

Minnesota Multiphasic Personality Inventory, admixture analysis, 32:311

Minnesota Multiphasic Personality Inventory, schizophrenia, 32:311

Perceptual Aberration Scale, admixture analysis, 33:243

Perceptual Aberration Scale, schizophrenia, 33:243

principal components, affective symptoms, 34:43

principal components, categorical/dimensional differentiation, 34:43

receiver operating characteristics, dexamethasone suppression, 31:49

schizophrenia, admixture analysis, 32:311, 33:243

schizophrenia, Minnesota Multiphasic Personality Inventory, 32:311

schizophrenia, Perceptual Aberration Scale, 33:243

statistical isolinear multiple components analysis, symptoms, 34:43

suicide risk, Cox proportional hazard model, 31:99

ventricle-brain ratio, admixture analysis, 35:61

Yule's Y, diagnostic interview, 31:145

Stress

catecholamines, physostigmine, 34:259, 34:271

cholinergic system, heart rate, 34:259, 34:271

cortisol, catecholamines, 34:259

DNA content, phorbol esters, 33:59

heart rate, cortisol, 34:259

leukocytes, DNA content, 33:59

normal volunteers, leukocytes, 33:59

phorbol esters, normal volunteers, 33:59

physostigmine, cholinergic system, 34:259

Structured Clinical Interview for DSM-III-R (SCID)

biological markers, vital depression, 34:59

cluster analysis, thyroid and HPA axis function, 34:29

personality disorder, reliability, 32:85

thyroid and HPA axis function, vital depression, 34:29

vital depression, thyroid and HPA axis function, 34:29

Substance abuse

alcoholism, apomorphine, 33:151

alcoholism, cocaine, 33:151

alcoholism, growth hormone, 33:151

alcoholism, prolactin, 33:151

alpha power, cocaine, 35:95

alpha power, computerized electroencephalographic topography, 35:95

apomorphine, alcoholism, 33:151

apomorphine challenge, cocaine, 33:161

apomorphine challenge, craving, 33:161

apomorphine challenge, growth hormone response, 33:161

apomorphine challenge, prolactin response, 33:161

apomorphine, growth hormone, 33:151

apomorphine, prolactin, 33:151

cocaine, apomorphine challenge, 33:161

cocaine, craving, 33:161

cocaine, growth hormone response, 33:161

cocaine, prolactin response, 33:161

cocaine, alcoholism, 33:151

cocaine, alpha power, 35:95

cocaine, apomorphine, 33:151

cocaine, computerized electroencephalographic topography, 35:95

cocaine, electroencephalogram, 35:95

cocaine, growth hormone, 33:151

cocaine, prolactin, 33:151

computerized electroencephalographic topography, alpha power, 35:95

computerized electroencephalographic topography, cocaine, 35:95

Substance abuse continued

- craving, apomorphine challenge, 33:161
- craving, cocaine, 33:161
- craving, growth hormone response, 33:161
- craving, prolactin response, 33:161
- electroencephalogram, alpha power, 35:95
- electroencephalogram, cocaine, 35:95
- electroencephalogram, computerized electroencephalographic topography, 35:95
- growth hormone response, apomorphine challenge, 33:161
- growth hormone response, cocaine, 33:161
- growth hormone response, craving, 33:161
- growth hormone, alcoholism, 33:151
- growth hormone, apomorphine, 33:151
- growth hormone, cocaine, 33:151
- prolactin, alcoholism, 33:151
- prolactin, apomorphine, 33:151, 33:161
- prolactin, cocaine, 33:151, 33:161
- prolactin response, craving, 33:161

Substance P

- cerebrospinal fluid, schizophrenia, 34:229
- dynorphin, endorphin, 34:229
- schizophrenia, endorphin, 34:229

Suicide

- affective disorder, caudate nucleus, 32:159
- affective disorder, circannual rhythms, 32:253
- affective disorder, endorphin, 32:159
- affective disorder, frontal lobe, 32:159
- affective disorder, hypothalamus, 32:159
- affective disorder, laterality, 32:159
- affective disorder, seasonal affective disorder, 32:253
- affective disorder, sunlight, 32:253
- affective disorder, temporal lobe, 32:159
- affective disorder, weather, 32:253
- caudate nucleus, affective disorder, 32:159
- caudate nucleus, endorphin, 32:159
- caudate nucleus, laterality, 32:159
- chromosomal translocation, genetics, 32:1
- circannual rhythms, seasonal affective disorder, 32:253
- circannual rhythms, sunlight, 32:253
- circannual rhythms, weather, 32:253
- Cox proportional hazard model, prior attempts, 31:99
- endorphin, affective disorder, 32:159
- endorphin, caudate nucleus, 32:159
- endorphin, frontal lobe, 32:159
- endorphin, hypothalamus, 32:159
- endorphin, laterality, 32:159
- endorphin, temporal lobe, 32:159
- frontal lobe, affective disorder, 32:159

Suicide continued

- frontal lobe, endorphin, 32:159
- frontal lobe, laterality, 32:159
- genetics, chromosomal translocation, 32:1
- hypothalamus, affective disorder, 32:159
- hypothalamus, endorphin, 32:159
- hypothalamus, laterality, 32:159
- laterality, affective disorder, 32:159
- laterality, caudate nucleus, 32:159
- laterality, endorphin, 32:159
- laterality, frontal lobe, 32:159
- laterality, hypothalamus, 32:159
- laterality, temporal lobe, 32:159
- Mood Adjective Checklist, risk factors, 32:191
- Mood Adjective Checklist, serotonin, 32:191
- pineal gland, serotonin binding, 32:19
- risk factors, Mood Adjective Checklist, 32:191
- risk factors, serotonin, 32:191
- seasonal affective disorder, circannual rhythms, 32:253
- seasonal affective disorder, sunlight, 32:253
- seasonal affective disorder, weather, 32:253
- serotonin binding, pineal gland, 32:19
- serotonin, Mood Adjective Checklist, 32:191
- serotonin, risk factors, 32:191
- sunlight, affective disorder, 32:253
- sunlight, circannual rhythms, 32:253
- sunlight, seasonal affective disorder, 32:253
- temporal lobe, affective disorder, 32:159
- temporal lobe, endorphin, 32:159
- temporal lobe, laterality, 32:159
- weather, affective disorder, 32:253
- weather, circannual rhythms, 32:253
- weather, seasonal affective disorder, 32:253

Sylvian fissure

- Alzheimer's disease, magnetic resonance imaging, 35:115
- magnetic resonance imaging, sulcal width, 35:115
- sulcal width, Alzheimer's disease, 35:115

Symptom patterns

- affective disorder, panic disorder, 31:179
- panic disorder, personality disorder, 31:179
- personality disorder, affective disorder, 31:179

Tardive dyskinesia

- habituation, neuroleptic treatment, 34:19
- habituation, schizophrenia, 34:19
- habituation, skin conductance, 34:19
- homovanillic acid, Scale for the Assessment of Negative Symptoms, 33:259
- homovanillic acid, schizophrenia, 33:259
- neuroleptic treatment, habituation, 34:19

Tardive dyskinesia continued

- neuroleptic treatment, parkinsonian symptoms, 34:19
- neuroleptic treatment, schizophrenia, 34:19
- neuroleptic treatment, skin conductance, 34:19
- parkinsonian symptoms, neuroleptic treatment, 34:19
- parkinsonian symptoms, schizophrenia, 34:19
- parkinsonian symptoms, skin conductance, 34:19
- Scale for the Assessment of Negative Symptoms, homovanillic acid, 33:259
- Scale for the Assessment of Negative Symptoms, schizophrenia, 33:259
- schizophrenia, habituation, 34:19
- schizophrenia, homovanillic acid, 33:259
- schizophrenia, neuroleptic treatment, 34:19
- schizophrenia, parkinsonian symptoms, 34:19
- schizophrenia, Scale for the Assessment of Negative Symptoms, 33:259
- schizophrenia, skin conductance, 34:19
- skin conductance, habituation, 34:19
- skin conductance, neuroleptic treatment, 34:19
- skin conductance, parkinsonian symptoms, 34:19
- skin conductance, schizophrenia, 34:19

Temperature

- blood pressure, eating disorders, 33:1
- eating disorders, heart rate, 33:1
- heart rate, isoproterenol, 33:1
- isoproterenol, weight, 33:1
- weight, blood pressure, 33:1

Temporal lobe

- affective disorder, caudate nucleus, 32:159
- affective disorder, endorphin, 32:159
- affective disorder, frontal lobe, 32:159
- affective disorder, hypothalamus, 32:159
- affective disorder, laterality, 32:159
- affective disorder, suicide, 32:159
- age, intracranial volume, 35:15
- age, limbic system, 35:15
- age, magnetic resonance imaging, 35:15
- age, ventricular volume, 35:15
- caudate nucleus, affective disorder, 32:159
- caudate nucleus, endorphin, 32:159
- caudate nucleus, laterality, 32:159
- caudate nucleus, suicide, 32:159
- endorphin, affective disorder, 32:159
- endorphin, caudate nucleus, 32:159
- endorphin, frontal lobe, 32:159
- endorphin, hypothalamus, 32:159

Temporal lobe continued

- endorphin, laterality, 32:159
- endorphin, suicide, 32:159
- ethanol, glucose metabolic rate, 35:39
- ethanol, positron emission tomography, 35:39
- frontal lobe, affective disorder, 32:159
- frontal lobe, endorphin, 32:159
- frontal lobe, laterality, 32:159
- frontal lobe, suicide, 32:159
- genetics, laterality, 35:137
- genetics, schizophrenia, 35:137
- genetics, sibling pairs, 35:137
- genetics, ventricle-brain ratio, 35:137
- glucose metabolic rate, ethanol, 35:39
- glucose metabolic rate, positron emission tomography, 35:39
- hypothalamus, affective disorder, 32:159
- hypothalamus, endorphin, 32:159
- hypothalamus, laterality, 32:159
- hypothalamus, suicide, 32:159
- intracranial volume, age, 35:15
- intracranial volume, limbic system, 35:15
- intracranial volume, magnetic resonance imaging, 35:15
- intracranial volume, ventricle-volume, 35:15
- intracranial volume, volume reduction, 35:15
- laterality, affective disorder, 32:159
- laterality, caudate nucleus, 32:159
- laterality, endorphin, 32:159
- laterality, frontal lobe, 32:159
- laterality, genetics, 35:137
- laterality, hypothalamus, 32:159
- laterality, magnetic resonance imaging, 35:137
- laterality, schizophrenia, 35:137
- laterality, sibling pairs, 35:137
- laterality, suicide, 32:159
- laterality, ventricle-brain ratio, 35:137
- limbic system, age, 35:15
- limbic system, intracranial volume, 35:15
- limbic system, magnetic resonance imaging, 35:15
- limbic system, schizophrenia, 35:1
- limbic system, ventricular volume, 35:15
- limbic system, volume reduction, 35:1, 35:15
- magnetic resonance imaging, age, 35:15
- magnetic resonance imaging, intracranial volume, 35:15
- magnetic resonance imaging, laterality, 35:137
- magnetic resonance imaging, limbic system, 35:1, 35:15

Temporal lobe continued

- magnetic resonance imaging, schizophrenia, 35:1, 35:137
- magnetic resonance imaging, sibling pairs, 35:137
- magnetic resonance imaging, ventricle-brain ratio, 35:137
- magnetic resonance imaging, ventricular volume, 35:15
- positron emission tomography, ethanol, 35:39
- positron emission tomography, glucose metabolic rate, 35:39
- schizophrenia, genetics, 35:137
- schizophrenia, laterality, 35:137
- schizophrenia, limbic system, 35:1
- schizophrenia, magnetic resonance imaging, 35:1, 35:137
- schizophrenia, sibling pairs, 35:137
- schizophrenia, ventricle-brain ratio, 35:137
- sibling pairs, genetics, 35:137
- sibling pairs, laterality, 35:137
- sibling pairs, magnetic resonance imaging, 35:137
- sibling pairs, schizophrenia, 35:137
- sibling pairs, ventricle-brain ratio, 35:137
- suicide, affective disorder, 32:159
- suicide, caudate nucleus, 32:159
- suicide, endorphin, 32:159
- suicide, frontal lobe, 32:159
- suicide, hypothalamus, 32:159
- suicide, laterality, 32:159
- ventricle-brain ratio, genetics, 35:137
- ventricle-brain ratio, laterality, 35:137
- ventricle-brain ratio, magnetic resonance imaging, 35:137
- ventricle-brain ratio, schizophrenia, 35:137
- ventricle-brain ratio, sibling pairs, 35:137
- ventricular volume, age, 35:15
- ventricular volume, intracranial volume, 35:15
- ventricular volume, limbic system, 35:15
- ventricular volume, magnetic resonance imaging, 35:15
- volume reduction, age, 35:15
- volume reduction, intracranial volume, 35:15
- volume reduction, limbic system, 35:1, 35:15
- volume reduction, magnetic resonance imaging, 35:1, 35:15
- volume reduction, ventricular volume, 35:15

Thalamus

- ethanol, glucose metabolic rate, 35:39
- glucose metabolic rate, positron emission tomography, 35:39

Thalamus continued

- positron emission tomography, ethanol, 35:39

Third ventricle

- age, computed tomography, 31:1
- Alzheimer's disease, magnetic resonance imaging, 35:115
- computed tomography, glutathione peroxidase, 31:1
- glutathione peroxidase, monoamine oxidase, 31:1
- magnetic resonance imaging, Alzheimer's disease, 35:115
- monoamine oxidase, neuroleptics, 31:1
- monoamine oxidase, schizophrenia, 31:1
- monoamine oxidase, ventricle-brain ratio, 31:1
- neuroleptics, ventricle-brain ratio, 31:1
- schizophrenia, age, 31:1
- schizophrenia, computed tomography, 31:1
- schizophrenia, glutathione peroxidase, 31:1
- schizophrenia, monoamine oxidase, 31:1
- schizophrenia, neuroleptics, 31:1
- schizophrenia, ventricle-brain ratio, 31:1
- ventricle-brain ratio, monoamine oxidase, 31:1
- ventricle-brain ratio, neuroleptics, 31:1
- ventricle-brain ratio, schizophrenia, 31:1

Thyroid stimulating hormone

- adrenocorticotrophic hormone, affective disorder, 34:29, 34:59
- adrenocorticotrophic hormone, cortisol, 34:29, 34:59
- adrenocorticotrophic hormone, depressive symptoms, 34:59
- adrenocorticotrophic hormone, dexamethasone suppression test, 34:59
- adrenocorticotrophic hormone, thyroxine, 34:29, 34:59
- adrenocorticotrophic hormone, tryptophan, 34:29, 34:59
- adrenocorticotrophic hormone, vital depression, 34:29
- affective disorder, adrenocorticotrophic hormone, 34:29, 34:59
- affective disorder, bipolar, 34:13
- affective disorder, cortisol, 34:29, 34:59
- affective disorder, depressive symptoms, 34:59
- affective disorder, dexamethasone suppression test, 34:59
- affective disorder, motor activity, 34:213
- affective disorder, psychotic depression, 33:321
- affective disorder, rapid cyclers, 34:13

Thyroid stimulating hormone continued

affective disorder, sleep deprivation, 34:213
 affective disorder, thyroxine, 34:29, 34:59
 affective disorder, triiodothyronine, 33:321, 34:13, 34:213
 affective disorder, tryptophan, 34:29, 34:59
 affective disorder, vital depression, 34:29
 amino acids in serum, drug-naïve patients, 34:137
 amino acids in serum, schizophrenia, 34:243
 bipolar, affective disorder, 34:13
 bipolar, rapid cyclers, 34:13
 bipolar, triiodothyronine, 34:13
 cortisol, adrenocorticotrophic hormone, 34:29, 34:59
 cortisol, affective disorder, 34:29, 34:59
 cortisol, depressive symptoms, 34:59
 cortisol, dexamethasone suppression test, 34:59
 cortisol, thyroxine, 34:29, 34:59
 cortisol, tryptophan, 34:29, 34:59
 cortisol, vital depression, 34:29
 depressive symptoms, adrenocorticotrophic hormone, 34:59
 depressive symptoms, affective disorder, 34:59
 depressive symptoms, cortisol, 34:59
 depressive symptoms, dexamethasone suppression test, 34:59
 depressive symptoms, thyroxine, 34:59
 depressive symptoms, tryptophan, 34:59
 dexamethasone suppression test, adrenocorticotrophic hormone, 34:59
 dexamethasone suppression test, affective disorder, 34:59
 dexamethasone suppression test, cortisol, 34:59
 dexamethasone suppression test, depressive symptoms, 34:59
 dexamethasone suppression test, thyroxine, 34:59
 dexamethasone suppression test, tryptophan, 34:59
 drug-naïve patients, amino acids in serum, 34:243
 drug-naïve patients, schizophrenia, 34:243
 motor activity, affective disorder, 34:213
 motor activity, sleep deprivation, 34:213
 motor activity, triiodothyronine, 34:213
 psychotic depression, affective disorder, 33:321
 psychotic depression, triiodothyronine, 33:321
 rapid cyclers, affective disorder, 34:13

Thyroid stimulating hormone continued

rapid cyclers, bipolar, 34:13
 rapid cyclers, triiodothyronine, 34:13
 schizophrenia, amino acids in serum, 34:243
 schizophrenia, drug-naïve patients, 34:243
 sleep deprivation, affective disorder, 34:213
 sleep deprivation, motor activity, 34:213
 sleep deprivation, triiodothyronine, 34:213
 thyroxine, adrenocorticotrophic hormone, 34:29, 34:59
 thyroxine, affective disorder, 34:29, 34:59
 thyroxine, cortisol, 34:29, 34:59
 thyroxine, depressive symptoms, 34:59
 thyroxine, dexamethasone suppression test, 34:59
 thyroxine, tryptophan, 34:29, 34:59
 thyroxine, vital depression, 34:29
 triiodothyronine, affective disorder, 33:321, 34:13, 34:213
 triiodothyronine, bipolar, 34:13
 triiodothyronine, motor activity, 34:213
 triiodothyronine, psychotic depression, 33:321
 triiodothyronine, rapid cyclers, 34:13
 triiodothyronine, sleep deprivation, 34:213
 tryptophan, adrenocorticotrophic hormone, 34:29, 34:59
 tryptophan, affective disorder, 34:29, 34:59
 tryptophan, cortisol, 34:29, 34:59
 tryptophan, depressive symptoms, 34:59
 tryptophan, dexamethasone suppression test, 34:59
 tryptophan, thyroxine, 34:29, 34:59
 tryptophan, vital depression, 34:29
 vital depression, adrenocorticotrophic hormone, 34:29
 vital depression, affective disorder, 34:29
 vital depression, cortisol, 34:29
 vital depression, thyroxine, 34:29
 vital depression, tryptophan, 34:29

Thyroxine

adrenocorticotrophic hormone, affective disorder, 34:29, 34:59
 adrenocorticotrophic hormone, cortisol, 34:29, 34:59
 adrenocorticotrophic hormone, depressive symptoms, 34:59
 adrenocorticotrophic hormone, dexamethasone suppression test, 34:59
 adrenocorticotrophic hormone, thyroid stimulating hormone, 34:29, 34:59
 adrenocorticotrophic hormone, tryptophan, 34:29, 34:59
 adrenocorticotrophic hormone, vital depression, 34:29

Thyroxine continued

affective disorder, adrenocorticotrophic hormone, 34:29, 34:59
 affective disorder, cortisol, 34:29, 34:59
 affective disorder, depressive symptoms, 34:59
 affective disorder, dexamethasone suppression test, 34:59
 affective disorder, thyroid stimulating hormone, 34:29, 34:59
 affective disorder, tryptophan, 34:29, 34:59
 affective disorder, vital depression, 34:29
 amino acids in serum, schizophrenia, 34:243
 antidepressants, depressive mood, 32:241
 antidepressants, triiodothyronine, 32:241
 bipolar affective disorder, lithium treatment, 34:13
 cortisol, adrenocorticotrophic hormone, 34:29, 34:59
 cortisol, affective disorder, 34:29, 34:59
 cortisol, depressive symptoms, 34:59
 cortisol, dexamethasone suppression test, 34:59
 cortisol, thyroid stimulating hormone, 34:29, 34:59
 cortisol, tryptophan, 34:29, 34:59
 cortisol, vital depression, 34:29
 depressive mood, antidepressants, 32:241
 depressive mood, triiodothyronine, 32:241
 depressive symptoms, adrenocorticotrophic hormone, 34:59
 depressive symptoms, affective disorder, 34:59
 depressive symptoms, cortisol, 34:59
 depressive symptoms, dexamethasone suppression test, 34:59
 depressive symptoms, thyroid stimulating hormone, 34:59
 depressive symptoms, tryptophan, 34:59
 desimipramine, rat brain, 34:217
 dexamethasone suppression test, adrenocorticotrophic hormone, 34:59
 dexamethasone suppression test, affective disorder, 34:59
 dexamethasone suppression test, cortisol, 34:59
 dexamethasone suppression test, depressive symptoms, 34:59
 dexamethasone suppression test, thyroid stimulating hormone, 34:59
 dexamethasone suppression test, tryptophan, 34:59
 lithium treatment, bipolar affective disorder, 34:13
 rat brain, desimipramine, 34:217

Thyroxine continued

schizophrenia, amino acids in serum, 34:243
 thyroid stimulating hormone, affective disorder, 34:29, 34:59
 thyroid stimulating hormone, cortisol, 34:29, 34:59
 thyroid stimulating hormone, depressive symptoms, 34:59
 thyroid stimulating hormone, dexamethasone suppression test, 34:59
 thyroid stimulating hormone, tryptophan, 34:29, 34:59
 thyroid stimulating hormone, vital depression, 34:29
 triiodothyronine, depressive mood, 32:241
 tryptophan, adrenocorticotrophic hormone, 34:29, 34:59
 tryptophan, affective disorder, 34:29, 34:59
 tryptophan, cortisol, 34:29, 34:59
 tryptophan, depressive symptoms, 34:59
 tryptophan, dexamethasone suppression test, 34:59
 tryptophan, thyroid stimulating hormone, 34:29, 34:59
 tryptophan, vital depression, 34:29
 vital depression, adrenocorticotrophic hormone, 34:29
 vital depression, affective disorder, 34:29
 vital depression, cortisol, 34:29
 vital depression, thyroid stimulating hormone, 34:29
 vital depression, tryptophan, 34:29

Thyroxine binding

bipolar affective disorder, lithium treatment, 34:13

Tourette's syndrome

age, 3-methoxy-4-hydroxyphenylglycol, 31:279
 age of onset, neuropsychological performance, 33:73
 age of onset, tics, 33:73
 age, phenylethylamine, 31:279
 frontal lobe, Wisconsin Card Sort Test, 33:73
 homovanillic acid, normetanephrine, 31:279
 5-hydroxyindoleacetic acid, homovanillic acid, 31:279
 3-methoxy-4-hydroxyphenylglycol, age, 31:279
 motor tics, trace amines, 31:279
 motor tics, neuropsychological tests, 33:73
 neuropsychological performance, age of onset, 33:73
 neuropsychological performance, tics, 33:73

Tourette's syndrome continued

neuropsychological tests, motor tics, 33:73
 normetanephrine, homovanillic acid, 31:279
 phenylethylamine, age, 31:279
 tics, age of onset, 33:73
 tics, neuropsychological performance, 33:73
 trace amines, motor tics, 31:279
 Wisconsin Card Sort Test, frontal lobe, 33:73

Triiodothyronine

affective disorder, bipolar, 34:13
 affective disorder, motor activity, 34:213
 affective disorder, psychotic depression, 33:321
 affective disorder, rapid cyclers, 34:13
 affective disorder, sleep deprivation, 34:213
 affective disorder, thyroid hormone, 33:321
 affective disorder, thyroid stimulating hormone, 34:13, 34:213
 amino acids in serum, schizophrenia, 34:243
 antidepressants, depressive mood, 32:241
 antidepressants, thyroxine, 32:241
 bipolar, affective disorder, 34:13
 bipolar, rapid cyclers, 34:13
 bipolar, thyroid stimulating hormone, 34:13
 depressive mood, antidepressants, 32:241
 depressive mood, thyroxine, 32:241
 motor activity, affective disorder, 34:213
 motor activity, sleep deprivation, 34:213
 motor activity, thyroid-stimulating hormone, 34:213
 psychotic depression, affective disorder, 33:321
 psychotic depression, thyroid hormone, 33:321
 rapid cyclers, affective disorder, 34:13
 rapid cyclers, bipolar, 34:13
 rapid cyclers, thyroid stimulating hormone, 34:13
 schizophrenia, amino acids in serum, 34:243
 sleep deprivation, affective disorder, 34:213
 sleep deprivation, motor activity, 34:213
 sleep deprivation, thyroid stimulating hormone, 34:213
 thyroid stimulating hormone, affective disorder, 34:13, 34:213
 thyroid stimulating hormone, bipolar, 34:13
 thyroid stimulating hormone, motor activity, 34:213
 thyroid stimulating hormone, rapid cyclers, 34:13
 thyroid stimulating hormone, sleep deprivation, 34:213
 thyroid hormone, affective disorder, 33:321
 thyroid hormone, psychotic depression, 33:321

Triiodothyronine continued

thyroxine, antidepressants, 32:241
 thyroxine, depressive mood, 32:241

Tryptophan

adrenocorticotrophic hormone, affective disorder, 31:57, 34:29, 34:59
 adrenocorticotrophic hormone, bipolar, 31:57
 adrenocorticotrophic hormone, cortisol, 31:57, 34:29, 34:59
 adrenocorticotrophic hormone, depressive symptoms, 34:59
 adrenocorticotrophic hormone, dexamethasone suppression test, 34:59
 adrenocorticotrophic hormone, growth hormone, 31:57
 adrenocorticotrophic hormone, prolactin, 31:57
 adrenocorticotrophic hormone, thyroxine, 34:29, 34:59
 adrenocorticotrophic hormone, vital depression, 34:29
 affective disorder, adrenocorticotrophic hormone, 31:57, 34:29, 34:59
 affective disorder, amitriptyline, 31:201
 affective disorder, antidepressants, 31:201
 affective disorder, Beck Depression Inventory, 31:201
 affective disorder, bipolar, 31:57
 affective disorder, cortisol, 31:57, 34:29, 34:59
 affective disorder, depressive symptoms, 34:59
 affective disorder, dexamethasone suppression test, 34:59
 affective disorder, growth hormone, 31:57, 31:201
 affective disorder, heart rate, 31:57
 affective disorder, prolactin, 31:57, 31:201
 affective disorder, thyroid stimulating hormone, 34:29, 34:59
 affective disorder, thyroxine, 34:29, 34:59
 affective disorder, vital depression, 34:29
 affective disorder, weight loss, 31:201
 amino acids, catecholamines, 34:243
 amino acids, cortisol, 34:243
 amino acids, melatonin, 34:243
 amino acids, neuroleptics, 34:243
 amino acids, schizophrenia, 34:243
 amitriptyline, affective disorder, 31:201
 amitriptyline, antidepressants, 31:201
 amitriptyline, Beck Depression Inventory, 31:201
 amitriptyline, growth hormone, 31:201
 amitriptyline, prolactin, 31:201
 amitriptyline, weight loss, 31:201

Tryptophan continued

antidepressants, affective disorder, 31:201
 antidepressants, amitriptyline, 31:201
 antidepressants, Beck Depression Inventory, 31:201
 antidepressants, growth hormone, 31:201
 antidepressants, prolactin, 31:201
 antidepressants, weight loss, 31:201
 Beck Depression Inventory, affective disorder, 31:201
 Beck Depression Inventory, antidepressants, 31:201
 Beck Depression Inventory, prolactin, 31:201
 Beck Depression Inventory, weight loss, 31:201
 bipolar, adrenocorticotrophic hormone, 31:57
 bipolar, affective disorder, 31:57
 bipolar, cortisol, 31:57
 bipolar, growth hormone, 31:57
 bipolar, prolactin, 31:57
 catecholamines, amino acids, 34:243
 catecholamines, cortisol, 34:243
 catecholamines, melatonin, 34:243
 catecholamines, neuroleptics, 34:243
 catecholamines, schizophrenia, 34:243
 cortisol, affective disorder, 31:57, 34:29, 34:59
 cortisol, amino acids, 34:243
 cortisol, bipolar, 31:57
 cortisol, catecholamines, 34:243
 cortisol, depressive symptoms, 34:59
 cortisol, dexamethasone suppression test, 34:59
 cortisol, growth hormone, 31:57
 cortisol, melatonin, 34:243
 cortisol, neuroleptics, 34:243
 cortisol, prolactin, 31:57
 cortisol, schizophrenia, 34:243
 cortisol, thyroid stimulating hormone, 34:29, 34:59
 cortisol, thyroxine, 34:29, 34:59
 cortisol, vital depression, 34:29
 depressive symptoms, adrenocorticotrophic hormone, 34:59
 depressive symptoms, affective disorder, 34:59
 depressive symptoms, cortisol, 34:59
 depressive symptoms, dexamethasone suppression test, 34:59
 depressive symptoms, thyroid stimulating hormone, 34:59
 depressive symptoms, thyroxine, 34:59

Tryptophan continued

dexamethasone suppression test, adrenocorticotrophic hormone, 34:59
 dexamethasone suppression test, affective disorder, 34:59
 dexamethasone suppression test, cortisol, 34:59
 dexamethasone suppression test, depressive symptoms, 34:59
 dexamethasone suppression test, thyroid stimulating hormone, 34:59
 dexamethasone suppression test, thyroxine, 34:59
 growth hormone, adrenocorticotrophic hormone, 31:57
 growth hormone, affective disorder, 31:57, 31:201
 growth hormone, amitriptyline, 31:201
 growth hormone, antidepressants, 31:201
 growth hormone, Beck Depression Inventory, 31:201
 growth hormone, bipolar, 31:57
 growth hormone, cortisol, 31:57
 growth hormone, prolactin, 31:57
 growth hormone, weight loss, 31:201
 heart rate, affective disorder, 31:57
m-chlorophenylpiperazine, panic disorder, 31:209
m-chlorophenylpiperazine, serotonin, 31:209
 melatonin, amino acids, 34:243
 melatonin, catecholamines, 34:243
 melatonin, cortisol, 34:243
 melatonin, neuroleptics, 34:243
 melatonin, schizophrenia, 34:243
 neuroleptics, amino acids, 34:243
 neuroleptics, catecholamines, 34:243
 neuroleptics, cortisol, 34:243
 neuroleptics, melatonin, 34:243
 neuroleptics, schizophrenia, 34:243
 panic disorder, *m*-chlorophenylpiperazine, 31:209
 panic disorder, serotonin, 31:209
 prolactin, adrenocorticotrophic hormone, 31:57
 prolactin, affective disorder, 31:57, 31:201
 prolactin, amitriptyline, 31:201
 prolactin, antidepressants, 31:201
 prolactin, Beck Depression Inventory, 31:201
 prolactin, bipolar, 31:57
 prolactin, cortisol, 31:57
 prolactin, sex differences, 31:57

Tryptophan continued

- prolactin, weight loss, 31:201
- schizophrenia, amino acids, 34:243
- schizophrenia, catecholamines, 34:243
- schizophrenia, cortisol, 34:243
- schizophrenia, melatonin, 34:243
- schizophrenia, neuroleptics, 34:243
- serotonin, *m*-chlorophenylpiperazine, 31:209
- serotonin, panic disorder, 31:209
- sex differences, prolactin, 31:57
- thyroid stimulating hormone, affective disorder, 34:29, 34:59
- thyroid stimulating hormone, depressive symptoms, 34:59
- thyroid stimulating hormone, dexamethasone suppression test, 34:59
- thyroid stimulating hormone, vital depression, 34:29
- thyroxine, affective disorder, 34:29, 34:59
- thyroxine, depressive symptoms, 34:59
- thyroxine, dexamethasone suppression test, 34:59
- thyroxine, vital depression, 34:29
- vital depression, adrenocorticotrophic hormone, 34:29
- vital depression, affective disorder, 34:29
- vital depression, cortisol, 34:29
- vital depression, thyroid stimulating hormone, 34:29
- vital depression, thyroxine, 34:29
- weight loss, affective disorder, 31:201
- weight loss, amitriptyline, 31:201
- weight loss, antidepressants, 31:201
- weight loss, Beck Depression Inventory, 31:201
- weight loss, growth hormone, 31:201
- weight loss, prolactin, 31:201

Tyramine

- Tourette's syndrome, amine metabolites, 31:279

Tyrosine hydroxylase

- affective disorders, genetics, 32:275
- genetics, restriction fragment length polymorphism, 32:275
- restriction fragment length polymorphism, affective disorders, 32:275

Vanillylmandelic acid

- schizophrenia, evoked potentials, 31:297

Vasopressin

- affective disorder, electroconvulsive therapy, 32:201
- affective disorder, oxytocin, 32:201
- blood pressure, clonidine, 31:311
- blood pressure, growth hormone, 31:311

Vasopressin continued

- clonidine, blood pressure, 31:311
- clonidine, growth hormone, 31:311
- clonidine, heart rate, 31:311
- electroconvulsive therapy, affective disorder, 32:201
- electroconvulsive therapy, oxytocin, 32:201
- growth hormone, blood pressure, 31:311
- growth hormone, clonidine, 31:311
- growth hormone, heart rate, 31:311
- heart rate, clonidine, 31:311
- heart rate, growth hormone, 31:311
- oxytocin, affective disorder, 32:201
- oxytocin, electroconvulsive therapy, 32:201

Ventricle

- age, computed tomography, 35:115
- computed tomography, volumetric measurement, 35:115
- volumetric measurement, age, 35:115

Ventricle-brain ratio

- admixture analysis, age, 35:61
- admixture analysis, computed tomography, 35:61
- admixture analysis, schizophrenia, 35:61
- age, admixture analysis, 35:61
- age, computed tomography, 31:1, 35:61
- age, glutathione peroxidase, 31:1
- age, intracranial volume, 35:15
- age, limbic system, 35:15
- age, magnetic resonance imaging, 35:15
- age, monoamine oxidase, 31:1
- age, neuroleptics, 31:1
- age, schizophrenia, 31:1, 35:61
- age, temporal lobe, 35:15
- age, third ventricle, 31:1
- age, volume reduction, 35:15
- computed tomography, admixture analysis, 35:61
- computed tomography, age, 31:1, 35:61
- computed tomography, frontal lobe, 31:221
- computed tomography, glutathione peroxidase, 31:1
- computed tomography, HLA antigen, 31:221
- computed tomography, laterality, 31:221
- computed tomography, monoamine oxidase, 31:1
- computed tomography, neuroleptics, 31:1, 31:221
- computed tomography, schizophrenia, 31:1, 31:221, 35:61
- computed tomography, third ventricle, 31:1
- frontal lobe, computed tomography, 31:221
- frontal lobe, HLA antigen, 31:221

Ventricle-brain ratio continued

frontal lobe, laterality, 31:221
 frontal lobe, neuroleptic response, 31:221
 frontal lobe, schizophrenia, 31:221
 genetics, laterality, 35:137
 genetics, magnetic resonance imaging, 35:137
 genetics, schizophrenia, 35:137
 genetics, sibling pairs, 35:137
 genetics, temporal lobe, 35:137
 glutathione peroxidase, age, 31:1
 glutathione peroxidase, computed tomography, 31:1
 glutathione peroxidase, monoamine oxidase, 31:1
 glutathione peroxidase, neuroleptics, 31:1
 glutathione peroxidase, schizophrenia, 31:1
 glutathione peroxidase, third ventricle, 31:1
 HLA antigen, computed tomography, 31:221
 HLA antigen, frontal lobe, 31:221
 HLA antigen, laterality, 31:221
 HLA antigen, neuroleptic response, 31:221
 HLA antigen, schizophrenia, 31:221
 intracranial volume, age, 35:15
 intracranial volume, magnetic resonance imaging, 35:15
 intracranial volume, volume reduction, 35:15
 laterality, computed tomography, 31:221
 laterality, frontal lobe, 31:221
 laterality, genetics, 35:137
 laterality, HLA antigen, 31:221
 laterality, magnetic resonance imaging, 35:137
 laterality, neuroleptic response, 31:221
 laterality, schizophrenia, 31:221, 35:137
 laterality, sibling pairs, 35:137
 laterality, temporal lobe, 35:137
 limbic system, age, 35:15
 limbic system, intracranial volume, 35:15
 limbic system, magnetic resonance imaging, 35:15
 limbic system, temporal lobe, 35:15
 limbic system, volume reduction, 35:15
 magnetic resonance imaging, age, 35:15
 magnetic resonance imaging, intracranial volume, 35:15
 magnetic resonance imaging, laterality, 35:137
 magnetic resonance imaging, limbic system, 35:15
 magnetic resonance imaging, schizophrenia, 35:137

Ventricle-brain ratio continued

magnetic resonance imaging, sibling pairs, 35:137
 magnetic resonance imaging, temporal lobe, 35:15, 35:137
 magnetic resonance imaging, volume reduction, 35:15
 monoamine oxidase, age, 31:1
 monoamine oxidase, computed tomography, 31:1
 monoamine oxidase, glutathione peroxidase, 31:1
 monoamine oxidase, neuroleptics, 31:1
 monoamine oxidase, schizophrenia, 31:1
 monoamine oxidase, third ventricle, 31:1
 neuroleptic response, computed tomography, 31:221
 neuroleptic response, frontal lobe, 31:221
 neuroleptic response, HLA antigen, 31:221
 neuroleptic response, laterality, 31:221
 neuroleptic response, schizophrenia, 31:221
 neuroleptics, age, 31:1
 neuroleptics, computed tomography, 31:1
 neuroleptics, glutathione peroxidase, 31:1
 neuroleptics, monoamine oxidase, 31:1
 neuroleptics, schizophrenia, 31:1
 neuroleptics, third ventricle, 31:1
 schizophrenia, admixture analysis, 35:61
 schizophrenia, age, 31:1, 35:61
 schizophrenia, computed tomography, 31:1, 31:221, 35:61
 schizophrenia, frontal lobe, 31:221
 schizophrenia, genetics, 35:137
 schizophrenia, glutathione peroxidase, 31:1
 schizophrenia, HLA antigen, 31:221
 schizophrenia, laterality, 31:221, 35:137
 schizophrenia, magnetic resonance imaging, 35:137
 schizophrenia, monoamine oxidase, 31:1
 schizophrenia, neuroleptic response, 31:1, 31:221
 schizophrenia, sibling pairs, 35:137
 schizophrenia, temporal lobe, 35:137
 schizophrenia, third ventricle, 31:1
 sibling pairs, genetics, 35:137
 sibling pairs, laterality, 35:137
 sibling pairs, magnetic resonance imaging, 35:137
 sibling pairs, schizophrenia, 35:137
 sibling pairs, temporal lobe, 35:137
 temporal lobe, age, 35:15
 temporal lobe, genetics, 35:137
 temporal lobe, intracranial volume, 35:15
 temporal lobe, laterality, 35:137

Ventricle-brain ratio continued

- temporal lobe, magnetic resonance imaging, 35:15, 35:137
- temporal lobe, schizophrenia, 35:137
- temporal lobe, sibling pairs, 35:137
- temporal lobe, volume reduction, 35:15
- third ventricle, age, 31:1
- third ventricle, computed tomography, 31:1
- third ventricle, glutathione peroxidase, 31:1
- third ventricle, monoamine oxidase, 31:1
- third ventricle, neuroleptics, 31:1
- third ventricle, schizophrenia, 31:1
- volume reduction, age, 35:15
- volume reduction, limbic system, 35:15
- volume reduction, temporal lobe, 35:15

Verbal fluency

- frontal lobe, Halstead-Reitan Battery, 31:15
- Halstead-Reitan Battery, negative symptoms, 31:15
- negative symptoms, schizophrenia, 31:15
- schizophrenia, Wechsler Adult Intelligence Scale, 31:15
- Wechsler Adult Intelligence Scale, frontal lobe, 31:15

Viral antigens

- cytomegalovirus, schizophrenia, 33:11
- ELISA technique, herpes virus, 33:11
- Epstein-Barr, schizophrenia, 33:11
- herpes virus, immunoglobulins, 33:11
- immunoglobulins, ELISA technique, 33:11
- measles, mumps, 33:11
- schizophrenia, cytomegalovirus, 33:11
- schizophrenia, ELISA technique, 33:11
- schizophrenia, Epstein-Barr, 33:11
- schizophrenia, herpes virus, 33:11
- schizophrenia, immunoglobulins, 33:11
- schizophrenia, measles, 33:11
- schizophrenia, mumps, 33:11

Wechsler Adult Intelligence Scale (WAIS)

- attention, distractibility, 31:169
- attention, formal thought disorder, 31:169
- attention, schizophrenia, 31:169
- attention, span of apprehension, 31:169
- distractibility, schizophrenia, 31:169
- distractibility, span of apprehension, 31:169
- formal thought disorder, schizophrenia, 31:169
- frontal lobe, Halstead-Reitan Battery, 31:15
- frontal lobe, negative symptoms, 31:15
- frontal lobe, schizophrenia, 31:15
- frontal lobe, verbal fluency, 31:15
- Halstead-Reitan Battery, frontal lobe, 31:15

Wechsler Adult Intelligence Scale continued

- Halstead-Reitan Battery, negative symptoms, 31:15
- Halstead-Reitan Battery, verbal fluency, 31:15
- negative symptoms, frontal lobe, 31:15
- schizophrenia, attention, 31:169
- schizophrenia, distractibility, 31:169
- schizophrenia, formal thought disorder, 31:169
- schizophrenia, frontal lobe, 31:15
- schizophrenia, Halstead-Reitan Battery, 31:15
- schizophrenia, negative symptoms, 31:15
- schizophrenia, span of apprehension, 31:169
- schizophrenia, verbal fluency, 31:15
- span of apprehension, schizophrenia, 31:169
- verbal fluency, frontal lobe, 31:15

Weight

- blood pressure, eating disorders, 33:1
- blood pressure, isoproterenol, 33:1
- blood pressure, temperature of body, 33:1
- circannual rhythm, diurnal rhythm, 32:221
- circannual rhythm, eating disorder, 32:221
- circannual rhythm, melatonin, 32:221
- diurnal rhythm, eating disorder, 32:221
- diurnal rhythm, melatonin, 32:221
- eating disorder, blood pressure, 33:1
- eating disorder, circannual rhythm, 32:221
- eating disorder, diurnal rhythm, 32:221
- eating disorder, heart rate, 33:1
- eating disorder, isoproterenol, 33:1
- eating disorder, melatonin, 32:221
- eating disorder, temperature of body, 33:1
- haloperidol, Japanese patients, 31:111
- haloperidol, plasma concentration, 31:111
- heart rate, eating disorders, 33:1
- heart rate, isoproterenol, 33:1
- heart rate, temperature of body, 33:1
- isoproterenol, eating disorders, 33:1
- Japanese patients, haloperidol, 31:111
- Japanese patients, plasma concentration, 31:111
- left ventricular mass, panic disorder, 32:55
- melatonin, circannual rhythm, 32:221
- melatonin, diurnal rhythm, 32:221
- melatonin, eating disorder, 32:221
- panic disorder, left ventricular mass, 32:55
- plasma concentration, haloperidol, 31:111
- plasma concentration, Japanese patients, 31:111
- temperature of body, eating disorders, 33:1
- temperature of body, isoproterenol, 33:1

Wisconsin Card Sort Test

- frontal lobe, Tourette's syndrome, 33:73
- neuropsychological deficit, Scale for the Assessment of Negative Symptoms, 31:15
- neuropsychological deficit, schizophrenia, 31:15
- Scale for the Assessment of Negative Symptoms, schizophrenia, 31:15
- schizophrenia, neuropsychological deficit, 31:15

Wisconsin Card Sort Test continued

- Tourette's syndrome, frontal lobe, 33:73

Yale-Brown Scale

- clomipramine response, dermatitis, 34:223
- clomipramine treatment, scale reliability, 34:99

Yohimbine

- Sensation Seeking Scale, normal volunteers, 32:125